

CURRICULUM VITAE

Richard J. Johnson, M.D.

1. GENERAL BIOGRAPHICAL INFORMATION

A. PERSONAL

Home Address: 15857 E Aberdeen Ave, Centennial CO 80016

Office: Richard Johnson, M.D., F.A.C.P.
Professor of Medicine
Tomas Berl Professor of Medicine
University of Colorado Denver
Box C281
12700 East 19th Avenue
Research 2, Room 7015
Aurora, Colorado 80045
Phone: 303-724-4865
Fax: 303-724-4831
E-mail: Richard.Johnson@ucdenver.edu

2. EDUCATION

Undergraduate: University of Wisconsin, Madison, Wisconsin; B.S. (with honors)
(1971-1975). Anthropology

Medical School: University of Minnesota, Minneapolis, Minnesota
(1975-1979)

POSTGRADUATE TRAINING

Internship: University of Washington, Seattle, WA. (Internal Medicine)
(Internal Medicine 1979-1980)

Residency: University of Washington, Seattle, WA. (Internal Medicine)
(Internal Medicine 1980-1982)

Dual Fellowship: Divisions of Nephrology and Infectious Diseases,
(1982-1986) Department of Medicine, University of Washington, Seattle, WA.

3. ACADEMIC APPOINTMENTS

Acting Instructor/Senior Fellow - June, 1986 - October 1987, Division of

Nephrology/Department of Medicine and the Division of Infectious Disease, University of Washington.

Assistant Professor of Medicine - October, 1987 - June, 1991, Division of Nephrology/Department of Medicine, University of Washington.

Associate Professor of Medicine - July 1, 1991 to July 1996, Division of Nephrology/Department of Medicine, University of Washington.

Adjunct Professor of Pathology, 1995 – July 2000, University of Washington.

Professor of Medicine - July 1, 1996 to June, 2000, Division of Nephrology/Department of Medicine, University of Washington.

Affiliate Professor of Medicine, University of Washington - July 2000 to present

Professor of Pathology, Baylor College of Medicine, Houston, TX - November 2001 – August 2003

Professor of Medicine and Chief, Renal Section, Baylor College of Medicine, Houston, TX, July 2000 to August 2003

Director of Kidney/Pancreas Transplantation, Baylor-Methodist Program, July 2000-August 2003

Adjunct Professor of Medicine, Baylor College of Medicine, Houston, Sep 2003 to 2006

Director, Hypertension Physiology Center, University of Florida September 2003-2004

J. Robert Cade Professor of Nephrology, and Professor of Medicine and Chief, Section of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, September 2003- September 30, 2008

Professor, Physiology and Functional Genomics, University of Florida, March 2004 - September 30, 2008

Adjunct Professor of Medicine and Physiology, and Functional Genomics, University of Florida, Oct 2008- present

Tomas Berl Professor of Medicine and Chief, Division of Renal Diseases and Hypertension , University of Colorado Denver Health Sciences, Denver CO Oct 1, 2008-

Associate Director, Colorado Obesity Research Initiative July 2010-present

Professor of Medicine in the Division of Endocrinology and Metabolism, July 2010-present

Professor of Pharmacology, University of Colorado, Denver, 2012-present

4. HOSPITAL OR PROFESSIONAL POSITIONS

5. HONORS

Honors Program/Honors Thesis in Anthropology, University of Wisconsin

1974 Phi Beta Kappa (Junior year), University of Minnesota

1978 Alpha Omega Alpha (Junior year), University of Minnesota, 1978

National Kidney Foundation American Society of Nephrology Hoffman

La Roche Fellowship Award 1983-1984

Science in Medicine Lecture, University of Washington, June, 1990

Inaugural Priscilla Kincaid-Smith Visiting Professor, Melbourne, Australia, February, 1993

Research Career Development Awards, National Institute of Health, 1992-1997

Tokyo Forum, Speaker 1993

Young Investigator Award, American Society of Nephrology and American Heart Association, Orlando, Florida, 1994

American Society of Clinical Investigation, 1995

Keynote Speaker "Glomerular Response to Injury", International Society of Pediatric Nephrology, Santiago, Chile, 1995

Robert Ecklund Visiting Professor, Case Western Reserve, 1997

Keynote Speaker, Japanese Society of Nephrology, 1999

Keynote Speaker, Australian Society of Nephrology, 1999

Guy's Hospital Visiting Professor for the Year 2000, London

British Medical Association Book Competition in Medicine, Highly Commended award for Comprehensive Clinical Nephrology, First edition

Keynote Speaker, Egyptian Society of Nephrology, 2001, Cairo

Arthur Gordon Visiting Professor, UCLA 2001

Outstanding Volunteer Award, National Kidney Foundation of Southeast Texas, 2002

Brenner Lecture, American Society of Nephrology meeting, San Diego, 2003

Elected to Thomas Reuters ISIhighlycited.com as highly cited in Clinical Medicine for period from 1992 to 2012 (>41,000 citations)

Everett Anderson Visiting Professor, U of Arkansas, March 2004

"Honoris Causa" Sterling Professor of the Mexican Society of Hypertension, 2006

Thomas Ferris Lecture, U of Minnesota 2006

Herbert Chassis Lecture, NYU, 2006

Jaime Herrera Lecture, Mexican Society of Nephrology, 2006

Sir Stanley Davidson Lecturer, Royal College of Physicians of Scotland, Edinburgh Oct 2006

Faculty Achievement Recognition Award, U of Florida, 2007

Theodore Goodfriend Visiting Professor, Univ of Wisconsin, Madison 2007
 Donald Seldin Lecture, AHA annual meeting, Orlando FL Nov 2007
 Jaime Herrera Lecture, 17th Annual Meeting of the Instituto Mexicano Investigaciones Nephrology, Puerto Vallarta, Mexico December 2007
 Hugh DeWardener Lecture, British Society of Hypertension, Glasgow May 2008
 University of Florida Dept of Medicine Honors for Excellence in Teaching to Residents 2008
 Best Doctors in America 1996 to 2006 and 2009 to 2014
 Theodore Woodward Award, American Clinical and Climatologic Association, 2009
 Who's Who in America (Marquis)
 Who's Who in America (Madison)
 Honorary Member, Polish Society of Nephrology, 2010
 Honorary Professorship, Beijing Anzhen Hospital, June 2011
 University of Colorado Denver Medical Campus New Inventor of the Year 2011
 Best Doctors of Denver 2014

6. MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

PROFESSIONAL SOCIETIES (Current)

American Heart Association
 (Council on High Blood Pressure Research and Council on Kidney in Cardiovascular Disease)
 American Clinical and Climatological Society
 American Diabetes Association
 American Society of Clinical Investigation
 American Society of Nephrology
 American Society of Nutrition
 American Society of Hypertension
 American College of Physicians (Fellow, 1989)
 International Society of Nephrology
 Australian and New Zealand Society of Nephrology (Honorary Member)
 Association of Subspecialty Professors
 American Physiological Society
 National Kidney Foundation
 American Diabetes Association
 Polish Society of Nephrology (Honorary Member)

7. MAJOR COMMITTEE AND SERVICE RESPONSIBILITIES

NATIONAL and INTERNATIONAL COMMITTEES / RESPONSIBILITIES

Regional Representative for UNOS 6 (pancreas transplant)	1990-1994
National Kidney Foundation, Council on Glomerular Disease	1992-1993
Abstract Review - ASN (1989, 1991, Chair, Basic/Experimental Immunology 1993), National AFCR (1992)	
Grant Review - NIH O'Brien Center Grant	1991

Grant Review, NKF Fellowship	1992-1994
Co-organizer, Glomerulonephritis Section, International Society Nephrology, Madrid	1995
Reviewer, Louisiana Education Quality Support Fund	1994
Co-organizer, Glomerulonephritis Section, National Kidney Foundation Meeting	1996
CME course, American Society of Nephrology Board Review	1996-1997, 1999-2000
Organizing Committee, National Kidney Foundation	1996
Ad hoc Reviewer, NIH Med B Study Section	1996
ASN Awards Committee	1995-1998
ASN Career Enhancement Award Committee	1998-2000
ASN Carl Gottschalk Research Scholarship Committee	1998-2000
Ad hoc Reviewer and Chairman, NIH extramural Grant	1999
NKF Young Investigator Award Committee, Co-chairman	2000-2003
ISN COMGAN Research Committee – National / International	9/2001-2008
Chair, Basic Science Review Board, National Kidney Foundation	2002-04
Scientific Advisory Board, National Kidney Foundation	2003-04
ISN Scientific Program Committee, Singapore	2005
ASN Abstract Reviewer	2002, 2003
ISN Guidelines Committee	2004-2010
ISN, Member of the Council (North America Representative)	2004-2011
NIH Pathobiology of Kidney Disease Study Section, NIH NIDDK	2005-2006
Board Member, Gout and Hyperuricemia Society (nonprofit)	2005-2006
John Peters Award Committee, American Society of Nephrology	2006-2009
ASN Abstract Reviewer	2006, 2006
ASN Council Election Committee	2007-2008
NIH Ad Hoc Study Reviewer for PPG	2007
NIH Pathobiology of Kidney Disease Study Section	2007
NIH NIDDK George O'Brien Center Reviewer	3/2008
ISN Nexus Symposia Core Committee	2008
Program Committee, AHA Council on Kidney in Cardiovascular Disease	2008-
Chairman, Scientific Committee, ISN, in Vancouver, British Columbia	2011
ISN, Executive Council	2009-2011
NIH Reviewer, NHLBI, Hypertension Microvascular section	2011
ASH Scientific Co-chairman, Pathophysiology Research Section	5/2012
Amway/Nutriline Scientific Advisory Board	2011-present
Gatorade Science Museum Board of Advisors	2011-2012
NIH Hypertension and Microcirculatory Study Section, NHLBI	2012-2018
NIDDK Study Section, ad hoc	July 2013
Gout and Uric acid Education Society, Board Member	2008-
External Advisory Board, Center of Biomedical Research Excellence (COBRE grant) at University of Mississippi, PI John Hall	2013-
Editorial Board, Kidney International	2009-2019

Editorial Board, Am J Kidney Disease
External Reviewer, U MI NIH COBRE Center

2012-2014
2014

LOCAL RESPONSIBILITIES at University of Colorado

Deans Advisory Committee, 2009-2012
Steering Committee, Health and Wellness Design, 2009
Research Action Committee (RAC), 2010
Nutrition Research Core Committee, 2010-2012
Associate Director, Colorado Obesity Research Initiative

FUND RAISING AND DEVELOPMENT OF ENDOWED CHAIRS AND PROFESSORSHIPS

1. Garabed Eknayan Visiting Professorship: Established at Baylor 2001
2. J Robert Cade Visiting Professorship: Established at U FL 2003
3. C Craig Tisher Visiting Professorship: Established at U FL 2003
4. Hypertension and Kidney Disease Research and Education Fund: Established 2004 at U FL; raised over \$280,000
5. R Glenn Davis Endowed Chair: Raised \$2,000,000. Raised in 2006
6. C Craig Tisher Endowed Chair: Raised \$900,000, raised in 2007
7. Robert Schrier Lectureship Help Raised \$400,000
8. Mats Wahlstrom Lectureship \$100,000
9. Lawrence Chan Endowed Chair Actively \$50,000
10. Melissa Yanover Lecturship \$100,000
11. Marvin Bernstein Lectureship \$100,000
12. Josh Thurman Lecturehip \$100,000

SCIENTIFIC ADVISORY BOARD

Nephromics	2005-2007
Gout and Hyperuricemia Society of America	2005-present
Amway (Nutrilite) Scientific Board	2011-present
XORT Scientific Board	2013-present

STARTUP COMPANIES

Colorado Research Partners, LLC (CEO and President)	2014-
---	-------

8. LICENSURE AND BOARD CERTIFICATIONS

BOARD CERTIFICATION

Board certified in Internal Medicine, 10/82
Board certified in Nephrology, 10/84
Board certified in Infectious Diseases, 10/86

LICENSE TO PRACTICE

Washington, June 1979-November, 2000 - LIC # 0018778

Texas, September, 2001 -8/31/03 LIC #L2355, DPS #L0121092

Florida, 11/14/03-1/09, LIC# ME89150

Colorado, 46977, 8/12/2008-present

9. INVENTIONS AND PATENTS

PATENTS

1. US Patent No. 6,352,975 B1, Issued March 5, 2002 (Application No. 09/392,932, filed 09/09/1999) “Methods of Treating Hypertension and Compositions for Use Therein” Inventors George Schreiner and Richard J Johnson
2. US Patent No 6,677,300. Issued Jan 13, 2004. (Application No. 09/392, 931, filed 09/09/99) “Treatment of Microvascular Angiopathies” Inventors George Schreiner and Richard J Johnson
3. US Patent No. 7,030,083 B2 Issued April 18, 2006 (Application No. 10/418,529, Filed 4/16/2003) Issued Nov 10, 2005 “Treatment of eclampsia and preeclampsia” Inventors Richard Johnson and George Schreiner
4. US Patent No 7,799,794 B2, Issued Sep 21, 2010, (Application 09/892,505; Filed Jun 28, 2001 Treatment for Cardiovascular Disease Inventors Salah Kivlighn, Richard Johnson and Marilda Mazzali
5. Remedy/preventive for vascular and hypertension and method of screening the same. Inventors: Endou, Hitoshi; Kanai, Yoshikatsu; Johnson Richard J; and Price, Karen Leigh Patent No. approved date and country: 4660376, 2011/1/7, Japan
6. US Patent No 8,236,488. Method of screening for therapeutic compounds for vascular disorders and hypertension based on URAT1 activity modulation . August 7th, 2012, Inventors: Endou H, Kanai; Yoshikatsu (Tokyo, JP), Johnson; Richard J. (Gainesville, FL), Price; Karen L; Human Cell Systems, Inc. (Tokyo, JP)
7. U. S. Patent No. 8,557,831 issued 10/15/2013 for COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF INSULIN RESISTANCE Serial No. 11/572,270; filed January 18, 2007 Based on PCT/US05/25910; filed July 21, 2005 (Richard J. Johnson et al.). Our Docket No. 10457-061US; UF# 11514
8. U.S. Patent No. 8,697,628 SELECTIVE AMPD2 INHIBITORS AND METHODS FOR USING THE SAME Inventors: Gabriela Garcia, Richard Johnson, Christopher Rivard, & Miguel Lanasp-Garcia Serial No. 13/521,881; filed July 12, 2012, Our Docket No. 11906-004; Your Ref: CU2511H-US1

PATENT APPLICATIONS

1. U. S. National Stage Patent Application for METHODS AND COMPOSITIONS FOR AMELIORATING THIAZIDE INDUCED HYPERLIPIDEMIA (Richard J. Johnson, Sirirat Reungjui and Takahiko Nakagawa) Serial No. 13/598,304; filed August 29, 2012. Divisional of Serial No. 12/531,120; filed September 14, 2009. Based on

- PCT/US08/60550; filed April 17, 2008. Priority to U. S. Serial No. 60/912,293; filed April 17, 2007. Our Docket No. 10457-107USD; UF # 14603
2. US National Stage Application for **METHODS AND COMPOSITIONS FOR THE INHIBITION OF FRUCTOKINASE** Serial No. 13/814,568; filed 2/6/2013, Based on Serial No. PCT/US2011/46938; filed 08/08/2011, Claims Priority to: Serial No. 61/371,255; filed 08/06/2010; Inventors: Richard Johnson et al. Our Docket No. 11906-002US; Your Ref: CU2580H
 3. U. S. Patent Application for **METHODS FOR FRUCTANASE AND FRUCTOKINASE INHIBITION** Inventors: Richard Johnson, Stephen Dreskin & Miguel Lanasp-Garcia. Serial No. 13/686,877; filed 11/27/2012 Claims priority to Serial No. 61/563,806; filed 11/27/2011 Our Docket No. 11906-003; Your Ref: CU2981H-PPA1
 4. U.S. Continuation Application for **COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUENCES**. Serial No. 13/364,313; Filed February 1, 2012. Cont. of 11/995,943; filed 1/17/2008 which is a CIP of PCT/US05/25910; filed 7/21/2005 which claims priority to Serial No. 60/589,921; filed 07/21/2004. Our Docket No. 11160-006 **DIABETIC NEPHROPATHY** Patent published on August 30, 2012 under Publication No. US-2012-0220607-A1
 5. US Provisional Patent. **PLANT-BASED INHIBITORS OF KETOHEXOKINASE FOR THE SUPPORT OF WEIGHT MANAGEMENT**. Inventors Richard J Johnson, Myphuong Le, Miguel Lanasp, Jatinder Randa, Jeffrey Scholten, and R. Keith Randolph, Filed July 2013.
 - 6.

10. REVIEW AND REFEREE WORK

EDITORIAL BOARDS

- Reviewing Editor, Journal of the American Society of Nephrology 1992-2001
- Member of Editorial Board, Journal of the American Society of Nephrology 2001-2002
- Consulting Editor, Kidney International 1996-1999
- Consulting Editor, Nephrology 1995-1997
- Associate Editor, American Journal of Kidney Disease 1996-2001
- Member of Editorial Board, American Journal of Physiology, Renal Physiology 2000-2004
- Member of Editorial Board, Hypertension, 2003 - 2010
- Member of Editorial Board, Kidney International 2004-2006
- Member of Editorial Board, American Journal of Nephrology, 2003-present
- Advisory Board, "In Translation" Feature for American Journal of Kidney Diseases, 2007-2014
- Editorial Board, Nephron Experimental Nephrology, 2007-2010
- Internal and Emergency Medicine, Advisory Board (2007-)
- Editorial Board, Internet Journal of Nephrology (2007-)
- Editorial Board, Am J Physiol Renal Physiol (2008-2011)

Advisory Board, Nature Reviews Nephrology 2009-present
 Member of Editorial Board, Kidney International 2012-present

11. MAJOR PRESENTATIONS

INVITED GUEST SPEAKER AND VISITING PROFESSORSHIPS

Northwest Renal Society Invited Speaker	1986; 1988; 1993-1994; 1997; 2000
University of Washington, Grand Rounds, Seattle	
Children's Hospital Medical Center, Seattle, Grand Rounds	1990
Madigan Army Hospital, Tacoma, Grand Rounds	1990
Invited Speaker, American Society of Nephrology, Role of Platelets in Glomerulonephritis, Washington, D.C.	1990
Invited Speaker, International Society of Nephrology, Tokyo, Japan	1990
Invited Speaker, Chinese Society of Nephrology, 4th Asian Pacific Congress, Beijing, China	1990
American College of Physicians Board Review Course, Seattle, WA	1991
Invited Speaker, Forefronts in Nephrology, Kloster Blanz FRG	1991
Invited Speaker, 3rd Roma Conference of Nephrology, Fiuggi, Italy	1991
Invited Speaker, American Society of Nephrology, Role of PDGF in Glomerulonephritis, Baltimore, MD	1992
Invited Speaker, Bari Conference of Molecular Biology in Nephrology, Bari, Italy	1992
Visiting Professor, Washington University, St. Louis, MO	1992
American College of Physicians Board Review Course, Seattle, WA	1992
Invited Speaker, American Society of Nephrology, In Vivo Models of Mesangial Injury, Boston, MA	1993
Invited Speaker, Priscilla Kincaid-Smith Visiting Professorship, Melbourne, Australia	1993
Visiting Professor, The Royal Melbourne Hospital, Melbourne	
Visiting Professor, Monash University, Melbourne	
Visiting Professor, Albert Hospital, Melbourne	
Visiting Professor, St. Vincents Hospital, Melbourne	
American College of Physicians Board Review Course, Seattle, WA	1993
Visiting Professor, University of Calgary, Alberta	1993
Visiting Professor, University of Edmonton, Alberta	1993
Visiting Professor, University Hospital, Leicester, United Kingdom	1993
Invited Speaker, Royal College of Physicians, "Glomerulus - From Tissue to Man," LONDON, UK	1993
Visiting Professor, University College of London	1993
Visiting Professor, Hoffman-La Roche, Basel, Switzerland	1991-1993
Invited Speaker, XIth International Basement Membrane Symposium, Fuji, Japan	1993
Keynote Speaker, <u>Tokyo Forum</u> , Tokyo, Japan	1993

Visiting Professor, Hirosaki University, Hirosaki, Japan	1993
Invited Speaker, ISN Satellite Symposium on Progressive Renal Disease, Tiberias, Israel, June	1993
Invited Speaker, National Kidney Foundation Annual Meeting "Role of Platelets in Glomerulonephritis."	1993
Visiting Professor, Hennepin County Medical Center, Minneapolis, Minnesota	1993
Keynote Speaker, Nephrology Forum, Kidney International, "Glomerular Response to Injury," Nephrology Day, Seattle, WA	1994
Visiting Professor, University of Pennsylvania, Philadelphia	1993
Invited Speaker, EDTA 30th Annual Session, Glasgow, Scotland	1993
University of Washington, Grand Rounds, Department of Medicine	1989; 1994
Invited Speaker, American Society of Pediatric Nephrology Annual Meeting Seattle, May	1994
Invited Speaker, University of Utah, CME Course, April	1994
American College of Physicians Board Review Course, Seattle, WA	1994
Invited Speaker, American Society of Nephrology, Osteopontin and Tubulointerstitial Disease, San Diego, CA	1995
Invited Speaker, International Symposium on Progressive Glomerular Disease, Taipei, Taiwan	1995
Invited Speaker, "Growth Factors in Cardiovascular and Renal Disease, " University of British Columbia, Vancouver B.C., Canada, March	1995
Medical Grand Rounds, Madigan Army Hospital, Tacoma, WA	1995
Invited Speaker, National AFCR, San Diego, California "The Glomerular Response to Injury: Interactions Among Growth Factors, Cytokines and Matrix."	1995
Visiting Professor, Hennepin County Hospital, Minneapolis, MN, March	1995
Invited Speaker, "Gift of Life Celebration," National Kidney Foundation of the Upper Midwest, Minneapolis, MN, March	1995
Invited Speaker, N.Y. Society of Nephrology, Cornell University, N.Y.	1995
Visiting Professor, SUNY at Stony Brook, N.Y., April	1995
Visiting Professor, Montefiore Medical Center, Albert Einstein University, Bronx, N.Y.	1995
Invited Speaker, International Symposium on Progression of Chronic Renal Disease, Mt. Fuji, Japan, May	1995
Visiting Professor, Kanazawa University, Kanazawa, Japan, May	1995
Invited Speaker, Inaugural Showa University Forum of Nephrology and Hypertension, Tokyo, Japan, May	1995
Invited Speaker, Fifth Annual Hepatitis Educators Conference, Amelia Island, Florida, June	1995
State-of-Art Speaker, "Future Treatments of Kidney Disease," International Society of Nephrology, Madrid, Spain, July, Society of Pediatric Nephrology, Santiago, Chile, August	1995
Visiting Professor, Hines VA Medical Center, Chicago, IL, June	1995
Visiting Professor, University of Lima, Peruvian Society of Nephrology, August	1995

Invited Speaker, 28th Annual Meeting of National Kidney Foundation of Northern California, San Francisco, September	1995
Invited Speaker, National Kidney Foundation Annual Meeting, "HCV and Glomerulonephritis: Role of α -Interferon Therapy:", San Diego, CA	1995
Invited Speaker, ASN Satellite Symposium on Immunologic Renal Disease, "Platelets and Selectins", San Diego, CA	1995
Visiting Professor, Sun Yat Sen University, Guangzhou, China	1995
Visiting Professor, Second Medical University, Shanghai, China	1995
Visiting Professor, Guandong Medical hospital, Fushan, China	1995
Visiting Professor, Medical College of Wisconsin, Milwaukee	1995
Visiting Professor, University of British Columbia, Vancouver, Canada	1996
Visiting Professor, University of Texas, San Antonio	1996
Visiting Professor, Wilford Hall, Lackland Air Force Base	1996
Invited Speaker, XXIII Winter Nephrology Symposium, Banff, Canada	1996
Invited Speaker, Renal Short Course "Pathogenesis and Treatment of Glomerular Disease", London, England	1996
Invited Speaker, Fibrosis Workshop, Nile Cruise, Egypt	1996
Medical Grand Rounds, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom	1996
Visiting Professor Loayza Hospital, University Cayetano Heredia of Peru, Lima	1996
Invited Speaker, Roche Laboratories, Lima, Peru	1996
Visiting Professor, Hospital for Sick Children, Toronto, Canada	1996
Visiting Professor, University of Toronto, Canada	1996
Visiting Professor, Amsterdam Medical Center, University of Amsterdam	1996
Visiting Professor, University of Leiden, Leiden, Netherlands	1996
American College of Physicians Board Review Course, Seattle, WA	1996
Invited Speaker, American Society of Nephrology Board Review, San Francisco, CA	1996
Invited Speaker, Fibrogen, Sunnyvale, CA	1996
Visiting Professor, New England Medical University, Boston, MA	1996
State-of-Art Speaker, 18 th Brazilian Congress of Nephrology, Sao Paolo, Brazil	1996
Invited Speaker, 9 th International Congress of the Peruvian Society of Internal Medicine, Lima, Peru, October	1996
Invited Speaker, Special Symposium on Interstitial Renal Disease, Tokai University	1996
Invited Speaker, International IgA Symposium, Tokyo, Japan (organized by H. Sakai)	1996
Visiting Professor, Okayama University (Dr. H Makino)	1996
Visiting Professor, Showa University, Yokohama (Dr. Ideura)	1996
Visiting Professor, University of Iowa (Dr. DiBona)	1996
Invited Speaker, Advanced Nephrology for the Consultant, UC San Diego	1997
Visiting Professor, University of Alabama, Birmingham	1997
Visiting Professor, Stanford, Palo Alto, CA	1997
Visiting Professor, University of Colorado, Denver	1997

Visiting Professor, Louisiana State University, Shreveport	1997
Invited Speaker National Kidney Foundation Spring meeting, Dallas	1997
Visiting Professor, University of Manitoba, Winnipeg	1997
State-of-the-Art Speaker, Satellite Symposium of ISN, Progression of Clinical Renal Disease, Coolum, Australia	1997
Invited Chairperson, Fifth International Satellite Symposium on Diabetes and Hypertension, ISN annual meeting, Coolum, Australia	1997
Invited Speaker, Northwest Renal Society, Nephrology Day, Seattle	1997
Invited Chairperson, International Society of Nephrology, Sydney, Australia	1997
University of Washington Medicine Grand Rounds	1997
Robert Ecklund Visiting Professor, Case Western Reserve, Cleveland, Ohio	1997
Invited Speaker, American College of Physicians Board Review, Seattle	1997
Invited Speaker, American Society of Nephrology Board Review, San Francisco	1997
Visiting Professor, Daniel Carrion Hospital, Lima, Peru	1998
Invited Speaker, Hospital Loayza, Heredia Cayetano University, Lima, Peru	1998
Winter Nephrology Symposium, Invited Speaker, Aspen, Colorado	1998
Sabbatical (March 1, 1998 - June 1, 1998)	
Invited Speaker, Nephrology Day, Northwest Renal Society	1998
Visiting Professor, Spokane Heart Institute	1998
Rush University Grand Rounds, Chicago, Illinois	1998
Invited Speaker, Nephrology Symposium, Heidelberg, Germany	1998
Invited Speaker, University of Erlangen-Nürnberg, Germany	1998
Visiting Professor, University of Vienna, Vienna, Austria	1998
Visiting Professor, University of Bari, Bari, Italy	1998
Visiting Professor, Bergamo, Italy	1998
Visiting Professor, Rome, Italy (University of Rome ALa Sapienza@)	1998
Visiting Professor, Florence, Italy (University of Florence)	1998
Invited Speaker, Merck Symposium on Hypertension, Scottsdale, AZ	1998
Invited Speaker, University of Florida, Gainesville, FL	1998
Invited Speaker, Japanese Society of Nephrology, Tokyo, Japan	1998
Invited Speaker, Kyoto University, Japan	1998
Invited Speaker, University of Nagoya, Japan	1998
Invited Speaker, University of Niigata, Japan	1998
Invited Speaker, Hirosaki University, Japan	1998
Invited Speaker, Showa University, Yokohama, Japan	1998
Invited Speaker, Merck Symposium on Hypertension, Istanbul	1998
Invited Speaker, Merck Symposium, International Society of Hypertension, Amsterdam	1998
Invited Speaker, XVIII Course on Nephrology, Institute of Investigative Nephrology, Mexico City, Mexico	1998
Invited Speaker, VI International Course on Nephrology, ISN, Mexico City, Mexico	1998
Invited Speaker, X International Course on Nephrology, ISN, Ecuador	1998

Invited Speaker, ACP Board Review, Seattle, WA	1998
Invited Speaker, Hypertension Symposium, Cancun, Mexico	1998
Invited Speaker, Merck Symposium, Istanbul, Turkey	1998
Invited Speaker, ASN Board Review, San Francisco	1998
Visiting Professor, Medical University of South Carolina, Charleston	1998
Invited Speaker, NW Regional Cardiovascular Consultant Conference (Astra), Seattle	1998
Invited Speaker, Merck Symposium, ASN, Philadelphia	1998
Invited Speaker, 35th Annual Australian/New Zealand Society of Nephrology Keynote Speaker, Brisbane	1999
Invited Speaker at graduate course, Brisbane	1999
Medical Grand Rounds, Royal Brisbane Hospital	
Invited Speaker, Monash Medical Center, Melbourne	
Invited Speaker, Merck Annual Symposium, Scottsdale, AZ	
Invited Speaker, American College of Cardiology, New Orleans, LA	1999
Invited Speaker, Satellite Symposium at the ISN, Buenos Aires, Argentina	1999
Visiting Professor, University of Miami	1999
Keynote Speaker, 41st Meeting of the Japanese Society of Nephrology, Yokohama	1999
Invited Speaker, American Society of Nephrology Annual Meeting, Miami	1999
Keynote Speaker, ASN Satellite Symposium, “Renal Fibrosis”, Birmingham, AL	1999
Visiting Professor, UCLA, Los Angeles	2000
Invited Speaker, “Hypertension and the Kidney”, Madrid	2000
Invited Speaker, “Vascular Nephropathies”, Rome	2000
Invited Speaker, Nephrology Day, Northwest Renal Society, Seattle	2000
Guy’s Hospital Richard Bright Visiting Professor for the Year 2000, London	2000
Visiting Professor, Vanderbilt University, Nashville, TN	2000
Invited Speaker, National Kidney Foundation Spring Meeting, Atlanta, GA	2000
Invited Speaker, Merck Annual Symposium, Turtle Creek, FL	2000
Invited Speaker, American Society of Nephrology, San Francisco, CA	2000
Medicine Grand Rounds, Baylor College of Medicine, Houston, TX	2000
Invited Speaker, Merck Headquarters, Whitehouse, NJ	2001
Keynote Speaker, Egyptian Society of Nephrology	2001
Keynote Speaker, Hypertension Symposium, Sydney, Australia	2001
Invited Speaker, Merck Symposium, Tokyo, Japan	2001
Invited Speaker, Merck Symposium, Thailand	2001
Medical Grand Rounds, St. Luke’s, Houston, TX	2001
Invited Speaker, Gulf Hematology Society, Houston, TX	2001
Medical Grand Rounds, Methodist Hospital, Houston, TX	2001
Invited Speaker, Merck Symposium, Hypertension, Bangkok, Thailand	2001
Invited Speaker, Merck Symposium, Lipid, Tokyo Japan	2001
Visiting Professor, Mayo Clinic, Rochester, MN	2001
Medicine Grand Rounds, UT Medical Center- Galveston	2001

Invited Speaker, Hypertension Symposium, COMGAN, ISN, Merida, Venezuela	2001
Visiting Professor, Spokane Heart Institute	2001
Invited Speaker, American Society of Nephrology Annual Meeting, San Francisco	2001
Invited Speaker, Cleveland Clinic Foundation	2001
Arthur Gordon Visiting Professor, Department of Medicine, UCLA	2001
Rheumatology Grand Rounds, Baylor College of Medicine	2001
Visiting Professor, University of Utah, Salt Lake City, UT	2002
Visiting Professor, University of Washington, Seattle, WA	2002
Invited Speaker, Glomerular Disease Symposium, Seattle, WA	2002
Invited Speaker, National Meeting of Systemic Hypertension of Mexico, Mexico City	2002
Keynote Speaker, TEXAN meeting, Austin, Texas	2002
Medicine Grand Rounds, CPC, Baylor College of Medicine, Houston, TX	2002
Medicine Grand Rounds, VA Medical Center, Houston, TX	2002
Visiting Professor, University of Indiana, Indianapolis, IN	2002
Keynote Speaker, National Kidney Foundation of Southeast Texas Annual Meeting, Houston	2002
Invited Speaker, U of Alabama, Birmingham	2002
Invited speaker, VIII Peruvian Congress, Peruvian Society of Nephrology, Lima, Peru	2002
Invited speaker, Chilean Society of Hypertension, Pucon, Chile	2002
Visiting Professor, Johns Hopkins University	2002
Visiting Professor, University of Texas Health Science Center – Lubbock, TX	2002
Visiting Professor, University of Texas Health Science Center - San Antonio, TX	2002
Visiting Professor, Medical College of Wisconsin, Milwaukee	2002
Visiting Professor, University of Colorado, Denver	2002
Medicine Grand Rounds, University of Texas Health Science Center , Houston, TX	2002
Invited Speaker, American College of Rheumatology, National Meeting, New Orleans, LA	2002
Medicine Grand Rounds, Nassau University Medical Center, East Meadow, New York	2003
Medicine Grand Rounds, New York Medical College, Westchester County, New York	2003
Renal Grand Rounds and Visiting Professor, Albert Einstein Medical Center, Bronx, N.Y.	2003
Invited Speaker, National Kidney Foundation, Stephen Z. Fadem, MD Update Symposium, Houston, Texas	2003
Invited Speaker, 9 th Asian Pacific Congress of Nephrology, Pattaya Thailand	2003
Invited Speaker, Hypertension-Lipid Symposium, Koh Chang, Thailand	2003
Invited Speaker, Korean Society of Nephrology, Seoul, Korea	2003
Visiting Professor, Beth Israel Hospital, Harvard Medical School, Boston MA	2003
Visiting Professor, University of Florida, Gainesville, FL	2003

State-of-the-Art lecture, 15th Scientific Meeting of the InterAmerican Society of Hypertension, San Antonio TX	2003
Visiting Professor, Tulane, New Orleans, LA	2003
Brenner Lecture, American Society of Nephrology, San Diego, CA	2003
Invited Speaker, IX meeting of the Brazilian Society of Nephrology, Sao Paolo State, Ribreiro Preto, Brazil	2003
Invited speaker, Renal Symposium, Curitiba, Brazil (M Riella, host)	2003
Invited Speaker, Symposium on Gout, Sanofi, Chicago, IL	2003
Rheumatology Science in Medicine lecture, Montreal Society of Rheumatology	2003
Renal Grand Rounds, Hospital Hôtel-Dieu de Quebec, Quebec	2003
Cardiology Research Rounds, Centre de Recherche de l'Hôpital Laval, Quebec	2003
Medicine Grand Rounds, Centre Hospitalier Universitaire de Sherbrooke, Quebec	2003
Invited Speaker, 3 rd Annual Ray Gifford Symposium, Cleveland, OH	2003
Invited Speaker, Nephrology Update, Cleveland, OH	2003
Medicine Grand Rounds and Renal Grand Rounds, Maine Medical Center, Portland, ME	2003
Invited speaker, Zoological Society of San Diego, San Diego Zoo	2003
Medicine Grand Rounds, University of Florida, December	2003
Nephrology: A Case Based Approach for the Nephrologist, Harvard Course, Naples	2004
Master of Ceremonies, J Robert Cade Lectureship Dinner, Gainesville FL	2004
Everett Anderson Visiting Professor, Univ of Arkansas, Little Rock	2004
State of the Art Lecture, FASEB meeting, Washington DC	2004
Rheumatology and Nephrology Rounds, Dalhousie University, Halifax, Nova Scotia	2004
Medicine Grand Rounds, Memorial University, St Johns, Newfoundland	2004
Invited Speaker, American Society of Hypertension, New York City	2004
Opening Speaker, Summer FASEB conference on Renal Microcirculation and Hemodynamics, Pine Mountain (Callaway Gardens), Georgia	2004
Invited Speaker, 31 st Renal Disease and Electrolyte Disorders, Summer symposium of the University of Colorado, Aspen, Colorado	2004
Medicine Grand Rounds, Univ of Florida, August 2004	2004
Visiting Professor, Univ of Alabama, Birmingham (Dr Suzanne Oparil)	2004
Brigham and Womens Hospital Intensive Board Review, Boston, Speaker	2004
Renal Grand Rounds, Brown Univ, Providence, Rhode Island	2004
Chairman and Organizer of Hypertension Course at Renal Week, ASN, St Louis with 2 lectures and chairing of numerous sessions	2004
Invited Speaker, ASN, St Louis in Renal Toxicology Section	2004
Debate at ASN on the Role of Uric acid in CV Disease, St Louis	2004
Speaker, Salt and Water Club, Sarasota, Florida, 2004	2004
Renal Grand Rounds, Duke Medical Center	2005
NIH Glomerular Disease Symposium, Chairman	2005
Keynote Speaker, South African Hypertension Society, Capetown SA	2005
Invited Speaker, Ray Gifford Symposium, Cleveland Clinic	2005
Medicine Grand Rounds, Cleveland Clinic (with publication in the Cleveland Clinic Journal of Medicine)	2005

Humanities Grand Rounds, the Cleveland Clinic 2005

The Kasperzak Lecturer, Nephrology Update, Cleveland Clinic 2005

Visiting Professor, Mt Sinai School of Medicine, New York 2005

Invited Speaker, 7th Amelia Island Cardiovascular /Kidney Diseases Focus on Oxidative Stress, Amelia Island Plantation, Florida 2005

Keynote Speaker, ERA-EDTA 42nd Congress, Istanbul, Turkey, June 2005

Invited Speaker, Chairman of Several Sessions, and Organizer, 3rd World Congress Of Nephrology, Singapore, June 24-30 2005

Invited Presentation, NIH NHLBI Vascular Biology Section 2005

Medicine Grand Rounds, U of Florida 2005

Keynote Speaker, 41st Australian New Zealand Society of Nephrology meeting, Wellington NZ 2005

Moderator for Angiogenesis Symposium and for MPGN symposia at the ASN, Philadelphia, PA 2005

Invited Speaker, Washington DC Rheumatism Society, Cosmos Club, Washington DC 2005

Key note speaker, 25th Egyptian Society of Nephrology, Sharm El-Sheikh, Egypt, Feb 2006

5th International Conference on Hypertension and the Kidney, Madrid Spain Feb 2006

Video conference Lecture to the Brazilian Society of Nephrology, Curitiba Brazil March 2006

Speaker, Topics in Internal Medicine, U of Florida March 2006

State of the Art Speaker, Harvard CME Board Review Course, Naples, Florida March 2006

Invited Speaker, ISN Forefronts Endothelial Biology Symposium, New York March, 2006

Invited Speaker, University of Toronto, Toronto (Lectures at St Michaels and at Toronto General) May 2006

Invited Speaker, ERA-EDTA Highlights, Italian Society of Nephrology, Rome, Italy May 2006

Herbert Chasis Lecture, Medicine Grand Rounds, NYU, New York City June 2006

Thomas Ferris Lecture, U of Minnesota, Nephrology Graduating Class June 2006

Invited Speaker, Pepsi and Gatorade Sports Science Institute, Chicago June 2006

Invited Speaker, Uric acid Lab Values Advisory Board, Chicago June 2006

Invited Speaker, XIII Puerto Rican Congress of Cardiology July 2006

Invited Speaker, Forefronts in Glomerular Diseases, Nanjing Forum, Sept 2006

Invited Speaker, Sun Yat Sen University, Guanzhou, China Sept 2006

Invited Speaker, Tibet Society of Nephrology (First ever international speaker), Lhasa, Tibet Sept 2006

Invited Speaker, Schechuan University, Western China School of Science, Chengdu, China Sept 2006

Invited Speaker, Beijing University, First Hospital, Beijing China Sept 2006

Medicine Grand Rounds speaker and Renal Grand Rounds Speaker, U of WA Sept 2006

Medicine Grand Rounds and Renal Grand Rounds, U of Florida Sept 2006

Primetime Institute Speaker, Gainesville, Florida Oct 2006

Sir Stanley Davidson Lecturer, Royal College of Physicians of Scotland, Edinburgh Oct 2006

Jaime Herrera Lecturer and Opening Keynote Speaker, Mexican Society of Hypertension

(XIV Sociedad de Hipertension Arterial de Mexico)	Oct 2006
Invited Speaker, ASN Annual Meeting, San Diego	Nov 2006
Invited Speaker, CME Symposium on Uric acid, Henry Ford Medical Center, Detroit Michigan	Jan 2007
Videoconference to Brazilian Society of Nephrology, Sao Paulo	Jan 2007
Visiting Professor, Vanderbilt University, Nashville	Feb 2007
Visiting Professor and Medicine Grand Rounds, Univ of Alabama	Feb 2007
Invited Speaker, 26 th Egyptian Society of Nephrology, Luxor Egypt	Feb 2007
Visiting Professor and Keynote Speaker, Tokyo Renal Conference, Tokyo University	March 2007
Visiting Professor, Showa University, Fugigaoka Hosptial, Yokohama	March 2007
Keynote Speaker, Yokohama City Wide Nephrology Conference, Yokohama	March 2007
Visiting Professor, World Kidney Day Speaker, University of Niigata, Niigata	March 2007
Keynote Speaker, 10 th Sendai Symposium on Hypertension, Tohoku Medical Society	March 2007
Grand Rounds, Family Medicine, University of Florida	March 2007
Special Lecture, College of Journalism, University of Florida	March 2007
Topics of Internal Medicine, Hilton Hotel, Gainesville	April 2007
Transplant Grand Rounds, U of Florida	April 2007
Visiting Professor, Medical University of South Carolina, Charleston, SC	April 2007
Invited Speaker, Ray Gifford Symposium, National Kidney Foundation, Orlando	April 2007
Invited Speaker, World Congress of Nephrology, Rio de Janeiro	April 2007
Invited Speaker and Organizer, Satellite Meeting of World Congress in Buzios, Brazil	April 2007
Pharmacology and Pharmacogenomics Grand Rounds, U Florida	May 2007
Theodore Goodfriend Visiting Professor, Medicine Grand Rounds, Univ of Wisconsin, Madison	June 2007
Invited Speaker, Purine and Pyrimidine Society, Chicago,	June 2007
Invited Speaker, Association of Physicians of Pakistani Descent, Orlando	June 2007
Medicine Grand Rounds, U of Florida	August 2007
History of Medicine Lecture, U of Florida	
Invited Speaker, Chilean Congress of Nephrology	Sept 2007
Peruvian Society of Nephrology and Special Lecture for the 50 th Anniversary of Hospital Loayza of Cayetano Heredia University	Sept 2007
Moderator, Renal Week and ASN meeting, San Francisco	Nov 2007
Donald Seldin Lecture, AHA Annual Meeting, Orlando,	Nov 5, 2007
Invited lecture, American Medical Student Association, local affiliate, Florida	Nov 14, 2007
Rheumatology Grand Rounds, NYU, NYC	Nov 15, 2007
Jaime Herrera Honored Lecture , Instituto de Mexicano de Investigaciones Nefrológicas, Puerto Vallarta, Mexico	Dec 5-8, 2007
Nuzhet Atuk Distinguished Lecture in Medicine, Medicine and Renal Grand Rounds, U of Virginia	Jan 15, 2008

Video Speaker, Southern Chapter of the Indian Society of Nephrology, Myore India Feb 8-10, 2008

CPC, Morbidity and Mortality Conference, University of Florida March 2008

Invited Speaker, Icelandic Renal Association, Reykjavik, Iceland March 2008

The Brigham Update in Internal Medicine Course, Naples Florida March 30-31, 2008

Nephrology: A Case Based Approach for the Nephrologist, Harvard Board course March 2008

Invited Speaker, Magee Research Dept, Obstetrics and Gynecology Dept, Pittsburgh April 2008

Obesity Society Lecture, University of Florida April 2008

Distinguished Visiting Professor, Renal Divisions, Beth Israel and the Brigham Women's Hospital, Boston May, 2008

Hugh DeWardener Lecture, British Renal Society and UK Renal Association, Glasgow, Scotland, May 16-18, 2008

NIH Visiting speaker, NHLBI May, 2008

Community Speaker, Shands Eastside Education Series and Community Relations, University of Florida May, 2008

Cardiology Grand Rounds, University of Florida May, 2008

Hypertension Symposium, Dept of Family, Youth & Community Sciences May 2008

Invited Speaker, XIth Peruvian Society of Nephrology June 2008

ISN Nexus Symposium speaker, Nexus symposium of diabetes, Dublin June 2008

Invited speaker, Mongolian Nephrology Units of Hohhot, Hohhot, Inner Mongolia, China July 2008

Plenary (and first International Speaker), Mongolian society of Nephrology Halaar, Inner Mongolia, China July 2008

CPC, University of Florida August 2008

Invited Speaker, Florida Society of Nephrology September 2008

Invited Speaker, U of Florida Hypertension Center September 2008

Jacksonville Cardiovascular Renal Meeting, Jacksonville Mississippi October 2008

CPC, American Society of Nephrology Meeting, Philadelphia November 2008

University of Colorado Medicine Grand Rounds November 2008

Arab Society of Nephrology, Aswan, Egypt January 2009

Steve Fadem Lecture, NKF of Houston Feb 2009

Gifford Symposium Speaker, NKF Annual Meeting, Nashville March 2009

Invited Speaker, Gilead Inc, Boulder CO March 2009

Grand Rounds, St Joseph Hospital, Denver March 2009

Rochester NY Medicine Grand Rounds April 2009

Speaker, Summit on Food Addiction and the Obesity Epidemic , Islandwood, Bainbridge Island, Washington April 2009

Invited Speaker, Irish Nephrology Society, Dublin May 2009

Invited Speaker, University of Cork City, County Cork, Ireland May 2009

Invited Speaker, Adelaide and Meath Hospital, Dublin May 2009

Invited Speaker, International Society of Nephrology, Milan Italy May 2009

Invited Speaker, Japanese Society of Nephrology, Yokohama June 2009

Invited speaker, Preeclampsia Meeting, Napa Valley California	June 2009
Invited speaker, Aspen Meeting, U of Colorado	July 2009
Plenary Speaker, European Society of Pediatric Nephrology, Birmingham	UK Sep 2009
Plenary Speaker, Kidney Research UK Fellows Day, Henley-on-Thames, UK	Sept 2009
Plenary Speaker, Symposium on Obesity, Birmingham Children's Hospital, UK	Sept 2009
Poster presentation, AHA 63 rd High Blood Pressure Council Meeting, Chicago	Sept 2009
Lecture and Membership, 122 nd American Clinical and Climatological Association, Hot Springs, VA	Oct 2009
Moderator, CPC, American Society of Nephrology Annual Meeting, San Diego	2009
Visiting Professor, U of British Columbia	Nov 2009
Invited Speaker, 7 th World Congress on Insulin Resistance, San Francisco	Nov 2009
Invited Speaker, Berlin Dialysis Seminar 2009, Berlin Germany	Dec 2009
Invited Speaker Baylor College of Medicine Renal Grand Rounds	Feb 2010
Invited Speaker University of Utah, Salt Lake City Medicine Grand Rounds	Feb 2010
Invited Speaker, World Kidney Day, Doha, Qatar	March 2010
Visiting Professor, Kuwait	March 2010
Invited Speaker, Sudanese Society of Nephrology, Khartoum	Feb 2010
Invited Speaker, Cameroon Society of Nephrology, Yaounde	Feb 2010
Invited Speaker, CME, Ethiopian Society of Medicine, Addis Ababa	Feb 2010
Medicine Grand Rounds and Renal Grand Rounds, Univ of Utah, Salt Lake City	Feb 2010
Visiting Professor, Columbia University, New York	April 2010
Invited Speaker, American College of Rheumatology, Chicago	April 2010
Invited Speaker, Biomarkers in Cardiovascular Disease, San Diego CA	April 2010
Forefronts of Nephrology Symposium on Inflammation, Speaker and Organizer, Sylt Germany	May 2010
Plenary Speaker and Honorary Member, Polish Society of Nephrology	May 2010
Plenary Speaker, 12 th Asian Pacific Congress of Nephrology, Seoul Korea	June 2010
Invited Speaker, Nexus Symposium on Renal Fibrosis and 50 th Anniversary of ISN, Geneva Switzerland	
Grand Rounds, Presbyterian St Lukes, Denver, Colorado	July 2010
Invited speaker, 37 th Renal Disease and Electrolyte Disorders Course, UCD, Aspen	July 2010
Medicine Grand Rounds, University of Colorado	August 2010
Invited Speaker, Brazilian Society of Nephrology, Vittoria Brazil	Sept 2010
Invited speaker, Strategic Surveillance, Amway, Grand Rapids Michigan	Sept 2010
Invited Speaker, Renal Grand Rounds, UAB, Birmingham AL	Oct 2010
Invited Speaker, Mexican Society of Nephrology, Puebla Mexico	Oct 2010
Invited Speaker, CME course, Denver Colorado	Oct 2010
Invited speaker, World Congress of Insulin Resistance, Los Angeles CA	Oct 2010
University of Florida, Introductions for Cade Lectureship, Gainesville	Oct 2010
American Society of Nephrology, Lecturer for Renal Week, Denver CO	Nov 2010
Speaker, Astellas Horizon ASN Review, Denver	Nov 2010
Univ of Colorado Physiology Seminar, Boulder CO	Nov 2010
Café Scientifique, Denver CO	Dec 2010
Speaker, International Life Sciences Institute, North America	(by telephone) Dec 2010

Medicine Grand Rounds, and Renal Grand Rounds, U Cal San Diego	Jan 2011
Metabolism Seminar, U Colorado	Jan 2011
Health Fair Speaker, Indian Ridge Elementary School	Jan 2011
Renal Grand Rounds, Drexel (Hahnemann Univ), Philadelphia	Feb 2011
Meira and Shaul G Massry Visiting Professor	March 2011
Nephrology Grand Rounds Harbor UCLA	
Research Lecture, Harbor UCLA	
Medicine Grand Rounds, Harbor UCLA	
Renal Grand Rounds, LongBeach VA	
UC Irvine Renal Grand Rounds	
USC Medicine Grand rounds	
Rnela Grand Rounds, USC	
VA Wadsworth Renal GR	
UCLA Olive View Medicine GR	
VA Greater Los Angeles Area, Renal Grand Rounds	
Speaker, Novartis Thought Leaders Meeting , Las Vegas	March 2011
Speaker, Fourth Annual COAST/UCOP Obesity Symposium, Davis CA	March 2011
Plenary Speaker, Israeli Society of Nephrology, Kfar Blum, Israel	March 2011
Speaker, Danone Symposium, Intetrnational Society of Nephrology Meeting	April 2011
Speaker, 10 th Annual Ray Gifford Symposium, National Kidney Foundation Annual Meeting, Las Vegas	April 2011
Leslie and Grazia Dornfeld Lecturer , George Washington University, Washington DC	April 2011
Cardiology Grand Rounds, University of Colorado, Denver	May 2011
Invited Speaker, University Club, Denver Colorado	May,2011
Invited Speaker, American Society of Hypertension, New York	May 2011
Invited Speaker, Five Continents Cardiovascular Meeting, Beijing Anzhen Medical Center	June 2011
Invited Speaker, Annual Xinjiang Nephrology Meeting, in Urumuchi, China	June 2011
Invited Speaker, Danone Company, Evian, France	July 2011
Invited Speaker, Colorado Renal Conference, Aspen CO	July 2011
Invited Speaker, Argentina Society of Nephrology, Cordoba	Sep, 2011
Inaugural Speaker, Cade Foundation of Cordoba, Argentina	Sep 2011
Invited Speaker, Karolinska Institutie, Stockholm, Sweden	Oct 2011
PlenarySpeaker, Turkish Society of Nephrology, Antalaya, Turkey	Oct 2011
Speaker, Local Nursing Association, Denver	Oct 2011
Moderator, American Society of Nephrology, Philadelphia	Nov 2011
Invited Speaker, Danone Research symposia on Hydration and Kidney, Paris	Nov 2011
Plenary Speaker, Indian Society of Nephrology, Hyderabad, India	Dec2011
Plenary Speaker, 9 th Nephrology, Urology and Transplant Socieity of the SAARC countries (South Asian including Bangladesh, Nepal, Bhutan, India), Dhaka, Bangladesh	Dec2011
Plenary Speaker, Portuguese Society of Nephrology, Villamoura, Portugal	March 2012
Invited Speaker, Nephrology at the Limits, Capetown, South Africa,	March 2012
Invited Speaker, Department of Biochemistry, Univ of Colorado	March 2012

Invited Speaker, Colorado Biology Teachers Association (CBTA), Denver, March 2012
Kids Kidney Research Lecture, Pediatric Symposium, UCL Institute of Child Health, London, March 2012
Renal Grand Rounds, Univ of Colorado April 2012
Amway (Access Business Group) Lecture to Board, April 2012
Chairman, International conference on Podocytes, Miami April 2012
Invited Speaker and Chairman of Basic Science Committee, American Society of Hypertension NYC May 2012
Plenary Speaker, European Dialysis and Transplant Association, Paris, May 2012
Donald Fraley Lecture, Univ of Pittsburgh Medicine Grand Rounds, and Renal Grand Rounds, Univ of Pittsburgh June 2012
Invited Speaker, University of Colorado Renal Conference, Aspen CO July 2012
Invited Speaker, Brazilian Society of Nephrology, Sao Paolo September, 2012
Invited Speaker, Japanese College of Cardiology, Kanazawa Sept, 2012
Invited Speaker, Teikyo University (Dr Shunya Uchida) Sept 2012
Invited Speaker, California American Association of Clinical Endocrinology August, 2012
Medicine Grand Rounds, Stony Brook, New York City Sept, 2012
Invited Speaker, Healthy Agriculture, Health Nutrition, Healthy People, Rockefeller, Foundation Bellagio IT Oct, 2012
Invited Speaker, American Society of Nephrology, San Diego Nov, 2012
Invited Speaker, NIH Sponsored Symposium on Fructose, Wash DC Nov, 2012
Invited Speaker, American College of Rheumatology National Meeting, Wash DC Nov 2012
Invited Speaker, First International Research Workshop on Mesoamerican Nephropathy, San Jose Costa Rica Dec 2012
Medicine Grand Rounds, Florida State University, Tallahassee, FL Jan 2013
Grand Rounds, Childrens Hospital, Aurora CO Jan 2013
Renal Grand Rounds, University of Kansas, Kansas City Jan 2013
Invited Speaker, International Clinic, Lima Peru Feb 2013
Plenary Speaker, Egyptian Society of Nephrology, Cairo Feb 2013
Medicine Grand Rounds, University of Mississippi, Jackson Feb 2013
Medicine Grand Rounds, Univ of Colorado Denver March 2013
Bel Idelson Medicine Grand Rounds, Boston University, Boston March 2013
Pediatric Research Grand Rounds, Denver CO April 2013
Pediatric Grand Rounds, Childrens Hospital May 2013
Medicine Grand Rounds, St Joseph Hospital, Denver May 2013
International Society of Nephrology, Hong Kong (Chairman) June 2013
Invited Speaker, University of Colorado Aspen Renal Conference July 2013
Invited Speaker, 7th Asian Forum on Chronic Kidney Disease and the Annual Meeting of the Thai Society of Nephrology, Pattaya, Thailand Aug 2013
Invited Speaker, Nordic Society of Nephrology, Reykjavik Aug 2013
Guest and Speaker with Prince Daniel of Sweden, Stockholm Sept 2013
Invited Speaker, Karolinska Institute, Stockholm Sept 2013
Invited Guest and Speaker to Prince Daniel, Royal Palace, Stockholm Sept 2013

Invited Speaker, High Altitude Summit Meeting, Breckenridgre	Sept 2013
Invited Speaker, Nutrition Section, Washington University St Louis	Sept 2013
Invited Guest and Speaker, NUSI Foundation, San Diego, California	Sept 2013
Robert Cade Visiting Professor, University of Florida	Oct 2013
Distinguished Visitor to the Admiral of the US Ronald Reagan Aircraft Carrier, Mid-Pacific	Nov 2013
Speaker to Families with Nephrotic syndrome, Nephcure, Denver	Nov 2013
Anschutz Medical Campus Advancement Committee Lecture	Jan 2014
Invited speaker, Cardiovascular Seminar Series, Colorado State University	Jan 2014
Invited speaker, Pharmacy and Pharmaceutical Science Dept, U CO	Feb 2014
Auckland State Bank Visiting Professor, Auckland New Zealand	
Public Lectures (2)	
Invited speaker Sugary Drink Free Pacific by 2030 Symposium	Feb 2014
Invited speaker, Low Carb Conference, Aukcland	
Invited Speaker, University of Otago, Dunedin, NZ	
Invited Speaker, "Health Impact of Modernization" Jeddah, Saudi Arabia	March 2014
Invited Speaker, Egyptian Society of Nephrology, Alexandria, Egypt	March 2014
Medicine Grand Rounds, Hennepin County Medical Center	April 2014
Renal Grand Rounds, University of Minnesota, MPLS	April 2014
Dept of Medicine Innovation Conference	April 2014
Invited Speaker, Danone symposium, Experimental Biol Meetings, S Diego	April 2014
Medicine Grand Rounds, Univ of Colorado	May 2014
Speaker, President's Donor Reception, Univ of Colorado	May 2014
Rocky Mountain Symposium, speaker	May 2014
Invited Speaker, International Symposium on Hydration, Evian France	July 2014
Invited Speaker, Aspen Renal Conference, Aspen CO	July 2014
Invited Speaker, 50 th Peruvian Society of Nephrology, Lima Peru	July 2014
Invited Speaker, German Society of Nephrology, Berlin	September 2014
Invited Speaker, VIth El Salvador Society of Nephrology	October 2014
Opening Address/Plenary Speaker, From Gout to Cardiovascular Disaese, A Central Role for Uric acid, Bologna, Italy	Nov 2014
First Annual Meeting of the Directors of Centers for Genetics, Nutrition and Fitness in Health, Cost Naarfino, Pylos, Greece	Nov 2014
Invited Speaker, American Society of Nephrology, Philadelphia	Nov 2014
Plenary Speaker, Institute Mexican Investigation of Nephrology (IMIN),Cancun	Dec 2014

12. TEACHING

Fellowship Director, Baylor College of Medicine July 2000 to August 2004
T32 Principal Investigator, Baylor College of Medicine July 2003 to August 2003
T32 Principal Investigator, U Florida, September 2003 to Oct 2008
Excellence in Teaching Award, Dept of Internal Medicine, U of Florida 6/08
T32 Principal Investigator, University of CO, 2013 - present

RESEARCH TRAINEES LIST

1. Hideaki Yamabe MD (1987-1989). Visiting scholar with own government funding. Current position: Professor and Chief, Division of Nephrology, Hirosaki University, Japan. **Currently funded.**
2. Hiroyuki Iida, MD (1989-90). Visiting scholar with own government funding. Current position: Professor of Medicine and head of a regional hospital affiliated with Toyama University, Toyama, Japan.
3. Ashio Yoshimura, MD (1990-91). Visiting scholar with own government funding. Current position: Associate Professor of Medicine, Yokohama University, Yokohama, Japan. **Currently funded.**
4. Juergen Floege, MD (1990-92) Visiting scholar with own government funding. Current position: Professor and Chief of Nephrology, Aachen University, Germany. **Currently funded.**
5. Bessie Young, MD (1991-93) Research fellow funded by NIH T32 grant.. Current position: Acting Assistant Professor, University of Washington, Seattle. **funded.**
6. Eudora Eng, MD (1991-93) Research fellow funded by NIH training grant and NKF Research Fellowship. Current position: Assistant Professor, Northwestern University, Chicago IL. **Funded.**
7. Raimund Pichler, MD (1993-96) Research fellow with own funding. Now Assistant Professor at the University of Washington, Seattle.
8. Christian Hugo, MD (1993-96) Research fellow with his own funding but also with NKF research fellowship (1995-96) for which he received the 2nd place award. Current position: Assistant Professor, University of Nurnberg, Germany. **Funded.**
9. Stuart J. Shankland, MD (1994-96) Research fellow with his own government funding (Canada Kidney Foundation). Current position: Professor and Chief, University of Washington, funded NIH. **Funded.**
10. Vuddhidej Ophascharoensuk, MD (1995-97) **Funded** by ISN Research Scholarship. Associate Professor, University of Thailand in Chiang Mai, Thailand. **Funded.**
11. Charles Zachem MD (1995-1996). Univ of WA nephrology fellow. **Currently in private practice.**
12. Catherine Stehman-Breen (1995-1997). Univ of WA on T32 grant. Current position: Clinical Director, Amgen.
13. Masaomi Nangaku, MD (1995-97) **Funded** from Japan. Current position: Associate Professor, Tokyo University, Japan.
14. Jeremy Hughes, MD, PhD (1996-99) Supported by Wellcome Trust Fund. Current position: Professor, University of Edinburgh, Scotland. **Funded.**
15. Susan Thomas, MD (1996-98) Research fellow with her own funding. Current position: Assistant Professor in Pediatric Nephrology, University of Michigan.
16. Leah Haseley, MD (1997-98) Supported by NIH training grant. Current position: Assistant Professor, University of Washington, Seattle.
17. Shinichi Suga, MD (1997-99) **Funded** by the Cardiovascular Research Institute. Current position: Assistant Professor at Saiseikai Maebashi Hospital, Maebashi, Gunma
18. Yoon-Goo Kim, MD (1997-99) Supported with own funding and with an ISN Research Fellowship. Current position: Associate Professor, Sunkyukwan University, Seoul, Korea.

19. J. Ashley Jefferson, MD (1997-99) Supported by Merck extramural grant. Current position: Assistant Professor, University of Washington.
20. Duk-Hee Kang, MD, PhD (1998-2001) Supported with funding from Korean government and with ISN Research Fellowship. Current position: Associate Professor, Ewha University, Seoul, South Korea. Funded.
21. Marilda Mazzali, MD, PhD (1998-2001) Supported with funding from Brazilian government. Current position: Associate Professor, State University of Campinas, Sao Paulo, Brazil. Funded.
22. Takahiko Nakagawa, MD, PhD (2000-03) Supported by NIH (2000-01) and NKF (2002-03). Current position: Associate Professor of Medicine, Kyoto University
23. Susumu Watanabe, MD (2000-2003) Supported in part by his own funding and by NIH. Current position: Assistant Professor at Showa University, Japan.
24. John Kanellis, MD, PhD (2000-02) Supported by his own funding. Current position: Assistant Professor, Monash University, Melbourne, Australia
25. Ryuji Ohashi, MD, PhD (2001-03) Supported by his own funding (2001-02) and by NIH grant (2002-03). Postdoctoral Associate from Nippon Medical School. Current position: Fellow in Pathology (Renal) at Washington University
26. David Long, PhD (2003-2005) Supported by his own funding. Postdoctoral fellow from University College London, UK. Current position: Research Fellow at University of London, UK
27. Karen Price, PhD. (2003-2005). Supported by NIH grant. Postdoctoral fellow from University College, London. Current position: Research Fellow at University of London, UK
28. Michael Gersch MD (2004-2006). Nephrology Fellow, T32 training grant. Current position: Assistant Professor, Division of Nephrology, U of Florida (left for private practice opportunity, Arkansas, April 2008).
29. Sirirat Reungji MD (2005-2007). From the Khon Kaen University in Thailand. Supported by government grant from Thailand. Current position: Associate Professor, Khon Kaen University.
30. Waichi Sato, MD.(2005-present) Japanese Research Fellow from Nagoya University Graduate School of Medicine, Japan. Current position, Assistant Professor, Nagoya University Graduate School of Medicine (under Seiichi Matsuo)
31. Marcelo Heinig (2005-2007). ISN fellow from Universidades Pontificia Catolica do Parana, Curitiba, Brazil. Current position: Fellow, University of Curitiba
32. Pietro Cirillo MD (2006-present) Fellow from Foggia University, Italy on Italian Society of Nephrology fellowship grant. Current position: Fellow, Foggia University, Italy (L Gesualdo) under
33. Christine Gersch PhD (2004-2007), Research Fellow on T32 grant. Current position: Faculty, Dept of Urology, Univ of Florida (left with husband for private practice opportunity in Arkansas, April 2008)
34. Tomoki Kosugi (2007-2009), Nagoya University Graduate School of Medicine, Research Fellow with Japanese funding
35. Mohamed Shafiu (2007- 2008), from Nephrology Fellowship Program. Working on genomics of urate metabolism with Dr Julie Johnson and Dr RJ Johnson.

36. Takahiro Nakayama (2007-2010) from Showa University, Fujigaoka Hospital. Funded from Japan.
37. Michiko Shimada (2008-2011) from Hirosaki University School of Medicine, Hirosaki, Japan.
38. L Gabriela Sanchez-Lozada (2008-2010) from Cardiologia University, Mexico City, Mexico
39. MyPhuong Le, (2010- 2012), Assistant Professor, Univ of CO
40. Jeffrey Thomas (2010- 2012, Private Practice
41. Shinichiro Inabe, (2012- 2014) Instructor, Nagoya University
42. Takuji Ishimoto (2010-2014), Assistant Professor, Nagoya University
43. Yoshifuru Tamura, 2011-2013, Assistant Professor, Tokyo
44. Javier Alfonso 2013-2015
45. Thomas Jensen, 2014-2016

PhD THESIS COMMITTEE MEMBER

Mathew Parker (Pathology, Univ of Florida) 2008
 Youin Tain (Physiology, Univ of Florida) 2007
 Inge Hamming (Pathology, University of Groningnen, Netherlands) 2007
 Witcha Imaram (Chemistry, Univ of Florida) 2008
 MyPhuong Le (Pharmacology, Univ of Florida) 2008
 Monical Sandoval (Pharmacology, Univ of Colorado) 2014

13. RESEARCH INFORMATION

A. RESEARCH SUPPORT (Last 5 Years)-(Has had NIH Funding Since 1987)

JOHNSON, R.J.

ACTIVE

NIH 1R01DK080764-01 (Johnson, Garin) 09/01/11-08/31/14 2.4 calendar months
 NIH/NIDDK \$150,000 (50k to UC Denver, 100k to Univ Florida)
 CD80 Expression on Podocytes and the Pathogenesis of Minimal Change Disease
 The goal is to study the role of CD80 in Minimal Change Disease.

NIH 2P01AI045897-11A1A Tolerance Approach to Xenotransplantation (Sachs)
 07/15/11-06/30/16 0.6 calendar months \$50,865/yr to RJ laboratory
 Goal: To develop a model of xenotransplantation involving donation of pig kidneys to baboons

NIH 1UC4DK101108-01 PERL:A multicenter clinical trial of allopurinol to prevent GFR loss in T1D
 PI: Alessandro Doria, MD 09/30/2013 – 06/30/2018
 Colorado site PI: David Maahs RJ: 2.5% effort

NIH NHLBI R21 1R21HL113809-01A1 Proinflammatory Role of Uric acid in Lung Disease: Novel models and Clinical Validation.
Johnson (coPI with Richard Wright) \$150,000 07/01/2013-6/30/2015 0.6 months

NIH 2 T32 DK007135-40A1 Renal Electrolytes and Hypertension (Johnson)
07/01/2014 – 06/30/2019 1.2 months \$250,000
Training grant for fellows. Act as a principal investigator and oversees recruitment, placement, and evaluation of the fellows entering the program.

VA Merit Fructokinase and Nondiabetic- and Aging-associated Chronic Kidney Disease
7/1/2014-6/30/2018 150k/yr
To study the role of fructokinase in nondiabetic chronic kidney disease and aging associated kidney disease

DOD PR130106 Dehydration as a cause of chronic kidney disease: Role of Fructokinase (Johnson) 07/01/2014 – 06/30/2017 1.8 calendar \$250,000

5K01DK095930-02 (Lanaspa) 7/01/2012-06/30/17 .48 calendar months
NIH \$166,100 (to K awardee)
Role of Fructokinase in Acute kidney Injury
R Johnson Mentor

NIH K23DK088833 (Jalal) 09/15/10-08/31/15 .48 calendar months
NIH \$166,100
Is Uric Acid a Mediator of Endothelial Dysfunction in Patients with Chronic Kidney Disease?
R Johnson Mentor

Danone Research Foundation (Johnson) 06/01/2014–05/31/2015
Role of fructokinase in acute and chronic dehydration
06/01/2014 – 05/31/2015 1.2 calendar \$90,000

Thomas Maren Foundation Chronic Mountain Sickness: Searching for Etiologies and Treatments (Johnson) 04/01/2010-03/31/2012 .6 calendar months \$50,000
To perform a clinical trial with N acetylcysteine and acetazolamide for Chronic Mountain Sickness in Cerro de Pasco, Peru.

Amway Nutrilite Foundation, Developing Neutraceutical Inhibitors of Fructokinase
August 2013-10/31/2015 175,000 direct costs

JDRF Models Predicting Accelerated Cardiorenal Complications of Type 1 Diabetes 0.4 months
2/1/2013-2/31/2015 JDRF (Rewers)

Pending
Applications Submitted/Pending

NIAAA R21 (Johnson) 4/1/2015-3/30/2018
Could Alcohol-Induced Liver Injury be a Fructose- and Uric acid Dependent Disease?
Goal: To test the hypothesis that alcohol induced fatty liver is dependent on fructokinase

NIDDK R01 (Johnson) 4/1/2015-3/30/2018
Dietary Salt has an Unrecognized Role in Modulating Energy Intake and Metabolic Syndrome
Goal: To determine if salt, a noncaloric additive, can stimulate obesity via a fructokinase-dependent mechanism

R41 DK104432-01 (Johnson) 4/1/2015-3/30/2016
Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity (STTR phase I application)
Goal: To develop fructokinase inhibitors for the development of obesity

Funded but Expired:

1. **Forrest Pharmaceuticals**. Grant to investigate pharmacokinetics of ketoconazole in PD patients. 1983 R Johnson PI
2. **NIH First Award**, Myeloperoxidase H₂O₂ halide system in glomerular injury, (DKR29-DK39068) RJ PI, 8/87-7/31/92, 70k/year
Accompanied by a NIH Research Career Development Award (8/87-7/92)
(DK02412)

3. **Northwest Kidney Foundation Grants**
Mechanisms of Neutrophil Mediated GN, 1986-1987, RJ PI, 35k
Role of Platelets in Neutrophil Mediated GN, 1988-1989, RJ PI, 35k
Platelet and platelet growth factors in GN, 1990-1991, RJ PI, 35k
Role of Platelets in GN, 1991-1992, RJ PI, 35k
Role of SPARC in Resolution of glomerular injury, 1992-1994, RJ PI, 35k

4. **National Kidney Foundation Grants**
Richard Johnson 1984-1985 Hoffman La-Roche (WGCouser, PI)
Eudora Eng 1991-1993 Role of Sparc in glomerular disease
Christian Hugo 1995-1996
Leah Hasely, 1997-1998 Role of PDGF in crescentic nephritis
Takahiko Nakagawa, 2002-2004, Role of uric acid in Renal Progression

5. ISN Fellows

V. Ophascharoensuk Thailand 1995-1997
DH Kang, Korea 1997-1998
M Mazzali, Brazil, 1997-1998

4. **Platelets in Immune Glomerular Injury (RO1-DK43422) 8/91-7/31/96**
Principal investigator
8/91-7/30/97 100,000/yr

5. Mesangial Response to Injury (RO1-DK43422)

Principal Investigator
8/1/97 – 7/31/00 \$150,000/yr

6. Glomerular Endothelial Cell Proliferation in the Hemolytic Uremic Syndrome (RO1-DK52121)

Principal Investigator
9/30/96 - 8/31/00 \$117,000/yr
(Co-Investigator is Stuart Shankland)

13. Osteopontin in Tubulointerstitial Disease (Project Leader RJ)

(Renal Response to Injury. Subproject 4 Role of Osteopontin in Tubulointerstitial Injury
NIH George O'Brien Center, Project 4, **NIDDK- DK47659**
9/98 - 8/03 \$ 68,060/yr

14. Baxter Extramural Grant "Role of HCV in Glomerulonephritis in Peru" (NEA 96975)

Principal Investigator
1/96 - 1/99 (extended to 1/00) \$ 40,000/yr
A study of epidemiology of renal disease in Peru.

15. Merck Extramural Grant "Role of Uric Acid in Tubulointerstitial Disease and Hypertension"

Principal Investigator
6/98 – 6/00 \$ 60,000/yr
A study of pathogenesis of elevated uric acid in renal disease

10. **NIH/NIDDK "George M. O'Brien Research Center Grant - Renal Inflammation: Mechanisms and Consequences" (DK-64233) (Principal Investigator)**

Investigator, Project 1 10%
04/01/03 - 09/0/05 \$120,000/1st yr

The objective of this center grant is to further our understanding of the mechanisms involved in the initiation, maintenance and resolution of inflammation in renal disease.

Project 1 investigates the role of uric acid in the initiation of inflammation.

16. NIH Concept Development Administrative Supplement to Parent Grant RO-1-DK-64233

9/1/03-8/31/04 \$50,000/yr
Principal Investigator 10%

This grant is to provide monies to develop a clinical research application to investigate the role of uric acid in hypertension and renal disease.

12. **University of Florida Development Opportunity Fund**

Title: Urate Radical: A Potential Mediator
PI: R. J. Johnson

CoInvestigator: Alex Angerhofer
May 1, 2004 – April 30, 2005 \$90,000 Direct

To initiate pilot studies on the role of the urate radical in cardiovascular disease.

14. **NIH/NHLBI “Role of Uric Acid in Hypertension and Renal Disease” (1R01 HL68607-01)**

Principal Investigator 30%
1/01/02 – 012/31/06 \$250,000/yr

A study to better understand the pathogenic mechanisms involved in progressive renal disease and the renal mechanisms underlying the development of hypertension.

15. **Scios Pharmaceuticals** Studies on the Role of BNP in Renal Fibrosis

Principal Investigator Wei Mu
2005-2006 \$100,000 direct costs

The objective is to study the role of BNP in mitigating renal fibrosis in animal models.

16. **Sanofi Pharmaceuticals**

Principal Investigator Ahsan Ejaz, Consultant R Johnson (0%)
2005-2006 50,000 direct costs

The objective is to determine the effect of recombinant uricase to prevent acute renal failure in animal models of renal disease

17. **Scios Role of BNP** to Prevent Acute Renal Failure in Subjects undergoing aortic aneurysm repair. 2005-2007 \$366,000 direct costs PI Ahsan Ejaz, Consultant R Johnson (0%)

The objective is to determine if prophylactic administration of BNP can prevent acute renal failure in patients undergoing elective and or emergent aneurysm repair.

18. **Florida Dept of Health.** James and Esther King Biomedical Research Program. Smoking as a Novel Risk Factor for Progression of Renal Disease. Team Science Project. 625,000/yr

9/1/05-8/30/07 \$625,000/yr R Johnson PI (15% effort)

19. 5 T32DK007518-19 (Johnson, 10%) 7/1/85-6/30/12 1.2 calendar
NIH/NIDDK \$219,000/yr
“Pre and Postdoctoral Training in Nephrology and Hypertension”

The goal of this grant is to provide training of predoctoral and postdoctoral candidates into basic and clinical research related to nephrology with the purpose of providing the necessary training to become independent investigators.

20. **5 K23 DK064587 (Feig)** 09//03-8/08 0.12 calendar
NIH-NIDDK “Mentored Clinical Scientist Development Award (K23 award) (Feig PI, Johnson mentor, 1%) \$144,357
“Uric Acid in Childhood Hypertension”

The goal of this project is to investigate whether allopurinol will lower blood pressure in

adolescents with essential hypertension and whether lowering uric acid provides clinical benefit in children undergoing renal transplantation.

21. 1RO1 HL079352-01A1 (Segal) 8/1/05-4/30/09 1.2 calendar
NIH/NHLBI \$500,000

Uric Acid and Hypertension in African Americans

A clinical study of the role of diuretic induced hyperuricemia in inducing blood pressure elevation and endothelial dysfunction in the African American hypertensive population.

22. Novel Mechanisms and therapy targeting dysfunction endothelium (Grant)

7/01/06-6/30/09 1.2 calendar

Juvenile Diabetes Research Foundation (JDRF)

\$147,500

Project 2: Role of Uncoupling of VEGF with Endothelial NO in Diabetic Nephropathy (Johnson)

This is a multi-investigator plan of research studying the mechanism of endothelial injury and repair in type I diabetes. Project 2 will test the hypothesis that defects in endothelial NO production will result in a compensatory increase in VEGF, which then engages dysfunctional pathways.

23. 2RO1 DK052121-15 (Johnson) 9/30/96-7/31/10 1.2 calendar
NIH/NIDDK \$205,000

Endothelial Cell in Progressive Renal Disease

The major goals of this project are to study of the role of impaired angiogenesis in progressive renal disease.

24. R34 Reduction of Uric Acid to Prevent Hypertension--RAPHY Trial (Feig)

NIH/NICHD 2/10/09-1/31/10 1.2 calendar

Pediatric Obesity & Metabolic Syndrome

\$100,000

A planning grant to develop a multicenter trial to determine if lowering uric acid can prevent hypertension.

25. 3R01DK052121-15S1--Stimulus supplement (Johnson)

NIH/NIDDK 9/11/09-09/10/10 1.2 calendar

Endothelial Cell in Progressive Renal Disease

\$63,582

A stimulus to help support Dr Chris Rivard and to develop better methods for measuring endothelial function

26. RC4 DK090859 (Johnson) 09/30/10-08/31/13 2.4 calendar
months

NIH/NIDDK

\$1,799,943

Development of inhibitors of AMP Deaminase Isoform 2 as a Mechanism for Treating Diabetes, Obesity and Hypertension

The goal is to identify novel pathways for the etiology of obesity and metabolic syndrome, and potentially new therapies.

27. 2RO1 HL068607 (Johnson) 01/01/02-03/31/12 3.6 calendar

months

NIH/NHLBI \$281,839

Role of Uric Acid in Cardiovascular and Renal Disease

The goal is to better understand the pathogenic mechanisms involved in how fructose and uric acid may have a role in hypertension, metabolic syndrome and renal disease

28. **RC4 DK090859** (Johnson) 09/30/2010-08/31/2013

Development of inhibitors of AMP Deaminase Isoform 2 as a Mechanism for Treating Diabetes, Obesity and Hypertension

Goal: To identify novel pathways for the etiology of obesity and metabolic syndrome, and potentially new therapies.

29. **Questcor** (Johnson) 04/01/2012-04/30/2013

Effect of ACTH on CD80 Expression in Podocytes

Goal: To determining if ACTH blocks CD80 expression in response to activation of Toll-like receptors.

30. **Amway Nutrilite Foundation** (Johnson) 08/1/2012-07/31/2013

Developing of a Botanical for Obesity

Goal: To screen botanicals for fructokinase inhibitors.

14. BIBLIOGRAPHY

BOOKS

1. Comprehensive Clinical Nephrology, (First edition, eds RJ Johnson and J Feehally, Harcourt, London, 2000, 900 pp)
2. Comprehensive Clinical Nephrology, (Second edition, eds RJ Johnson and J Feehally, Elsevier, London, 2003, 1400 pp)
3. Comprehensive Clinical Nephrology, (Third edition, eds J Feehally, J Floege, and RJ Johnson, Elsevier, London, 2007, 1242 pp)
4. The Sugar Fix, 2008, by Richard J Johnson with Tim Gower, Rodale Press, NY and Simon and Schuster, 5 printings
5. Comprehensive Clinical Nephrology, (Fourth edition, eds J Feehally, RJ Johnson, and Juergen Floege, Elsevier, London, 2010)
6. The Fat Switch, by Richard J Johnson, Mercola.com, Hoffman Estates, IL Printed in USA, 2012, 311 pp
7. Comprehensive Clinical Nephrology, Fifth edition, eds RJ Johnson, J Floege, and JF Feehally, Elsevier, 2014

Guest Editorship, Seminars of Nephrology, “Uric acid in Hypertension and Renal Disease”,

January 2005 (eds, RJ Johnson and J Stewart Cameron)

Guest Editorship Seminars of Nephrology: Uric acid in CardioRenal Disease, Nov 2011

HIGHLY CITED (top 10)

1. 1044 Citations (ref 256) **Johnson RJ**, Kang D-H, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension* 2003 Jun;41(6):1183-1190
2. 946 citations Feig DI, Kang DH, **Johnson RJ**. Uric acid and cardiovascular risk. *N Engl J Med* 2008; 359:1811-21. PMID: PMC2684330
3. 899 Citations (ref 209) Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S and **Johnson, RJ**: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension*, 38:1101-6, 2001
4. 794 Citations (ref 61) - **Johnson RJ**, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE and Wilson R. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *New Engl J Med* 328:465-470, 1993.
5. 642 citations (ref 234) Kang D-H, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R and **Johnson RJ**: A role for uric acid in the progression of renal disease. *J Am Soc Nephrol* 2002 Dec;13(12):2888-2897.
6. 638 citations (ref 281) Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, **Johnson RJ**. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2005; 67:1739-1742
7. 619 citations (reference 314) Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, **Johnson RJ**. A causal role for uric acid in fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol* Epub Oct 18, 2005; 2006 Mar;290(3):F625-31
8. 549 citations (ref 223) Mazzali M, Kanellis J, Han L, Feng L, Xia Y-Y, Chen Q, Kang D-H, Gordon KL, Watanabe S, Nakagawa T, Lan HY, **Johnson RJ**: Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. *Am J Physiol Renal Physiol* June 2002;282(6):F991-997
9. 524 Kanellis, J, Watanabe, S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, **Johnson RJ**: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. *Hypertension* 2003; 41(6): 1287-1293
10. 521 Citations (ref 48) - **Johnson RJ**, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, and Schwartz SM. Renal injury from angiotensin II-mediated hypertension. *Hypertension* 19(5):464-474, 1992

ORIGINAL CONTRIBUTIONS (Peer-Reviewed, h factor 110, i10-index 426)

1. **Johnson RJ**, Johnson JR: Paragonimiasis in Indochinese refugees: Roentgenographic findings with clinical correlations. *Amer Rev Resp Dis* 1983;128:534-38.
2. **Johnson RJ**, Jong EC: Ciguatera fish poisoning - Caribbean and Indo-Pacific Fish

- Poisoning. *West J Med* 1983;132:872-874
3. Martin TR, Sandblom RL, **Johnson RJ**: Adult respiratory distress syndrome following thrombolytic therapy for pulmonary embolism. *Chest* 1983;83:151-153.
 4. **Johnson RJ**, Dunning SB, Minshew BH, Jong EC: Successful praziquantel treatment of paragonimiasis following bithionol failure: a case report. *Amer J Trop Med Hyg* 1983;32(6):1309-1311.
 5. **Johnson RJ**, Nolan CM, Wang SP, Shelton WR, Blaser MJ: Persistent *Campylobacter jejuni* infection in an immunocompromised patient. *Ann Intern Med* 1984;100: 832-834.
 6. **Johnson RJ**, Ramsey PG, Gallagher N, Ahmad S: Fungal peritonitis in patients on peritoneal dialysis: Incidence, clinical features and prognosis. *Am J Neph* 1985; 5:169-175.
 7. **Johnson RJ**, Blair A, Ahmad S: Ketoconazole kinetics in chronic peritoneal dialysis. *Clin Pharm Ther* 1985; 37:325-329.
 8. **Johnson RJ**, Jong EC, Dunning SB, Carberry WL, Minshew BH: Paragonimiasis: Diagnosis and use of praziquantel in treatment. *Rev Inf Dis* 1985;2(7):200-206.
 9. Ahmad S, **Johnson RJ**, Hillier S, Shelton WR, Rinaldi MG: Fungal peritonitis caused by *Lecythophora mutabilis*. *J Clin Micro* 1985;22(2):182-186.
 10. Perkinson DT, Baker PJH, Couser WG, **Johnson RJ**, Adler S: Membrane Attack Complex Deposition in Experimental Glomerular Injury. *Am J Path* 1985;120:121-128.
 11. Jong EC, Wasserheit J, **Johnson RJ**, Carberry W, Agosti J, Dunning S, Clark H: Praziquantel for treatment of Clonorchis/Opisthorus Infectious: Report of a double-blind placebo-controlled trial. *J Inf Dis* 1985;152(3): 637-640.
 12. Couser WG, Abrass C, Ochi R, Adler S, Johnson R, Kelly MR, Lovett D, Ratazzi T. Mechanisms of glomerular injury in immune complex disease. *Kidney Int* 1985; 28:569-583
 13. Adler S, Baker PJ, **Johnson RJ**, Ochi RF, Pritzl P, Couser WG: Complement membrane attack complex stimulates production of oxygen metabolites by cultured rat mesangial cells. *J Clin Invest* 1986;77:762-777.
 14. **Johnson RJ**, Couser WG, Chi EY, Adler S, Klebanoff SJ: New mechanism for glomerular injury: Myeloperoxidase-hydrogen peroxide-halide system. *J Clin Invest* 1987;79:1379-1387.
 15. **Johnson RJ**, Klebanoff SJ, Ochi RF, Adler S, Baker P, Sparks L, Couser WG: Participation of the myeloperoxidase-H₂O₂-halide system in immune complex nephritis. *Kidney Int* 1987;32:342-349.
 16. **Johnson RJ**, Guggenheim S, Klebanoff SJ, Ochi RF, Wass A, Baker PJ, Schulze M, Couser WG: Morphologic correlates of glomerular oxidant injury induced by the myeloperoxidase-hydrogen peroxide-halide system of the neutrophil. *Lab Invest* 1988;58:294-301.
 17. **Johnson RJ**, Alpers CE, Pritzl P, Schulze M, Baker P, Pruchno C, Couser WG: Platelets mediate neutrophil-dependent immune complex nephritis in the rat. *J Clin Invest* 1988;82:1225-1235.
 18. **Johnson RJ**, Couser WG, Alpers CE, Vissers M, Schulze M, Klebanoff SJ: The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo. *J Exp Med* 1988;168:1169-1174.
 19. Schulze M, Baker PJ, Perkinson DT, **Johnson RJ**, Ochi RF, Stahl RAK, Couser WG: Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. *Kidney Int* 1989;35:60-68.

20. Stahl RAK, Adler S, Baker PJ, **Johnson RJ**, Chen Y-P, Pritzl P, Couser WG: Cyclosporin A inhibits prostaglandin E₂ formation by rat mesangial cells in culture. *Kidney Int* 1989;35:1161-1167.
21. Horgan C, **Johnson RJ**, Gauthier VJ, Mannik M, Emlen W: Binding of double-stranded DNA to glomeruli of rats in vivo. *Arth Rheum* 1989;32:298-305.
22. Alpers CE, Marchioro TL, **Johnson RJ**: Monoclonal immunoglobulin deposition disease in a renal allograft: probable recurrent disease in a patient without myeloma. *Am J Kidney Dis* 1989;13:418-423.
23. Pruchno CJ, Burns MW, Schulze M, **Johnson RJ**, Baker PJ, Couser WG: Urinary excretion of the C5b-9 reflects disease activity in passive Heymann nephritis. *Kidney Int* 1989;36:65-71.
24. Fingerle J, **Johnson R**, Clowes AW, Majesky MW, Reidy MA: Role of platelets in smooth muscle cell proliferation and migration after vascular injury in the rat carotid artery. *Proc Natl Acad Sci* 1989; 86:8412-8416.
25. Baker PJ, Ochi RF, Schulze M, **Johnson RJ**, Campbell C, Couser WG: Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. *Am J Pathol* 1989;5:185-194.
26. **Johnson RJ**, Alpers CE, Pruchno C, Schulze M, Baker PJ, Pritzl P, Couser WG: Mechanisms and kinetics of platelet and neutrophil localization in immune complex nephritis. *Kidney Int* 1989; 36:780-789.
27. Wells CG, **Johnson RJ**, Qingli L, Bunt-Milam AH, Kalina RE: Retinal oxalosis: A clinicopathologic report. *Arch Ophthalmol* 1989;107:1638-1643.
28. **Johnson RJ**, Garcia RL, Pritzl P, Alpers CE: Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat. *Am J Pathol* 1990;136:369-374.
29. **Johnson RJ**, Couser WG: Editorial Review. Hepatitis B Infection and renal disease: clinical immunopathogenetic and therapeutic considerations. *Kidney Int* 1990; 37:663-676.
30. **Johnson RJ**: Platelets in inflammatory glomerular injury. *Sem Nephrol* 1991;11:276-284.
31. **Johnson RJ**, Pritzl P, Iida H, Alpers CE: Platelet-complement interactions in mesangial proliferative nephritis in the rat. *Am J Pathol* 1991;138:313-322.
32. Pruchno CJ, Burns M, Schulze M, **Johnson RJ**, Baker PJ, Alpers CE, Couser WG: Urinary excretion of the C5b-9 membrane attack complex of complement is a marker of immune disease activity in autologous immune complex nephritis. *Am J Pathol* 1991; 138:203-211.
33. **Johnson RJ**, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzl P, Gordon K, Gown AM: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: α -smooth muscle actin is a marker of mesangial cell proliferation. *J Clin Invest* 1991;87:847-858
34. Iida H, **Johnson RJ**: Platelet-derived growth factor (PDGF) and PDGF-receptor gene expression are upregulated in mesangial proliferative nephritis::an effect mediated by complement and platelets.*Acta Medica et Biol* 1991;39(S):103-104
35. Floege J, **Johnson RJ**, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. *Kidney Int* 1991;40:477-488.
36. Yoshimura A, Gordon K., Alpers CE, Floege J, Pritzl P, Ross R, Couser WG, Bowen-Pope

- DF, **Johnson RJ**: Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. *Kidney Int* 1991;40:470-476.
37. Iida H, Seifert R, Alpers CE, Gronwald RGK, Phillips PE, Pritzl P, Gordon K, Gown AM, Ross R, Bowen-Pope DF, **Johnson RJ**: Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. *Proc Natl Acad Sci (USA)*, 1991;88:6560-6564
 38. Schulze M, Donadio JV Jr, Pruchno CJ, Baker PJ, **Johnson RJ**, Stahl RAK, Watkins S, Martin DC, Wurzner R, Gotze O, Couser WG: Elevated urinary excretion of C5b-9 complex in membranous nephropathy. *Kidney Int* 1991;40:533-538.
 39. Couser WG, Ochi RF, Baker PJ, Schulze M, Campbell C, **Johnson RJ**: C6 depletion reduces proteinuria in experimental nephropathy induced by a nonglomerular antigen. *J Am Soc Nephrol* 1991;2:894-901.
 40. Alpers CE, Hudkins KL, Pritzl P, **Johnson RJ**: Mechanisms of clearance of immune complexes from peritubular capillaries in the rat. *Am J Pathol* 1991;139:855-867.
 41. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, **Johnson RJ**. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. *Kidney Int* 1992;42:297-309.
 42. Alpers CE, Hudkins KL, Gown AM, **Johnson RJ**. Enhanced expression of "muscle-specific" actin in glomerulonephritis. *Kidney Int* 1992;41:1134-1144.
 43. Floege JF, Alpers CE, Burns MW, Pritzl P, Gordon K, Couser WG, **Johnson RJ**: Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. *Lab Invest* 1992;66:485-497.
 44. Lovett DH, **Johnson RJ**, Marti H-P, Martin J, Davies M., Couser WG: Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. *Am J Pathol* 1992;141:85-98
 45. **Johnson RJ**, Yamabe H, Chen Y-P, Campbell C, Gordon K, Baker P, Lovett D, Couser WG: Glomerular epithelial cells secrete a glomerular basement membrane- degrading metalloproteinase. *J Am Soc Nephrol* 1992;2:1388-139
 46. **Johnson RJ**, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. *Hypertension* 1992;19:464-474.
 47. **Johnson RJ**, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers CE, Ross R: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. *J Exp Med* 1992;175:1413-1416.
 48. Alpers CE, Seifert RA, Hudkins KL, **Johnson RJ**, Bowen-Pope DF: Developmental patterns of PDGF B-chain, PDGF-receptor, and α -actin expression in human glomerulogenesis. *Kidney Int* 1992;42:350-359
 49. Floege J, **Johnson RJ**, Gordon K, Yoshimura A, Campbell C, Iruela-Arispe L, Alpers CE, Couser WG: Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. *Kidney Int* 1992;42:573-585.
 50. Floege JF, Alpers CE, Sage EH, Pritzl P, Gordon K, **Johnson RJ**, Couser WG: Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury *in vivo*: Expression of antiadhesive proteins and cytoskeletal changes. *Lab Invest* 1992;67:486-497.
 51. Schulze M, Pruchno CJ, Burns M, Baker PJ, **Johnson RJ**, Couser WG: Glomerular C3c

localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. *Am J Pathol* 1993;142:179-187.

52. Floege JF, Eng E, Alpers E, Lindner V, Alpers CE, Young B, Reidy MA, **Johnson RJ**: Rat glomerular mesangial cells synthesize basic FGF: Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. *J Clin Invest* 1992;90:2362-2369.
53. **Johnson RJ**, Iida H, Yoshimura A, Floege J, Bowen-Pope DF: Platelet-derived growth factor: A potentially important cytokine in glomerular disease. *Kidney Int* 1992;41:590-594.
54. **Johnson RJ**, Floege JF, Yoshimura A, Iida H, Couser WG, Alpers CE: The activated mesangial cell: a glomerular "myofibroblast"? *J Am Soc Nephrol* 1992;2:5190-5197.
55. Floege JF, **Johnson RJ**, Couser WG: Mesangial cells in the pathogenesis of progressive glomerular disease in animal models. *Klinische Wochenschrift* 1992;70:857-864.
56. Floege J, **Johnson RJ**, Alpers CE, Fatemi-Nainie S, Richardson C, Gordon K, Couser WG: Visceral glomerular epithelial cells can proliferate *in vivo* and synthesize platelet-derived growth factor B-chain. *Am J Pathol* 1992;142:637-650.
57. Alpers CE, Seifert RA, Hudkins KL, **Johnson RJ**, Bowen-Pope DF: PDGF-receptor localizes to mesangial cells, parietal epithelial, and interstitial cells in human and primate kidneys. *Kidney Int* 1993;43:286-294.
58. Floege J, Eng E, Young BA, Couser WG, **Johnson RJ**: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. *Kidney Int* 1993;43:369-380.
59. **Johnson RJ**, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Wilson R: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *New Engl J Med* 1993;328:465-470.
60. Iida H, Izumino K, Asaka M, Entani C, Takata M, **Johnson RJ**: Glomerulosclerosis in the rat induced by repeated immune-mediated mesangial cell injury. *Jap J Nephrol* 1993;35:905-912.
61. Floege J, Eng E, Young BA, Alpers CE, Barrett TB, Bowen-Pope DF, **Johnson RJ**: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. *J Clin Invest* 1993;92:2952-2962
62. Alpers CE, Hudkins KL, Ferguson M, **Johnson RJ**, Schatteman GC, Bothwell M: Nerve growth factor receptor expression in fetal, mature, and diseased human kidneys. *Lab Invest* 1993;69:703-713.
63. Floege J, Eng E, Young BA, **Johnson RJ**: Factors involved in the regulation of mesangial cell proliferation *in vitro* and *in vivo*. *Kidney Int* 1993;43:547-554.
64. **Johnson RJ**: Cytokine networks and the pathogenesis of glomerulonephritis. *J Lab Clin Med* 1993; 121:190-192.
65. Floege J, **Johnson RJ**: Cytokines in renal inflammation. *Curr Opin Neph and Hyper* 1993;2:449-457.
66. **Johnson RJ**, Floege J, Couser WG, Alpers CE: Role of platelet-derived growth factor in glomerular disease. *J Am Soc Nephrol* 1993;4:119-128.
67. **Johnson RJ**, Lovett D: *In vivo* gene transfer, Koch's postulates, and renal disease. *J. Clin Invest* 1993; 92:2568.

68. Giachelli CM, Pichler R, Lombardi D, Denhardt D, Alpers CE, Schwartz SM, **Johnson RJ**: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. *Kidney Int* 1994;45:515-524.
69. Breyse P, Couser WG, Alpers CE, Nelson K, Gaur L, **Johnson RJ**: Membranous nephropathy and formaldehyde exposure. *Annals Int Med* 1994;120:396-397.
70. Eng E, Veniant M, Floege J, Fingerle J, Alpers CE, Menard J, Clozel J-P, **Johnson RJ**: Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. *Am J Hypertension* 1994;7:177-185.
71. Savin VT, **Johnson RJ**, Couser WG: C5b-9 increases albumin permeability of isolated glomeruli *in vitro*. *Kidney Int* 1994;46:382-387.
72. Sirois MG, De Lima WT, de Brum Fernandes AJ, **Johnson RJ**, Plante GE, Sirois P: Effect of PAF on rat lung vascular permeability: role of platelets and polymorphonuclear leukocytes. *Br J Pharmacol* 1994;111:1111-1116.
73. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, Schwartz SM, **Johnson RJ**: Tubulointerstitial Disease in Glomerulonephritis: Potential Role of Osteopontin (Uropontin). *Am J Path* 1994;144:915-926.
74. Alpers CE, Hudkins KL, Floege J, **Johnson RJ**: Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. *J Am Soc Nephrol* 1994;5:201-210
75. Baker AJ, Mooney A, Hughes J, Lombardi D, **Johnson RJ**, Savill J: Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. *J Clin Invest* 1994;94:2105-2116.
76. Alpers CE and **Johnson RJ**: Facteurs de croissance et glomérule: du développement aux glomérulonéphrites. *Actualites Nephrologiques* pp. 31-50, 1994.
77. **Johnson RJ**, Yamabe H, Couser WG, Alpers CE, Davis C and Gretch D: Renal manifestations of hepatitis C virus infection. *Kidney Int* 1994;46:1255-1265.
78. **Johnson RJ**, Gretch DR, Yamabe H, Couser WG and Willson R: Interferon- α for the treatment of membranoproliferative glomerulonephritis associated with hepatitis C virus infection: Do we have enough data or are we still in the learning stage? (Editorial) *J Nephrol* 1994;7:336-9.
79. Yamabe H, **Johnson RJ**, Gretch DR, Alpers CE, Osawa H, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y, Sato A, Onodera K: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon- α . *Am J Kidney Dis* 1995;25:67-69.
80. **Johnson RJ**, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, Hart J, Willson R: Hepatitis C virus-associated glomerulonephritis. Effect of α -interferon therapy. *Kidney Int* 1994;46:1700-1704.
81. **Johnson RJ**, Lombardi D, Eng E, Gordon K, Alpers CE, Pritzl P, Floege J, Young B, Pippin J, Couser WG, Gabbiani G: Modulation of experimental mesangial proliferative nephritis by interferon- γ . *Kidney Int* 1995;47:62-69.
82. Wong L, Yamasaki G, **Johnson RJ**, Friedman SL: Induction of β -Platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. *J Clin Invest* 1994;94:1563-1569
83. Eng E, Floege J, Young BA, Couser WG, **Johnson RJ**: Does extracellular matrix expansion

- in glomerular disease require mesangial cell proliferation? *Kidney Int* 1994;45:S45-S48
84. **Johnson RJ**, Lovett D, Lehrer RI, Couser WG, Klebanoff SJ: Role of oxidants and proteases in glomerular injury. *Kidney Int* 1994;45:352-359.
 85. Floege J, Radeke HR, **Johnson RJ**: Glomerular cells in vitro versus the glomerulus in vivo. *Kidney Int* 1994;45:360-368.
 86. Eng E, Floege J, Young BA, Alpers CE, Couser WG, **Johnson RJ**: Is mesangial cell proliferation required for extracellular matrix expansion in glomerular disease? *Contrib Neph* 1994;107:156-162
 87. Couser WG, **Johnson RJ**: Mechanisms of progressive renal disease in glomerulonephritis. *Am J Kidney Dis* 1994;23:193-198.
 88. **Johnson RJ** (Principal Discussant):Nephrology Forum: The glomerular response to injury: Progression or resolution? *Kidney Int* 1994;45:1769-1782.
 89. Burdmann EA, Young BA, Andoh TF, Evans A, Alpers CE, Lindsley J, **Johnson RJ**, Couser W, Bennett WM: Mechanisms of cyclosporine-induced interstitial fibrosis. *Tranpl Proc* 1994;26:2588-2589.
 90. Willson RA, **Johnson RJ**: Glomerulonephritis in chronic HBV and HCV. *Int Med* 1994;15:18-31.
 91. Young BA, **Johnson RJ**, Alpers CE, Eng E, Gordon K, Floege J, Couser WG: Cellular events in the evolution of experimental diabetic nephropathy. *Kidney Int* 1995;47:935-944.
 92. Davis CL, Gretch DR, Perkins JD, Harris AW, Wener MH, Alpers CE, Lesniewski R, Lee W, de la Rosa C, **Johnson RJ**, Carithers RL: Hepatitis C-associated glomerular disease in liver transplant recipients. *Liver Transplant and Surgery* 1995;1:166-175.
 93. Yamabe H, **Johnson RJ**, Gretch DR, Fukushi K, Osawa H, Miyata M, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y, Onodera K: Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. *J Am Soc Neph* 1995;6:220-223.
 94. Couser WG, **Johnson RJ**, Young BA, Yeh CG, Toth CA, Shah D, Rudolph AR: The effects of soluble recombinant receptor 1 on complement-mediated experimental glomerulonephritis. *J Am Soc Neph* 1995;5:1888-1894.
 95. Alpers CE, Hudkins KL, Ferguson M, **Johnson RJ**, Rutledge JC: Platelet-derived growth factor A-chain expression in developing and mature human kidneys and in Wilms' Tumor. *Kidney Int* 1995;48:146-154.
 96. Young BA, Burdmann EA, **Johnson RJ**, Alpers CE, Giachelli C, Eng E, Andoh T, Bennett WM, Couser WG: Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. *Kidney Int* 1995;48:439-449.
 97. Young BA, Burdmann EA, **Johnson RJ**, Andoh T, Bennett WM, Couser WG, Alpers CE: Cyclosporine A induced arteriopathy in a rat model of chronic cyclosporine nephropathy. *Kidney Int* 1995;48:431-438.
 98. Gallay BJ, Alpers CE, Davis CL, Schultz MF, **Johnson RJ**: Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases. *Am J Kidney Dis* 1995;26:662-667.
 99. Stehman-Breen C, Alpers CE, Couser WG, Willson R and **Johnson RJ**: Hepatitis C virus associated membranous glomerulonephritis. *Clin Nephrol* 1995;44:141-147.
 100. Pichler R, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland S, Alpers CE, Bennett WM, Couser WG, **Johnson RJ**: Pathogenesis of cyclosporine

- nephropathy: roles of angiotensin II and osteopontin. *J Am Soc Neph* 1995;6(4):1186-1196.
101. Floege J, **Johnson RJ**: Multiple roles for platelet-derived growth factor in renal disease. *Mineral Electrolyte Metab* 1995;21:271-282.
 102. Pichler R, Giachelli C, Young B, Alpers CE, Couser WG and **Johnson RJ**: The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. *Mineral Electrolyte Metab* 1995;21:317-327
 103. Stehman-Breen C, Willson R, Alpers CE, Gretch D, **Johnson RJ**: Hepatitis C virus-associated glomerulonephritis. *Current Opinion in Neph and Hypertension* 1995;4:287-294.
 104. **Johnson RJ**, Alpers CE, Stehman-Breen C, Willson R and Couser WG: Pathogenesis of hepatitis C virus-associated glomerulonephritis. *Nephrology* 1995;1:11-16.
 105. Savill J, **Johnson RJ**: Glomerular remodelling after inflammatory injury. *Exp Nephrol* 1995;3:149-158.
 106. Alpers CE, **Johnson RJ**: Growth factors and the glomerulus: relationships between development and injury. *Adv Nephrol* 1995;24:33-52.
 107. **Johnson RJ**: The mystery of the antineutrophil cytoplasmic antibodies. *Am J Kidney Dis* 1995;26:57-61
 108. Hugo C, Pichler R, Meek R, Gordon K, Kyriakides T, Floege J, Bornstein P, Couser WG and **Johnson RJ**: Thrombospondin I is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF *in vivo*. *Kidney Int* 1995;48:1846-1856.
 109. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, **Johnson RJ**: Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. *Am J Path* 1995;147:1715-1727
 110. Nangaku M, **Johnson RJ**: Molecular biology of glomerulopathy and its potential clinical approach. *Medicina* 1995;32:1933-1941. (In Japanese)
 111. Brandt J, Pippin J, Schulze M, Hänsch GM, Alpers CE, **Johnson RJ**, Gordon K, Couser WG: Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. *Kidney Int* 1996;49:335-343.
 112. Nelson DR, Davis GL, Lau JYN, **Johnson RJ**, Gretch D, Willson R, Mizokami M: Anti-GOR in chronic HCV patients with membranoproliferative glomerulonephritis. *J Hepatol* 1996;24:248.
 113. Kleim V, **Johnson RJ**, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6- nephrectomized rats. *Kidney Int* 1996;49:666-678.
 114. Pichler RH, Bassuk JA, Hugo C, Reed JM, Eng E, Gordon KL, Pippin J, Alpers CE, Couser WG, Sage EH, **Johnson RJ**: SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-mediated mesangial cell proliferation in vitro. *Am J Path* 1996;148:1153-1169
 115. Hugo C, Hugo C, Pichler R, Gordon K, Schmidt R, Amieva M, Couser WG, Furthimayer H, **Johnson RJ**: The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. *J Clin Invest* 1996;97:2499-2508.
 116. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, **Johnson RJ**, Dousa TP: Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. *J Clin Invest* 1996;98(2):262-70.

117. Nangaku M, Meek R, Pippin J, Gordon K, Morgan BP, **Johnson RJ**, Couser WG: Transfected CD59 protects mesangial cells from injury induced by antibody and complement. *Kidney Int* 1996;50:257-266.
118. Shankland SJ, Pippin J, Pichler R, Gordon KL, Friedman S, Gold L, **Johnson RJ**, Couser WG: Differential expression of transforming growth factor- β isoforms and receptors in experimental membranous nephropathy. *Kidney Int* 1996;50:116-124
119. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, Andoh TF, Lombardi DM, Schwartz SM, Bennett WM, Alpers CE, Sage EH, **Johnson RJ**, Couser WG: SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. *Kidney Int* 1996;50:1978-1989.
120. Shankland SJ, Coats SR, Hugo CR, Coats SR, Nangaku M, Pichler RH, Gordon KL, Pippin J, Roberts JM, Couser WG, **Johnson RJ**: Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. *Kidney Int* 1996;50:1230-1236
121. Nangaku M, Pippin J, Richardson C, Schulze M, Young BA, Alpers CE, Gordon KL, **Johnson RJ**, Couser WG: Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. *Kidney Int* 1996;50:2054-2062.
122. Wener MH, **Johnson RJ**, Sasso EH, Gretch DR: Hepatitis C virus and rheumatic disease -- an editorial. *J Rheumatol* 23:953-959, 1996
123. **Johnson RJ**, Pichler R, Hugo C, Nangaku M, Savill J and Alpers CE: Glomerular healing. *Contrib Nephrol* 1996;118:54-58
124. Alpers CE, Pichler R, **Johnson RJ**: Phenotypic features of cortical interstitial cells potentially important in fibrosis. *Kidney Int* 1996;49(54):S28-S31.
125. **Johnson RJ**: Glomerulosclerosis and atherosclerosis: parallel cell biologic processes. American Heart Association - Council on Kidney Disease and High Blood Pressure, Newsletter, Winter 1996, pp.16-21).
126. **Johnson RJ**: The role of cytokines and growth factors in glomerulonephritis: a chance for future therapeutic intervention. *Nephron* 1996;73:506-514.
127. Floege J, Hackmann B, Kliem V, Kriz W, Alpers CE, **Johnson RJ**, Kühn KM, Koch KM, Brunkhorst R: Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats.: a podocyte disease. *Kidney Int* 1997;51:230-243.
128. Nangaku M, Quigg RJ, Shankland SJ, Okada N, **Johnson RJ**, Couser WG: Overexpression of Crry protects mesangial cells from complement-mediated injury. *J Am Soc Nephrol* 1997;8:223-233.
129. Hughes J, **Johnson RJ**, Mooney A, Jugo C, Gordon K, Savill J: Neutrophil fate in experimental glomerular capillary injury in the rat. Emigration exceeds in situ clearance by apoptosis. *Am J Pathol* 1997;150:223-234.
130. O'Brien JG, Farmer P, Battistini B, **Johnson RJ**, Zaharia F, Sirois P: Effects of tranexamic acid and aprotinin on PAF-induced vascular permeability in normal, thrombocytopenic or neutropenic rats. *Inflamm Res* 1997;46:S145-S146.
131. Nangaku M, Shankland SJ, Kurokawa K, Bomszyk K, **Johnson RJ**, Couser WG: Cloning of a new human gene with short consensus repeats using EST database. *Immunogenetics* 1997;46:99-103.
132. Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, Roberts JM,

- Couser WG, **Johnson RJ**: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27^{Kip1}. *Kidney Int* 1997;51:1088-1099.
133. Malyankar U, Almeida M, **Johnson RJ**, Pichler R, Giachelli CM: Osteopontin regulation in cultured rat renal epithelial cells: *Kidney Int* 1997;51:1766-1773.
134. Magil A, Pichler R, **Johnson RJ**: Osteopontin in chronic puromycin aminonucleoside nephrosis. *J Am Soc Nephrol* 1997;8:1383-1390.
135. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, Couser WG, **Johnson RJ**: A new model of renal microvascular endothelial injury. *Kidney Int* 1997;52:182-194.
136. **Johnson RJ**: Have we ignored the role of oncotic pressure in the pathogenesis of glomerulosclerosis? *Am J Kid Dis* 1997;29:147-152.
137. Hugo C, Shankland SJ, Bowen-Pope DF, Couser WG, **Johnson RJ**: Extraglomerular origin of the mesangial cell after injury. A new role of the juxtaglomerular apparatus. *J Clin Invest* 1997;100:786-794.
138. Shankland SJ, Floege J, Thomas SE, Nangaku M, Pippin J, Henne K, Hockenberry DM, **Johnson RJ**, Couser WG: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. *Kidney Int* 1997;52:404-413.
139. Zachem CR, Alpers CE, Way W, Shankland SJ, Couser WG, **Johnson RJ**: A role for P-selectin in neutrophil and platelet infiltration in immune complex glomerulonephritis. *J Am Soc Nephrol* 1997;8:1838-1844
140. **Johnson RJ**, Shankland S, Hugo C, Pichler R, Nangaku M, McClarinon M, Ophascharoensuk V, Zachem C, Kuan CJ, Thomas SE, Meek R, Couser WG: Mesangial response to injury: mechanisms of progression and repair. *Nephrology* 1997;3:S639-S643.
141. Couser WG, Nangaku M, Shankland S, **Johnson RJ**: Molecular mechanisms of experimental glomerulonephritis: an overview. *Nephrology* 1997;3:S633-S637.
142. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, **Johnson RJ**, Couser WG: Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. *Kidney Int* 1997;52:1570-1578.
143. **Johnson RJ**. Cytokines, growth factors and renal injury: where do we go now? *Kidney Int* 1997;63:52-56.
144. **Johnson RJ**. What mediates progressive glomerulosclerosis? The glomerular endothelium comes of age. *Am J Path* 1997;151:1179-1181
145. Hugo C, Nangaku M, Shankland SJ, Gordon KL, Amieva M, Couser WG, Furthmayr H, **Johnson RJ**: The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injury. *Kidney Int* 1998;54:1934-1944
146. **Johnson RJ**, Schreiner GF: Hypothesis: the role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. *Kidney Int* 1997;52:1169-1179
147. O'Brien JG, Battistini B, Farmer P, **Johnson RJ**, Zaharia F, Plante GE, Sirois P: Aprotinin, an antifibrinolytic drug, attenuates bradykinin-induced permeability in conscious rats via platelets and neutrophils. *Can J Physiol Pharmacol* 1997;75:741-749.
148. Nangaku M, **Johnson RJ**, Couser WG: Glomerulonephritis and complement regulatory proteins. *Exp Nephrol* 1997;5:345-354.

149. Lan HY, Yu XQ, Yang N, Nikolic-Paterson DJ, Mu W, Pichler R, **Johnson RJ**, Atkins RC: De novo glomerular osteopontin expression in rat crescentic glomerulonephritis. *Kidney Int* 1998;53:136-145
150. Yu XQ, Nikolic-Paterson DJ, Mu W, Giachelli C, Atkins RC, **Johnson RJ**, Lan HY: Functional role of osteopontin in experimental crescentic glomerulonephritis in the rat. *Proceedings of the Association of American Physicians*, 1998;110:50-64.
151. Hugo C, Shankland S, Pichler RH, Couser WG, **Johnson RJ**: Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. *Kidney Int* 1998;53:302-311
152. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, Morgan BP, **Johnson RJ**, Couser WG: CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. *J Am Soc Nephrol* 1998;9:590-597.
153. Ophascharoensuk V, Pippin J, Gordon KL, Shankland SJ, Couser WG, **Johnson RJ**: Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation: An experimental model of murine crescentic glomerulonephritis. *Kidney Int* 1998;54:416-425.
154. Floege J, Burg M, Hugo C, Gordon KL, van Goor H, Reidy M, Couser WG, Koch K-M, **Johnson RJ**: Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. *J Am Soc Neph* 1998;9:792-801.
155. Thomas SE, Anderson S, Gordon KL, Oyama TT, Shankland SJ, **Johnson RJ**: Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. *J Am Soc Nephrol* 1998;9:231-242.
156. Giachelli CM, Lombardi D, **Johnson RJ**, Murry CE, Almeida M: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. *Am J Path* 1998;152:353-358, 1998.
157. Thomas SE, Lombardi D, Giachelli C, Bohle, A, **Johnson RJ**: Osteopontin expression, tubulointerstitial disease and essential hypertension. *Am J Hypertension* 1998;11:954-961.
158. Thomas SE, Andoh TF, Pichler RH, Shankland SJ, Couser WG, Bennett WM, **Johnson RJ**: Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. *Kidney Int* 1998;53:897-908
159. Stehman-Breen CO, Emerson S, Gretch D, **Johnson RJ**: Risk of death among chronic dialysis patients infected with hepatitis C virus. *Am J Kid Dis* 1998;32:629-634.
160. Stehman-Breen C, **Johnson RJ**: Hepatitis C virus-associated glomerulonephritis. *Adv Int Med* 1998;43:79-97.
161. Shankland SJ, **Johnson RJ**: TGF- β in glomerular disease. *Mineral Electrolyte and Metabolism* 1998;24:168-173.
162. Nangaku M, Shankland S, Couser WG, **Johnson RJ**: A new model of renal microvascular injury. *Curr Opin Nephrol Hypert* 1998;7:457-462.
163. **Johnson RJ**, Hugo C, Haseley L, Pichler R, Bassuk J, Thomas S, Suga S, Couser WG, Shankland SJ: Mechanisms of progressive glomerulosclerosis and tubulointerstitial fibrosis. *Clin Exper Nephrol* 1998;2:307-312.
164. Stehman-Breen C, Alpers CE, Fleet WP, **Johnson RJ**: Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. *Nephron* 1999;81:37-40.
165. Hudkins KL, Giachelli CM, Cui Y, Couser WG, **Johnson RJ**, Alpers CE: Osteopontin expression in fetal and mature kidney. *J Am Soc Neph* 1999;10:444-457.

166. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, **Johnson RJ**: Salt-sensitive hypertension develops after short-term exposure to angiotensin II. *Hypertension* 1999;33:1013-1019.
167. Hugo C, Pichler RP, Schulze-Lohoff E, Pröls F, Adler S, Krutsch, HC, Murphy-Ullrich J, Couser WG, Roberts DD, **Johnson, RJ**: Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation *in vitro* and *in vivo* in experimental mesangial proliferative glomerulonephritis in the rat. *Kidney Int* 1999;55:2236-2249.
168. Yu XQ, Fan J-M, Nikolic-Paterson DJ, Yang N, Mu W, Pichler R, **Johnson RJ**, Atkins RC, Lan HY: IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. *Am J Pathol* 1999;154:833-841.
169. Kim Y-G, Alpers CE, Brugarolas J, **Johnson RJ**, Couser WG, Shankland SJ: The cyclin kinase inhibitor p21^{CIP1/WAF1} limits glomerular epithelial cell proliferation in experimental glomerulonephritis. *Kidney Int* 1999;55:2349-2361.
170. Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P, Liaw L, Schmidt R, Shankland SJ, Alpers CE, Couser WG, **Johnson RJ**: Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. *Kidney Int* 1999;56:571-580.
171. **Johnson RJ**, Gordon K, Suga S, Griffin K, Bidani A: Renal injury and salt-sensitive hypertension after exposure to catecholamines. *Hypertension* 1999;34:151-159.
172. Hughes J, **Johnson RJ**: Role of FAS (CD95) in tubulointerstitial disease induced by unilateral ureteric obstruction. *Am J Physiol* 1999;277:F26-F32.
173. Haseley LA, Hugo C, Reidy MA, **Johnson RJ**: Dissociation of mesangial cell migration and proliferation in experimental glomerulonephritis. *Kidney Int* 1999;56:964-972.
174. Hurtado A, Asato C, Escudero E, Stromquist C, Urcia J, Hurtado MD, de la Cruz S, Wener M, Zavala R, **Johnson RJ**: Clinicopathologic correlations in lupus nephritis in Lima, Peru. *Nephron* 1999;83:323-330.
175. **Johnson RJ**, Kivlighn SD, Kim Y-G, Suga S, Fogo A: Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular and renal disease. *Am J Kid Dis* 1999;33:225-234.
176. Jefferson JA, **Johnson RJ**: Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). *J Nephrol* 1999;12(5):297-307.
177. Hurtado A, Escudero E, Stromquist C, Urcia J, Hurtado ME, Gretch D, Watts D, Russell K, Asato C, **Johnson RJ**. Distinct patterns of glomerular disease in Lima, Peru. *Clinical Nephrology* 2000;53(5):325-332.
178. Bassuk J, Pichler R, Rothmier JD, Phippen J, Gordon K, Meek RL, Bradshaw AD, Lombardi D, Strandjord TP, Reed M, Sage EH, Couser WG, **Johnson R**: Induction of TGF- β by the matricellular protein SPARC in a rat model of glomerulonephritis. *Kidney Int* 2000 Jan;57(1):117-128.
179. Hudkins KL, Giachelli CM, Eitner F, Couser WG, **Johnson RJ**, Alpers CE: Osteopontin expression in human crescentic glomerulonephritis. *Kidney Int* 2000 Jan;57(1):105-116.
180. Hughes J, Nangaku M, Alpers CE, Shankland SJ, Couser WG, **Johnson RJ**: C5b-9 membrane attack complex mediates cell apoptosis in experimental glomerulonephritis. *Am J Physiol* 278(5):F747-F757, 2000.
181. Haseley LA, Pippin JW, Huang XR, Lan HY, Gordon KL, Seifert RA, **Johnson RJ**: The role of platelet-derived growth factor in a murine model of crescentic nephritis. *Nephrology*

2000 Oct ;5:193-199.

182. Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, **Johnson RJ**, Lai KN, Lan HY: Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. *Kidney Int* 2000;58:1469-1480.
183. **Johnson RJ**, Gordon KL, Giachelli C, Kurth T, Skelton MM, Cowley, Jr AW: Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. *J Hypertension* 2000;18:1497-1505.
184. Kim Y-G, Suga S, Kang D-H, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, **Johnson RJ**: Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. *Kidney Int* 2000;58:2390-2399.
185. Kim Y-G, Huang X-R, Suga S, Mazzali M, Tang D, Metz C, Bucala R, Kivlighn S, **Johnson RJ**, Lan HY: Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. *Molecular Med* 2000;6(10):837-848.
186. Tallquist MD, Klinghoffer RA, Heuchel R, Mueting-Nelsen, PF, Corrin PD, Heldin C-H, **Johnson RJ**, Soriano P: Retention of PDGFR- β function in mice in the absence of phosphatidylinositol 3'-kinase and phospholipase C γ signaling pathways. *Genes and Development* 2000;14:3179-3190.
187. Jefferson JA, **Johnson RJ**. Treatment of Hepatitis C-associated glomerular disease. *Semin Nephrol* 2000;20(3):286-292.
188. **Johnson RJ**, Tuttle KR. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. *Hypertension* 2000;35:E10-E10. <http://www.hypertensionaha.org>.
189. **Johnson RJ**. New Insights into the pathogenesis of proteinuria. *Am J Kidney Dis* 2000;36:214-219.
190. Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, Abraham JA, Hughes J, **Johnson RJ**, Schreiner GF: Vascular Endothelial Growth Factor (VEGF₁₂₁) protects rats from renal infarction in thrombotic microangiopathy. *Kidney Int* 2001;60(4):1297-1308.
191. Kang DH, Anderson S, Kim Y-G, Mazzali M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, **Johnson RJ**. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. *Am J Kid Dis* 2001;37(3):601-611.
192. Ray PE, Suga S, Liu X-H, Huang X, **Johnson RJ**: Chronic potassium depletion induces renal injury, salt sensitivity, and hypertension in young rats. *Kidney Int* 2001;59:1850-1858.
193. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson, JA, Hughes J, Kivlighn SD, Lan HY, **Johnson RJ**: Hyperuricemia exacerbates chronic cyclosporine nephropathy. *Transplantation* 71(7) April 2001; 900-905.
194. Lombardi DM, Viswanathan M, Vio CP, Saaverdra JM, Schwartz SM, **Johnson RJ**: Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor- dependent. *Nephron* 2001;87:66-74.
195. Kang DH, Kim Y-G, Andoh TF, Gordon KL, Suga S, Mazzali M, Jefferson JA, Hughes J, Bennett W, Schreiner GF, **Johnson RJ**: Post-cyclosporine mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. *Am J Physiology: Renal Physiology* 2001 April;280(4):F727-F736.

196. Kang DH, Joly AH, Oh S-W, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, **Johnson RJ**: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. *J Am Soc Nephrol* 2001;12(7):1434-1447.
197. Kang DH, Hughes J, Mazzali M, Schreiner GF, **Johnson RJ**: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. *J Am Soc Nephrol* 2001;12(7):1448-1457.
198. Rodríguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gómez-Garre D, Largo R, Egido J, **Johnson RJ**: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. *Kidney Int* 2001 June;59(6):2222-2232.
199. Franco M, Tapia E, Santamaría J, Zafra I, García-Torres R, Gordon KL, Pons H, Rodríguez-Iturbe B, **Johnson RJ**, Herrera-Acosta J: Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. *J Am Soc Nephrol* 12(11): 2263-2271, Nov 2001.
200. Tuttle KR, Short RA, **Johnson RJ**: Sex differences in uric acid and risk factors for coronary artery disease. *Am J Cardiol* 87:1411-1414, 2001.
201. Jandeleit-Dahm K, Wu LL, **Johnson RJ**, Cox A, Kelly D, Cooper ME, Gilbert RE: Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression in subtotal nephrectomy. *Nephrology* 2001;6:290-297.
202. Mazhar AR, **Johnson RJ**, Gillen D, Stivelman JC, Ryan MJ, Davis CL and Stehman-Breen CO: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. *Kidney Int* 60(1):324-332, July 2001.
203. Hudkins KL, Le QC, Segerer S, **Johnson RJ**, Davis CL, Giachelli CM, Alpers CE: Osteopontin expression in human cyclosporine toxicity. *Kidney Int* 60(2):635-640, Aug 2001.
204. Shao J, Miyata T, Yamada K, Hanafusa N, Wada T, Gordon KL, Inagi R, Kurokawa K, Fujita T, **Johnson RJ**, Nangaku M: Protective role of nitric oxide in a model of thrombotic microangiopathy in rats. *J Am Soc Nephrol* 12(10): 2088-2097, Oct 2001.
205. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang D-H, Gordon KL, Lan HY, Kivlighn S, **Johnson RJ**: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension* 2001 Nov;38(5):1101-1106.
206. Andoh TF, **Johnson RJ**, Lam T, Bennett WM: Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. *Am J Transpl* 2001 Sep1(3):222-227.
207. Suga S, Phillips MI, Ray PE, Raleigh JA, Vio CP, Kim Y-G, Mazzali M, Gordon KL, Hughes J, **Johnson RJ**: Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. *Am J Physiol:Renal Physiol* 281(4):F620-F629, Oct 2001.
208. Jefferson JA, Suga S, Kim Y-G, Pippin J, Gordon KL, **Johnson RJ**, Couser WG: Intravenous immunoglobulin protects against experimental thrombotic microangiopathy. *Kidney Int* 60:1018-1025, Sept 2001.
209. Quiroz Y, Pons H, Gordon KL, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, **Johnson RJ**, Rodríguez-Iturbe B: Mycophenolate mofetil

- prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. *Am J Physiol* 2001;July 281(1):F38-F47.
210. Rodríguez-Iturbe B, Pons H, Herrera-Acosta J, Schreiner GF, **Johnson RJ**: Role of immunocompetent cells in nonimmune renal diseases. *Kidney Int* 2001;59:1626-1640.
 211. **Johnson RJ**, Herrera-Acosta J, Schreiner GF, Rodríguez-Iturbe B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. *New Engl J Med* 2002 Mar;346 (12): 913-923.
 212. Rodríguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chávez M, Herrera-Acosta J, **Johnson RJ**, Pons HA: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. *Am J Physiol - Renal* 2002;282(2):F191-F201.
 213. Jefferson JA, Escudero E, Hurtado ME, Pando J, Tapia R, Swenson ER, Prchal J, Schreiner GF, Schoene RB, Hurtado A, **Johnson RJ**: Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. *Lancet* 2002 Feb; 359:407-408.
 214. Suga S, Mazzali M, Ray PE, Kang D-H, Johnson RJ: Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency. *Kidney Int* March 2002; 61:951-958.
 215. Kang D-H, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, **Johnson RJ**: Role of the microvascular endothelium in progressive renal disease. *J Am Soc Neph* 2002 Mar; 13(3):806-816 (review).
 216. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, **Johnson RJ**, Hughes J: Osteopontin – a molecule for all seasons. *Quart J Med* 2002 95:3-13.
 217. Watanabe S, Kanellis J, Nakagawa T, Han L, Ohashi R, Lan H, Feng L, **Johnson RJ**: Reducing uric acid as a means to prevent cardiovascular and renal disease. *Expert Opinion on Therapeutic Patents* 2002;12(2):193-199.
 218. Mazzali M, Hughes J, Dantas M, Liaw L, Steitz S, Alpers CE, Pichler RH, Lan HY, Giachelli CM, Shankland SJ, Couser WG, **Johnson RJ**: Effects of cyclosporine in osteopontin null mice. *Kidney Intl* July 2002;62(1):78-85.
 219. Mazzali M, Kanellis J, Han L, Feng L, Xia Y-Y, Chen Q, Kang D-H, Gordon KL, Watanabe S, Nakagawa T, Lan HY, **Johnson RJ**: Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. *Am J Physiol Renal Physiol* June 2002;282(6):F991-997.
 220. Kang D-H, Nakagawa T, Feng L, **Johnson RJ**: Nitric oxide modulates vascular disease in the remnant kidney model. *Am J Pathol* 2002 Jul;161(1):239-248.
 221. Jefferson JA, Escudero E, Hurtado M-E, Kelly JP, Swenson ER, Wener MH, Burnier M, Maillard M, Schreiner GF, Schoene RB, Hurtado A, **Johnson RJ**: Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia. *Am J Kid Dis* 2002 Jun;39(6):1135-1142.
 222. Li JH, Zhu H-J, Huang XR, Lai KN, **Johnson RJ**, Lan HY: Smad7 inhibits fibrotic effect of TGF- β on renal tubular epithelial cells by blocking Smad2 activation. *J Am Soc Nephrol* 2002 Jun;13(6):1464-1472.
 223. Nangaku M, Yamada K, Garipey CE, Miyata T, Inagi R, Kurokawa K, Yanagisawa M, Fujita T, **Johnson RJ**: ET β receptor protects the tubulointerstitium in experimental thrombotic microangiopathy. *Kidney Int* 2002 Sep;62(3):922-928.
 224. Hugo C, Kang D-H, **Johnson RJ**: Sustained expression of thrombospondin-1 is

associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model. *Nephron* 2002 Apr;90(4):460-470.

225. Watanabe S, Kang D-H, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, **Johnson RJ**: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. *Hypertension* Sep 2002;40(3):355-360.
226. **Johnson RJ**, Rodriguez-Iturbe B, Schreiner GF, Herrera-Acosta J: Hypertension: a microvascular and tubulointerstitial disease. *J Hypertens* 2002 Jun;20 (suppl 3) S1-S7. (review)
227. Rodriguez-Iturbe B, Quiroz Y, Herrera-Acosta J, **Johnson RJ**, Pons HA: The role of immune cells infiltrating the kidney in the pathogenesis of salt-sensitive hypertension: *J Hypertens* 2002 Jun;20 (suppl 3):S9-14. (review)
228. Rodriguez-Iturbe B, Herrera-Acosta J, **Johnson RJ**: Interstitial inflammation, sodium retention, and the pathogenesis of nephrotic edema: a unifying hypothesis. *Kidney Int* 2002 Oct;62(4):1379-1384.
229. Sánchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaría J, Nakagawa T, Rodríguez-Iturbe B, **Johnson RJ**, Herrera-Acosta J: Mild hyperuricemia induces glomerular hypertension in normal rats. *Am J Physiol Renal Physiol* 2002 Nov;283(5):F1105-F1110.
230. Kang D-H, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R and **Johnson RJ**: A role for uric acid in the progression of renal disease. *J Am Soc Nephrol* 2002 Dec;13(12):2888-2897.
231. Quiroz Y, Herrera-Acosta R, **Johnson RJ**, Rodriguez-Iturbe B. Mycophenolate mofetil treatment in conditions different from organ transplantation. *Transplant Proc* 2002 Nov;34(7):2523-2526.
232. Alpers CE, Hudkins KL, Segerer S, Sage EH, Pichler R, Couser WG, Johnson RJ, Bassuk JH. Localization of SPARC in developing, mature, and chronically injured human allograft kidneys. *Kidney Int* 2002 Dec;62(6):2073-2086.
233. Suga S, Yasui N, Yoshihara F, Horio T, Kawano Y, Kangawa K, **Johnson RJ**: Endothelin A receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms. *J Am Soc Neph* 2003 Feb;14(2):397-406.
234. Li J, Huang XR, Zhu H-J, Oldfield M, Cooper M, Truong LD, **Johnson RJ**, Lan HY: Advanced glycation end products activate Smad signaling via TGF- β -dependent and independent mechanisms: implications for diabetic renal and vascular disease. *FASEB J* 2004 Jan;18(1):176-8
235. Kang D-H, **Johnson RJ**. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. *Curr Opin Nephrol Hypertens* 2003 Jan;12(1):43-49.
236. Wesson JA, **Johnson RJ**, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman J, Hughes J. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. *J Am Soc Nephrol* 2003;14(1):139-147.
237. Nakagawa T, Mazzali M, Kang D-H, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, and **Johnson RJ**: Hyperuricemia causes glomerular hypertrophy in the rat. *Am J Nephrol* 2003 Jan-Feb;23(1):2-7.
238. Mazzali M, Jefferson A, Ni Z, Vaziri ND, **Johnson RJ**: Microvascular and

- tubulointerstitial injury associated with chronic hypoxia-induced hypertension. *Kidney Intl* 2003 Jun;63:2088-2093.
239. Hare JM, Johnson RJ: Uric acid predicts clinical outcomes in heart failure: insights regarding the role xanthine oxidase and uric acid in disease pathophysiology. *Circulation* 2003 Apr 22;107(15):1951-1953 (editorial).
 240. Jefferson JA, Simoni J, Escudero E, Hurtado M-E, Swenson ER, Wesson DE, Schreiner GF, Schoene RB, **Johnson RJ**, Hurtado A. Increased oxidative stress following acute and chronic high altitude exposure. *High Altitude Medicine Biology* 2004; 5:61-69.
 241. Li JH, Huang XR, Zhu H-J, **Johnson RJ**, Lan HY. Role of TGF- β signaling in extracellular matrix production under high glucose conditions. *Kidney Int* 2003;63:2010-2019.
 242. Matsui K, Nagy-Bojarsky K, Laakkonen P, Krieger S, Mechtler K, Uchida S, Geleff S, Kang D-H, **Johnson RJ**, Kerjaschki D: Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: aminopeptidase P and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. *J Am Soc Nephrol* 2003 Aug;14(8):1981-1989.
 243. Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodriguiz-Iturbe B, **Johnson RJ**: A single pathway for the development of essential hypertension. *Cardiol Rev* 2003 Jul/Aug 11(4):180-196.
 244. Seifert RA, Coats SA, Oganessian A, Wright MB, Dishmon M, Booth CJ, **Johnson RJ**, Alpers CE, Bowen-Pope DF: PTPRQ is a novel phosphatidylinositol phosphatase that can be expressed as a cytoplasmic protein or as a subcellularly localized receptor-like protein. *Exp Cell Res* 2003 Jul 15;287(2):374-386.
 245. Nakagawa T, Kang D-H, Ohashi R, Suga S, Herrera-Acosta J, Rodriguez-Iturbe B, **Johnson RJ**: Tubulointerstitial disease: role of ischemia and microvascular disease. *Current Opinion Neph Hypertens* 2003 May; 12(3):233-241.
 246. Kanellis J, Watanabe S, Li JH, Kang D-H, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, **Johnson RJ**: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. *Hypertension* 2003;41(6):1287-1293.
 247. **Johnson RJ**, Hurtado A, Merszei J, Rodriguez-Iturbe B, Feng L: Hypothesis: Dysregulation of immunological balance resulting from hygiene and socioeconomic factors may influence the epidemiology and etiology of glomerulonephritis worldwide. *Am J Kid Dis* 2003; 42:575-81.
 248. Feig DI, **Johnson RJ**: Hyperuricemia in childhood essential hypertension. *Hypertension* 2003; 42:247-252.
 249. Garcia GE, Xia Y, Harrison J, Wilson CB, **Johnson RJ**, Bacon KB, Feng L: Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. *Am J Pathol* 2003 Apr;162(4):1061-1073.
 250. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu H-J, Morishita R, **Johnson RJ**: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. *J Am Soc Nephrol* 2003 Jun;14(6):1535-1548.
 251. **Johnson RJ**, Kang D-H, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR,

- Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension* 2003 Jun;41(6):1183-1190.
252. Taneda S, Hudkins KL, Topouzis S, Gilbertson DG, Ophascharoensuk V, **Johnson RJ**, Alpers CE: Obstructive uropathy in mice: potential role for PDGF-D in the progression of tubulointerstitial Injury. *J Am Soc Nephrol* 2003 Oct 14(10):2544-55.
253. Kanellis J, **Johnson RJ**. Editorial Comment: Elevated uric acid and ischemic stroke: accumulating evidence that it is injurious and not neuroprotective. *Stroke* 2003 August 34:1956-1957.
254. **Johnson RJ**, Rodriguez-Iturbe B, Herrera-Acosta J: Nephron number and primary hypertension. *N Engl J Med* 2003 Apr 24;348(17):1717-1719.
255. Garcia GE, Xia Y, Ku G, **Johnson RJ**, Wilson CB, Feng L: IL-18 translational inhibition restricts IFN- γ expression in crescentic glomerulonephritis. *Kidney Int* 2003 Jul;64(1):160-169.
256. Quiroz Y, Bravo J, Herrera-Acosta J, **Johnson RJ**, Rodriguez-Iturbe B: Apoptosis and NF κ B activation are simultaneously induced in renall tubulointerstitium in experimental hypertension. *Kidney Int* 2003; 64 (suppl) 86:27-32
257. Sanchez-Lozada, Tapia E, **Johnson RJ**, Rodriguez-Iturbe B, Herrera-Acosta J: Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. *Kidney Int* 2003; 64 (suppl) 86:9-14.
258. Bravo J, Quiroz Y, Pons H, Parra G, Herrera-Acosta J, **Johnson RJ**, Rodriguez-Iturbe B: Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition. *Kidney Int* 2003; 64 (suppl) 86:46-51.
259. Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Ramirez RG, Schreiner GF, **Johnson RJ**: Inhibition of p38 MAPK augments progression of remnant kidney model by activating the ERK pathway. *Am J Pathol* 2004; 164:477-485.
260. Kanellis J, Bick R, Garcia G, Truong L, Tsao CC, Poindexter B, Feng L, **Johnson RJ**, Sheikh-Hamad D: Stanniocalcin-1 inhibits MCP1-mediated chemotaxis in murine macrophage-like RAW264.7 cells. *Am J Physiol Renal Physiol* 2004; 286:F356-362.
261. Kang D-H, Yu ES, Yoon K-I, **Johnson RJ**. The impact of gender on progression of renal disease: potential role of estrogen-mediated VEGF regulation and vascular protection: *Am J Pathol* 2004; 164: 679-688.
262. Kang D-H, Finch J, Nakagawa T, Karumanchi, Kanellis J, Granger J, **Johnson RJ**: Uric acid, endothelial dysfunction, and preeclampsia: searching for a pathogenetic link. *J Hypertens* 2004; 22:229-235
263. Long DA, Price KL, Herrera-Acosta J, **Johnson RJ**: How does angiotensin II cause renal injury? *Hypertension* (editorial) 2004; 43:722-723.
264. **Johnson RJ**, Rideout B: Uric acid and diet: insights into the Epidemic of Cardiovascular Disease. *N Engl J Med* (editorial) 2004; 350:1071-1074
265. Khosla U, **Johnson RJ**: Hypertension in the hemodialysis patient and the “lag phenomenon.” Insights into pathophysiology and clinical management. *Am J Kid Dis* 2004; 43: 739-751
266. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, **Johnson RJ**: Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all *Am J Physiol Renal Physiol* 2004; 286:F606-616.

267. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang D-H, Finch J, **Johnson RJ**: Uric acid, nephron number, and the pathogenesis of essential hypertension *Kidney International* 2004; 66:281-287
268. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Bottinger EP, Chen Y, Zhu HJ, Kang D-H, Schreiner GF, Lan HY, **Johnson RJ**: TGF- β induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. *Kidney Int* 2004; 66:605-13
269. Kanellis J, Garcia GE, Li P, Parra G, Wilson CB, Rao Y, Han S, Smith CW, **Johnson RJ**, Wu JY, Feng L: Modulation of inflammation by Slit protein *in vivo* in experimental crescentic glomerulonephritis. *Am J Pathol* 2004; 165:341-352
270. Stenvinkel P, Ketteler M, **Johnson RJ**, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T and Girndt M: IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia-The good, the bad, and the ugly. *Kidney Int* 2005; 67:1216-1233.
271. Nakagawa T, Lan HY, Zhu HJ, Kang DH, Schreiner GF, **Johnson RJ**: Differential regulation of VEGF by TGF- β and hypoxia in rat proximal tubular cells *Am J Physiol Renal Physiol* 2004 Oct;287(4):F658-64
272. **Johnson RJ**, Srinivas T, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. In *Uric acid in Cardiovascular and Renal Disease*. Eds Johnson R and Cameron JS. *Semin Nephrol* 2005; 25:3-8
273. Sanchez-Lozada LG, Tapia E, Rodriguez-Iturbe B, **Johnson RJ**, Herrera-Acosta J. Hemodynamics of hyperuricemia. In *Uric acid in Cardiovascular and Renal Disease*. Eds Johnson R and Cameron JS. *Semin Nephrol* 2005; 25:19-24.
274. Srinivas TR, Herrera-Acosta J, Feig DI, Kang DH, Segal MS, **Johnson RJ**. Diuretic induced hyperuricemia does not decrease cardiovascular risk *J Hypertens* 22:1415-1417, 2004
275. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, **Johnson RJ**. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2005; 67:1739-1742
276. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Nepomuceno T, Rodriguez-Iturbe B, **Johnson RJ**, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal rats and remnant kidney rats. *Kidney Int* 2005; 67:237-247
277. **Johnson RJ**, Cameron JS. Introduction. In *Uric acid in Cardiovascular and Renal Disease*. *Semin Nephrol* 2005; 25:1-2.
278. Watanabe S, Mu W, Kahn A, Jing N, Li J-H, Lan HY, Nakagawa T, Ohashi R, **Johnson RJ**. Role of the Jak/Stat pathway in IL-6 induced activation of vascular smooth muscle cells. *Am J Nephrol* 2004; 24:387-392
279. Nakagawa T, Lan HY, Glushakova O, Zhu HJ, Kang D-H, Schreiner GF, **Johnson RJ**, Sautin Y. Role of ERK1/2 and p38 Mitogen-Activated Protein Kinases in the Regulation of Thrombospondin-1 by TGF- β 1 in Rat Proximal Tubular Cells and Mouse Fibroblasts.. *J Am Soc Nephrol* 2005; 16(4):899-904
280. **Johnson RJ**, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. *Am J Hypertens* 2005; 18:431-40
281. Kanellis J, Feig DI, **Johnson RJ**. Does asymptomatic hyperuricaemia contribute to the

- development of renal and cardiovascular disease? An old controversy renewed. *Nephrology* 2004; 9:394-399
282. Short RA, **Johnson RJ**, Tuttle KR. Uric acid, microalbuminuria, and cardiovascular events in high risk patients. *Am J Nephrol* 2005 Feb 21;25(1):36-44
283. Standridge JB, Sealey JE, Laragh JH, Houston MC, Gavras H, **Johnson RJ**, Blumenfeld JD, Brown M, Egan BM, Meltzer JI, Shimosawa T, Fujita T. A free-ranging roundtable discussion on hypertension. *J Human Hypertension* 2005;19(4):259-66
284. Kang DH, Kang SW, Jeong HJ, Kim YS, Yang CW, **Johnson RJ**. Transplant Graft Vasculopathy : An Emerging Target for Prevention and Treatment of Renal Allograft Dysfunction. *Yonsei Med J* 2004; 45:1053-1058.
285. **Johnson RJ**, Feig DI, Kang DH, Herrera-Acosta J. Resurrection of uric acid as a causal risk factor for essential hypertension. *Hypertension* 2005; 45:18-20
286. **Johnson RJ**, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Feig DI, Herrera-Acosta J. Subtle renal injury is likely a common mechanism for salt-sensitive essential hypertension. *Hypertension* 2005; 45:326-330
287. Li QZ, Li P, Garcia GE, **Johnson RJ**, Feng L. Genomic profiling of neutrophil transcripts in Asian Qigong practitioners: A pilot study in gene regulation by mind/body interaction. *J Alt Compl Med* 2005 Feb;11(1):29-39
288. Franco M, Martinez F, Rodriguez-Iturbe B, **Johnson RJ**, Santamaria J, Montoya A, Nepomuceno T, Bautista R, Tapia E, Herrera-Acosta J: Angiotensin II, interstitial inflammation, and the pathogenesis of salt-sensitive hypertension. *Am J Physiol Renal Physiol*. 2006 Dec;291(6):F1281-7
289. Hediger MA, **Johnson RJ**, Miyazaki H, Endou H. Molecular physiology of urate transport. *Physiology* 2005; 20:125-133
290. Li P, Garcia G, Xia Y, Wu W, Gersch C, Park PW, Truong L, Wilson CB, **Johnson RJ**, Feng L. Blocking of monocyte chemoattractant protein-1 during tubulointerstitial nephritis resulted in delayed neutrophil clearance. *Am J Pathol* 2005 Sep;167(3):637-49
291. Long DA , Mu W, Prabhakar SS, Price KL, Truong LD, Feng L, Newaz MA, Oyekan AO, **Johnson RJ**. Loss of Nitric Oxide and Endothelial Derived Hyperpolarizing Factor Mediated Responses in Aging. *Kidney Int* 2005 Nov; 68:2154-63.
292. Kang D-H, Park SK, Lee IK, **Johnson RJ**: Uric acid induced C-Reactive Protein (CRP) expression: Implication on Cell Proliferation and Nitric Oxide Production in Human Vascular Cells *J Am Soc Nephrol* 2005 Dec;16(12):3553-3562. Epub 2005 Oct 26
293. Sadlier DM, Ouyang X, McMahon B, Mu W, Ohashi R, Rogers K, Murray D, Nakagawa T, Godson C, Doran P, Brady HR, **Johnson RJ**. Use of Microarray and Bioinformatics to identify novel and established genes in experimental mesangial proliferative glomerulonephritis. *Kidney Int* 2005; 68(6):2542-61
294. Eto N, Kojima I, Uesagi N, Inagi R, Miyata T, Fujita T, **Johnson RJ**, Shankland SJ, Nangaku M. Protection of endothelial cells by dextran sulfate in rats with thrombotic microangiopathy *J Am Soc Nephrol* 2005; 16: 2997-3005
295. **Johnson RJ**, Segal MS, Srinivas TR, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-Iturbe B, Kang DH, Herrera-Acosta J. Essential hypertension, progressive renal disease and uric acid: A pathogenetic link? *J Am Soc Nephrol* 2005 Jul;16(7):1909-19

296. Mu W, Ouyang X, Agarwal A, Long DA, Cruz PE, Roncal CA, Glushakova OY, Chiodo VA, Atkinson MA, Hauswirth WW, Flotte TR, Rodriguez-Iturbe B, **Johnson RJ**. Interleukin-10 suppresses chemokines, inflammation and fibrosis in a model of chronic renal disease *J Am Soc Nephrol* 2005 Dec;16(12):3651-60. Epub 2005 Oct 26
297. Long DA, Mu W, Price KL, **Johnson RJ**. Blood vessels and the aging kidney. *Nephron Nephron Exp Nephrol* 2005;101:e95-99
298. McMullen S, Langley-Evans SC-- **Johnson RJ**, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Feig DI, Herrera-Acosta J. Essential Hypertension: Defending the Contribution of a Congenital Nephron Deficit - Response Hypertension. 2005; 46:e4-e5
299. Rodriguez-Iturbe B, **Johnson RJ**, Herrera-Acosta J. Tubulointerstitial damage and progression of renal failure. *Kidney Int* 2005 Dec;(99):S82-6.
300. Sekhon I, Munjal S, Croker B, **Johnson RJ**, Ejaz AA. Glomerular tip lesion associated with nonsteroidal anti-inflammatory drug-induced nephrotic syndrome. *Am J Kid Dis* 2005 Oct;46(4):e55-8
301. Hurtado A, **Johnson RJ**. Hygiene hypothesis and the prevalence of glomerulonephritis. *Kidney Int* 2005; 68 (suppl 97):S1-S6.
302. Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, Tisher CC, **Johnson RJ**. Uncoupling of VEGF with NO causes excessive endothelial cell proliferation; Implications for diabetic vasculopathy. *J Am Soc Nephrol* 2006 Mar;17(3):736-45
303. Price KL, Sautin Y, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, **Johnson RJ**. Human vascular smooth muscle cells express a urate transporter. *J Am Soc Nephrol* 2006 Jul;17(7):1791-5.
304. Keller K, Daniel C, Schocklmann H, Endlich KH, Kerjaschki D, **Johnson RJ**, Hugo C. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. *Nephrol Dial Transpl* 2006 Oct;21(10):2724-35
305. Beaver TM, Winterstein AG, Shuster JJ, Gerhard T, Martin T, Alexander JA, **Johnson RJ**, Ejaz A, Hartzema AG. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. *Clinical Cardiology* 2006 Jan;29(1):18-24.
306. Ouyang X, Le TH, Roncal C, Gersch C, Herrera-Acosta J, Rodriguez-Iturbe B, Coffman TM, **Johnson RJ**, Mu W. Th1 inflammatory response with altered expression of profibrotic and vasoactive mediators in AT1A and AT1B double-knockout mice *Am J Physiol Renal Physiol* 2005 Oct; 289(4):F902-10.
307. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, Feng L, Nakagawa T, Watanabe S, Hosoyamada M, Endou H, Lipkowitz M, Abramson R, Mu W, **Johnson RJ**. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. *Am J Nephrol* 2005; 25:425-433.
308. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, **Johnson RJ**. A causal role for uric acid in fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol* Epub Oct 18, 2005; 2006 Mar;290(3):F625-31
309. Nakagawa T, Tuttle KR, Short RA, **Johnson RJ**. Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. *Nature Clinical Practice Nephrology*. 2006; 1:80-86

310. Rodriguez-Iturbe B, **Johnson RJ**. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. *Nephrol Dial Transpl* (Editorial Comment) 2006 Feb;21(2):260-3
311. Nakagawa T, Mazzali M, Kang DH, Sanchez-Lozada LG, Herrera-Acosta J, **Johnson RJ**. Uric acid—A uremic toxin? *Blood Purification* 2006; 24(1):67-70.
312. Sanchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, **Johnson RJ**, Herrera-Acosta J. Hormonal and cytokine effects of uric acid. *Current Opin Nephrol Hypertens* 2006 Jan;15(1):30-3
313. Thadhani R, **Johnson RJ**, Karumanchi SA. Hypertension during pregnancy: A disorder begging for pathophysiologic effect. *Hypertension* (Editorial) 2005 Dec;46(6):1250-1. Epub 2005 Oct 24
314. **Johnson R**. The Role of Acquired Renal Disease in Salt-Sensitive Hypertension. *Cardiovasc J. S. Africa* 2005; 12 (Suppl 2): 13.
315. **Johnson R**. The Role of Uric Acid in Hypertension, Renal Disease and the Metabolic Syndrome. *Cardiovasc J. S. Africa* 2005; 12(supplement 2):1243
316. Araya CE, Wasserfall CH, Brusko TM, Mu W, Segal MS, **Johnson RJ**, Garin EH. A Case of Unfulfilled Expectations. *Cytokines in Idiopathic Minimal Lesion Nephrotic Syndrome. Pediatric Nephrology* 2006 Mar 7; 2006 May;21(5):603-10
317. Segal MS, Baylis C, **Johnson RJ**. Endothelial Health and Diversity in the Kidney. *J Am Soc Nephrol* 2006 Feb;17(2):323-4
318. Nakagawa T, Sato W, Sautin Y, Glushakova O, Croker B, Atkinson M, Tisher C, Johnson R. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. *J. Am Soc Nephrol.* 2006 Mar; 17(3):736-45
319. Gersch MS, Mutig K, Bachmann S, Kumar S, Ouyang X, **Johnson RJ**. Letter to editor: Is salt-wasting the long awaited answer to the hyperuricemia seen in uromodulin storage diseases? *Nephrol Dial Transpl* 2006; 21:2028-9
320. Feig D, Mazzali M, Kang D, Nakagawa T, Price K, Kannelis J, **Johnson RJ**. Serum uric acid: a risk factor and a target for treatment? *J Am Soc of Nephrol* 2006 17:S69-S73
321. Nakagawa T, Kang DH, Feig D, Sanchez-Lozada LG, Srinivas TR, Sautin YY, Ejaz AA, Segal MS, **Johnson RJ**. Unearthing Uric Acid: An Ancient Factor with Recently Found Significance in Renal and Cardiovascular Disease *Kidney Int* 2006 May;69(10):1722-5
322. Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson GN, Tabah-Fische I, Keller B, Beaver TM, Nakagawa T, **Johnson RJ**. Could uric acid have a role in acute renal failure? *Clin J Am Soc Neph* 2007; 2:16-21.
323. Gersch MS, **Johnson RJ**. Uric acid and the immune response. (editorial) *Nephrol Dial Transpl* 2006 Nov;21(11):3046-7
324. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, **Johnson RJ**, Croker B. Diabetic Endothelial Nitric Oxide Synthase Knockout Mice Develop Advanced Diabetic Nephropathy. *J Am Soc Nephrol.* 2007; 18:539-550
325. Feig DI, Nakagawa T, Rodriguez-Iturbe B, and **Johnson RJ**. Nephron Number, Uric acid and Renal Microvascular and Inflammatory Disease in the Pathogenesis of Essential Hypertension. *Hypertension* 2006;48:25-6
326. Roncal C, Mu W, Croker B, Reunji S, Ouyang X, Tabah-Fische I, **Johnson RJ**, Ejaz AA.

- Effect of an elevated uric acid on cisplatin-induced acute renal failure. *Am J Physiol* 2007 Jan;292(1):F116-22
- 327.** Long DA, Mu W, Price KL, Roncal C, Schellenberger U, Schreiner GF, Woolf AS, **Johnson RJ**. Vascular Endothelial Growth Factor Administration Does Not Improve Microvascular Disease in the Salt-Dependent Phase of Post-Angiotensin II Hypertension. *Am J Physiol Renal Physiol*. 2006 Dec;291(6):F1248-54.
- 328.** Gersch MS, Sautin YY, Gersch C, Henderson G, Bankir L, **Johnson RJ**. Does Tamm Horsfall-uric acid binding have a significant role in urate homeostasis? *Nephrol Dial Transpl* 2006; 1:2398-234
- 329.** Sánchez-Lozada LG, Tapia E, Jiménez A, Bautista P, Cristóbal M, Nepomuceno T, Soto V, Ávila-Casado C, Nakagawa T, **Johnson RJ**, Herrera-Acosta J, Franco M. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats *Am J Physiol* 2007; 292:F423-9
- 330.** Feig DI, Kang DH, Nakagawa T, Mazzali M, **Johnson RJ**. Uric Acid and hypertension. *Curr Hypertens Rep*. 2006 May;8(2):111-5
- 331.** Sanchez-Lozada LG, Tapia E, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, **Johnson RJ**, Herrera-Acosta J, Franco M. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia *Am J Physiol* 2007 Apr;292(4):F1238-44
- 332.** Heinig M, **Johnson RJ**. Medical Grand Rounds. Role of uric acid in hypertension, renal disease, and metabolic syndrome. *Cleveland Clinic Journal of Medicine* 2006 Dec;73(12):1059-64
- 333.** Cirillo P, Sato W, Reungjui S, Heinig M, Gersch M, Sautin Y, Nakagawa T, **Johnson R**. Uric Acid, the Metabolic Syndrome, and Renal Disease. *Kidney Int (Supplement)*. 2006 Dec;17(12 Suppl 3):S165-8
- 334.** Schold J, Srinivas TR, Guerra G, Reed JV, **Johnson RJ**, Weiner ID, Oberbauer R, Harman JS, Hemming AW, Meier-Kriesche HU. A 'Weight-Listing' Paradox for Candidates of Renal Transplantation? *Am J Transplant*. 2007 Mar;7(3):550-9
- 335.** Germain AM, Romanik MC, Guerra I, Sandra S, Reyes MS, **Johnson RJ**, Price K, Karumanchi A, Valdes G. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? *Hypertension*. 2007 Jan;49(1):90-
- 336.** Suliman ME, **Johnson RJ**, Garcia-Lopez E, Qureshi AR, Molinari H, Carrero JJ, Heimbürger O, Barany P, Axelsson J, Lindholm B, Stenvinkel P. J-Shaped mortality relationship for uric acid in chronic kidney disease. *Am J Kid Dis*. 2006 Nov;48(5):761-771
- 337.** Feig DI, Johnson RJ. The Role of Uric Acid in Pediatric Hypertension. *J Ren Nutr*. 2007 Jan;17(1):79-83
- 338.** Garcia GE, Truong LD, Li P, Zhang P, Johnson RJ, Wilson CB, Feng L. Inhibition of CXCL16 Attenuates Inflammatory and Progressive Phases of Anti-Glomerular Basement Membrane Antibody-Associated Glomerulonephritis. *Am J Pathol*. 2007 May;170(5):1485-96
- 339.** Abboud O, Barsoum R, Berthoux F, Field M, **Johnson R**, Lin S, Massari P. European Best Practice Practice Guidelines for Peritoneal Dialysis acknowledged by ISN. *Nature Clinical Practice Nephrology* 2007; 3:6-7.
- 340.** Adroge HE, Borillo J, Torres L, Kale A, Zhou C, Feig D, Merszei J, **Johnson RJ**, Lou YH. Coincident activation of Th2 T cells with onset of the disease and differential expression

- of GRO-gamma in peripheral blood leukocytes in minimal change disease *Am J Nephrol* 2007;27(3):253-61
341. **Johnson RJ**, Segal M, Sautin Y, Nakagawa T, Feig DI, Kang DH, Gersch MS, Benner S, and Sanchez-Lozada LG. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. *Am J Clin Nutr.* 2007 Oct;86(4):899-906
 342. Sautin YY, Nakagawa T, Zharikov S, **Johnson RJ**. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *Am J Physiol Cell Physiol.* 2007 Aug;293(2):C584-96.
 343. Franco M, Martínez F, Quiroz Y, Galicia O, Bautista R, **Johnson RJ**, Rodríguez-Iturbe Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. *Am J Physiol Integr Com Physiol* 2007; 293:R251-6
 344. Rodriguez-Iturbe B, Romero F, **Johnson RJ**. Pathophysiological mechanisms of salt-dependent hypertension. *Am J Kidney Dis.* 2007 Oct;50(4):655-72.
 345. Reungjui S, Roncal CA, Mu W, Sriniva TR, Sirivongs D, **Johnson RJ**, Nakagawa T. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. *J Am Soc Nephrol.* 2007 Oct;18(10):2724-31
 346. Tantravahi J, Srinivas TR, **Johnson RJ**. Hyperfiltration: A sign of poor things to come in individuals with metabolic syndrome. *Nature Clinical Practice Nephrology* 2007; 3:474-5
 347. Nakagawa T, Segal MS, Croker B, **Johnson RJ**. A breakthrough in diabetic nephropathy: the role of endothelial dysfunction. *Nephrol Dial Transplant.* 2007 Oct;22(10):2775-7
 348. Sánchez-Lozada LG, Tapia E, Vega-Campos IP, Cristóbal M, Soto V, T Ávila-Casado C, Franco M, Zhao L, **Johnson RJ**. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricemia. *Nephrol Dial Transpl* 2008 Apr;23(4):1179-85
 349. Gersch MS, Mu W, Cirillo P, Reungjui S, Li Z, Roncal CA, Sautin YY, **Johnson RJ**, Nakagawa T. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. *Am J Physiol Renal Physiol.* 2007 Oct;293(4):F1256-61
 350. Reungjui S, Hu H, Mu W, Roncal CA, Croker BP, Patel JM, Srinivas TR, Byer K, Simoni J, Wesson D, Sitprija V, **Johnson RJ**. Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia *Kidney Int* 2007 Dec;72(12):1483-92
 351. Reungjui S, Roncal CA, Sato W, Glushakova OY, Ouyang X, Tungsanga K, Nakagawa T, **Johnson RJ**, Mu W. Hypokalemic Nephropathy is associated with Impaired Angiogenesis *J Am Soc Nephrol* 2008 Jan;19(1):125-34
 352. Hohenstein B, Braun A, Amann K, **Johnson RJ**, Hugo CPM. A Murine Model of Site specific Renal Microvascular Endothelial Injury and thrombotic microangiopathy. *Nephrol Dial Transpl* 2008 Apr;23(4):1144-56
 353. Segal MS, Gollub E, **Johnson RJ**. Is the fructose index more relevant with regards to cardiovascular disease than the glycemic index? *Eur J Nutr.* 2007; 46:406-17
 354. Roncal C, Mu W, Reungjui S, Kim KM, Henderson GN, Ouyang X, Nakagawa T, **Johnson RJ**. Lead, at low levels, accelerates arteriolopathy and tubulointerstitial injury in chronic kidney disease. *Am J Physiol Renal Physiol.* 2007 Oct;293(4):F1391-6
 355. Franco M, Sanchez-Lozada LG, , Bautista R, **Johnson R**, Rodriguez-Iturbe B.

- Pathophysiology of salt sensitive hypertension: a new scope of an old problem. *Blood Purification* 2008;26(1):45-8.
- 356. Johnson RJ**, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of Essential Hypertension: Historical Paradigms and Modern Insights. *J Hypertens* 2008; 26:381-391. PMID: PMC2742362
- 357.** Ejaz AA, **Johnson RJ**. Heart failure, natriuretic peptides, and the nephrologist. *Rev Cardiovas Med* 2007; 8: S30-S31.
- 358. Johnson RJ**, Gaucher E, Sautin YY, Henderson GN, Angerhofer AJ, Benner SA. The Planetary Biology of Ascorbate and Uric acid and their Relationship with the Epidemic of Obesity and Cardiovascular Disease. *Med Hypotheses* 2008;71(1):22-31. PMID: PMC2495042
- 359.** Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos I, Nakagawa T, Zhao L, Franco M, **Johnson RJ**. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol* 2008 Apr;294(4):F710-8
- 360.** Ouyang X, Cirillo P, Sautin YY, McCall S, Bruchette JL, Diehl AM, **Johnson RJ**, Abdelmalak M. Fructose Consumption as a Risk Factor for Nonalcoholic Fatty Liver Disease. *J Hepatol* 2008 Jun;48(6):993-9. PMID: PMC2423467
- 361.** Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale J, Zhao L, **Johnson RJ**. Effect of febuxostat on the progression of renal disease in 5/6th nephrectomy rats with and without hyperuricemia. *Nephron Physiology* 2008;108(4):p69-78
- 362.** Reungjui S, Pratipanawatr T, **Johnson RJ**, and Nakagawa T. Do Thiazides Worsen Metabolic Syndrome and Renal Disease: The pivotal roles for Hyperuricemia and Hypokalemia. *Current Opinion in Nephrology and Hypertension* 2008; 17:470-476. PMID: PMC2903051
- 363.** Dharnidharka VR, **Johnson RJ**. Uric acid-- a bad acid for the kidney? *Pediatric Transplantation* 2008; 12(8): p. 821-2.
- 364.** Sautin YY, **Johnson RJ**. Uric acid: the oxidant-antioxidant paradox. *Nucleosides Nucleotides and Nucleic Acids* 2008 Jun;27(6):608-19. PMID: PMC2895915
- 365.** Luks AM, **Johnson RJ**, Swenson ER. Chronic kidney disease at high altitude. *J Am Soc Nephrol* 2008;19:2262-71. NIHMSID: NIHMS212419
- 366.** Nakagawa T, Cirillo P, Sato W, Sautin M, Roncal C, Sanchez-Lozada, **Johnson RJ**. The conundrum of hyperuricemia, metabolic syndrome, and renal disease. *Intern Emerg Med* 2008; 3:313-8. PMID: PMC2895906
- 367.** Glushakova O, Kosugi T, Roncal C, Mu W, Heinig M, Cirillo P, Sanchez-Lozada LG, **Johnson RJ**, Nakagawa T. Fructose Induces the Inflammatory Molecule ICAM-1 in Endothelial Cells *J Am Soc Nephrol* 2008; 19:1712-1720. PMID: PMC2518440
- 368.** Le M, Shafiu M, Mu W, **Johnson RJ**. SLC2A9—a fructose transporter identified as a novel uric acid transporter. *Nephrol Dial Transpl* 2008; 23:2746-9. PMID: PMC2734172
- 369.** Feig DI, Kang DH, **Johnson RJ**. Uric acid and cardiovascular risk. *N Engl J Med* 2008; 359:1811-21. PMID: PMC2684330
- 370.** Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, Franco M, Rodriguez-Iturbe B, **Johnson RJ**. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. *Am J Physiol Renal Physiol* 2008; 295:F1134-41.

PMCID: PMC2576157

371. Feig DI, Soletsky B, **Johnson RJ**. Effect of Allopurinol on the Blood Pressure of Adolescents with Newly Diagnosed Essential Hypertension. *JAMA* 2008;300(8):922-30. PMCID: PMC2684336
372. Shapiro A, Mu W, Roncal C, Cheng KY, **Johnson RJ**, Scarpace PJ. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. *Am J Physiol Regul Integr Comp Physiol* 2008;295:R1370-5. PMCID: PMC2584858
373. Rodriguez-Iturbe B, Vaziri ND, **Johnson RJ**. Inflammation, angiotensin II, and hypertension. *Hypertension* 2008;52:e135; author reply e6.
374. Sanchez-Lozada LG, Le M, Segal M, **Johnson RJ**. How safe is fructose for persons with or without diabetes? *Am J Clin Nutr* 2008; 88:1189-90.
375. Zharikov S, Krotova K, Hu H, Baylis C, **Johnson RJ**, Block ER, Patel JM. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. *Am J Physiol Cell Physiol* 2008; 295:C1183-90. PMCID: PMC2584985
376. Gersch C, Palii SP, Kim KM, Angerhofer A, **Johnson RJ**, Henderson GN. Inactivation of nitric oxide by uric acid. *Nucleosides Nucleotides Nucleic Acids* 2008; 27:967-78. PMCID: PMC2701227
377. Becker GJ, Abboud O, Bellerin-Font E, Field M, Li PKT, **Johnson RJ**, Wanner C. The ISN clinical practice guidelines committee. *Nature Medicine Clinical Practice Nephrol* 2008; 4:463
378. Parra G, Quiroz Y, Salazar J, Bravo J, Pons H, Chavez M, **Johnson RJ**, Rodríguez-Iturbe B. Experimental induction of salt sensitive hypertension is associated with lymphocyte proliferative response to HSP70. *Kidney Int (suppl)* 2008; 111:S55-9
379. Hu H, Lu L, Mu W, **Johnson RJ**, Block ER, Patel JM. Priming donor lungs with thioredoxin-1 attenuates acute allograft injury in a rat model of lung transplantation. *J Heart Lung Transplant* 2008; 27:1142-9. PMCID: PMC2590662
380. Mohandas R, **Johnson RJ**. Uric acid levels increase risk for new-onset kidney disease. *J Am Soc Nephrol* 2008; 19:2251-3. NIHMSID: NIHMS212420
381. Tapia E, Sanchez-Gonzalez DJ, Medina-Campos ON, Soto V, Avila-Casado C, Martinez-Martinez CM, **Johnson RJ**, Rodriguez-Iturbe B, Pedraza-Chaverri J, Franco M, Sanchez-Lozada LG. Treatment with pyrroldine dithiocarbamate improves proteinuria, oxidative stress and glomerular hypertension in overload proteinuria. *Am J Physiol Renal Physiol* 2008; 295:F1431-9. PMCID: PMC2584905
382. Garin EH, Diaz LN, Mu W, Wasserfal C, Arraya C, **Johnson RJ**. Urinary CD80 Excretion Increases in Idiopathic Minimal-Change Disease. *J Am Soc Nephrol* 2009; 20:260-266. PMCID: PMC2637046
383. Kosugi T, Nakagawa T, Kamath D, **Johnson RJ**. Uric acid and hypertension: an age-related relationship? *J Hum Hypertens* 2009; 23:75-6.
384. **Johnson RJ**, Sautin YY, Oliver WJ, et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? *J Comp Physiol [B]* 2009;179:67-76. PMCID: PMC2684327
385. **Johnson RJ**, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, Shafiu M, Segal M, Glasscock RJ, Shimada M, Roncal C, Nakagawa T. Hypothesis: Could Excessive Fructose Intake and Uric Acid Cause Type 2 Diabetes? *Endocr Rev* 2009; 30: 96-

116. PMID: PMC2647706

- 386.** Lee SM, Lee AL, Winters TJ, Tam E, Jaleel M, Stenvinkel P, **Johnson RJ**. Low Serum Uric Acid Level is a Risk Factor for Death in Incident Hemodialysis Patients *Am J Nephrol* 2009; 29:79-85. PMID: PMC2786018
- 387.** Chen W, Chen W, Wang H, Dong X, Liu Q, Mao H, Tan J, Lin J, Zhou F, Luo N, He H, **Johnson RJ**, Yu X. Prevalence and risk factors associated with chronic kidney disease in an adult population from Southern China. *Nephrol Dial Transpl* 2009; 24:1205-1212. *PMC Journal – In Process*
- 388.** Cirillo P, Gersch MS, Mu W, Scherer PM, Kim KY, Gesualdo T, Henderson GN, **Johnson RJ**, Sautin YY. Ketohehexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells. *J Am Soc Nephrol* 2009 Mar;20(3):545-53. PMID: PMC2653686
- 389.** Cirillo P, Sautin YY, Kanellis J, Kang DH, Gesualdo L, Nakagawa T, **Johnson RJ**. Systemic inflammation, metabolic syndrome, and progressive renal disease. *Nephrol Dial Transpl* 2009; 24(5):1384-7. PMID: PMC2721462
- 390.** Mu W, Long DA, Ouyang X, Agarwal A, Connor T, Cruz PE, Roncal CA, **Johnson RJ**. Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. *Am J Physiol Renal Physiol* 2009;296:F145-52. PMID: PMC2636910
- 391.** Kim KM, Henderson GN, Frye RF, Galloway CD, Brown NJ, Segal MS, Imaran W, Angerhofer A, **Johnson RJ**. Simultaneous Determination of Uric Acid Metabolites Allantoin, 6-Aminouracil, and Triuret in Human Urine Using Liquid Chromatography-Mass Spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877:65-70. PMID: PMC2684329
- 392.** Nakayama T, Sato W, Kosugi T, Zhang L, Campbell-Thompson M, Yoshimura A, Croker BP, **Johnson RJ**, Nakagawa T. Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. *Am J Physiol Renal Physiol* 2009; 296:F317-F27. *PMC Journal – In Process*
- 393.** Gersch C, Pali SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, **Johnson RJ**, Henderson GN. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. *Nucleosides, Nucleotides, and Nucleic Acids*. 2009 Feb;28(2):118-49. PMID: PMC2742358
- 394.** Araya CE, Diaz LN, Wasserfall C, Atkinson M, Mu W, **Johnson RJ**, Garin EH. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. *Pediatr nephrol* 2009; 20:260-266. PMID: PMC2785122
- 395.** Ejaz AA, Martin TD, **Johnson RJ**, Winterstein AG, Klodell CT, Hess PJ, Ali AK, Whidden WM, Staples NL, Alexander JA, House-Francher MA, Beaver TM. Prophylactic Nesiritide Does Not Prevent Dialysis or All Cause Mortality in patients undergoing High-Risk Cardiac Surgery *J Thorac Cardiovas Surgery* 2009; 138:959-964
- 396.** Ejaz AA, Beaver TM, Shimada M, Sood P, Lingegowda V, Schold J, Kim T, **Johnson RJ**. Uric acid: A novel risk factor for acute kidney injury in high risk cardiac surgery patients? *Am J Nephrol* 2009; 30:425-429
- 397.** Roncal CA, Reungjui S, Sanchez-Lozada LG, Mu W, Sautin YY, Nakagawa T, **Johnson**

- RJ.** Combination of Captopril and Allopurinol Retards Fructose-Induced Metabolic Syndrome *Am J Nephrol* 2009; 30:399-404. PMID: PMC2783362
- 398.** Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez-Lozada LG, Roncal C, **Johnson RJ**, Nakagawa T. The Effect of Lowering Uric Acid on Renal Disease in the Type 2 Diabetic db/db Mice. *Am J Physiol Renal Physiol* 2009; 297:F481-8. PMID: PMC2724243
- 399.** Kim KM, Henderson GN, Ouyang X, Frye RF, Sautin YY, Feig DI, **Johnson RJ.** A Sensitive and Specific Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Intracellular and Intercellular Uric Acid. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877:2032-2038. PMID: PMC2752364
- 400.** Hovind P, Rossing P, Tarnow L, **Johnson RJ**, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes – an inception cohort study. *Diabetes* 2009; 58:1668-71. PMID: PMC2699868
- 401.** **Johnson RJ**, Rivard C, Nakagawa T, Sautin YY, Sanchez-Lozada LG. Uric acid: More to Learn, More Experiments to Do. *Am J Hypertens* 2009; 22:952-3 (commentary)
- 402.** Shimada M, **Johnson RJ**, May WS, Lingegowda V, Sood P, Nakagawa T, Van QC, Das B, Ejaz AA. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. *Nephrol Dial Transpl* 2009; 24:2960-4
- 403.** Sánchez-Lozada LG, Mu W, Roncal C, Sautin YY, Abdelmalak M, Reungjui S, Le M, Nakagawa T, Lan HY, Yu X, **Johnson RJ.** Comparison of Free Fructose and Glucose to Sucrose in the Ability to Cause Fatty Liver. *Eur J Nutr* 2010 Feb;49(1):1-9. PMID: PMC2805058
- 404.** Abdel-Hafez M, Shimada M, Lee PY, Johnson RJ, Garin EH. Idiopathic nephrotic syndrome and atopy: Is there a common link? *Am J Kid Dis* 2009;54(5):945-53. PMID: PMC2895907
- 405.** Sánchez-Lozada LG, Roncal C, Soto V, Madero M, Jalal D, Rivard C, Franco M, Feig DI, Nakagawa T, **Johnson RJ.** Hiperuricemia como factor de riesgo para el desarrollo de hipertensión, daño renal crónico y síndrome metabólico. *Archivos Latinoamericanos de Nefrologia Pediátrica* (Latinamerican archives of pediatric nephrology) 2009; 9:3-9.
- 406.** Kazumel R, Mazzali M, **Johnson RJ.** Could uric acid have a Pathogenic Role in Chronic Allograft Nephropathy? *Arab J Nephrol Transpl* 2009; 3: 37-41
- 407.** Perez-Pozo S, Schold J, Nakagawa T, Sanchez-Lozada, LG, **Johnson RJ**, Lopez Lillo J. Excessive Fructose Intake Induces Features of Metabolic Syndrome in Healthy Adult Males: Role of Uric Acid in the Hypertensive Response. *Int J Obesity (London)* 2010 Mar;34(3):454-61
- 408.** Osterberg KL, Horswill CA, **Johnson RJ**, Pallardy SE. Carbohydrate exerts a mild influence on fluid retention following exercise-induced dehydration. *J Applied Physiology* 2010 Feb;108(2):245-50
- 409.** Johnson RJ, Sanchez-Lozada LG, Rodriguez-Iturbe B. New treatment for systolic blood pressure? *Nat Rev Nephrol.* 2009 Dec;5(12):675-6
- 410.** Cirillo P, Sautin YY, **Johnson RJ.** Reply to Dr White. *Nephrol Dial Transpl* 2009 24: 3257-3258
- 411.** Todd AS, MacGinley RJ, Schollum JBW, **Johnson RJ**, Williams SM, Sutherland WHF, Mann JI, Walker RJ. Dietary Salt Loading Impairs Arterial Vascular Reactivity. *Am J Clin*

Nutr 2010 Mar;91(3):557-64

412. Zharikov SI, Swenson ER, Block ER, Patel, JM, **Johnson RJ**. Pulmonary Hypertension and Hyperuricemia: Association with Features of the Metabolic Syndrome. *Medical Hypotheses* 2010 Jun;74(6):1069-74
413. Jalal DI, Rivard CJ, **Johnson RJ**, Maahs DM, Rewers M, Snell-Bergeon JK. Serum Uric Acid Levels Predict the Development of Albuminuria over 6 years in Patients with Type 1 Diabetes. Findings from the Coronary Artery Calcification in Type 1 Diabetes study. *Nephrol Dial Transpl* 2010 Jun;25(6):1865-9
414. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida C, Colvin R, **Johnson RJ**, Diehl AM.. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology* 2010 Jun;51(6):1961-71
415. Jalal DI, Smits G, **Johnson RJ**, Chonchol M. Increased Fructose Associates with Elevated Blood Pressure. Findings from the National Health and Nutrition Examination Survey (2003-2006). *J Am Soc Nephrol* 2010 Sep;21(9):1543-9
416. Nakayama T, Kosugi T, Connor T, Gersch M, Sanchez-Lozada LG, Roncal C, Perez-Pozo, SE, **Johnson RJ**, Nakagawa T. Dietary Fructose Causes Tubulointerstitial Injury In The Normal Rat Kidney *Am J Physiol*. 2010 Mar;298(3):F712-20. PMID: PMC2838595
417. Yu, MA, Sanchez-Lozada LG, **Johnson RJ**, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction . *J Hypertens* 2010 Jun;28(6):1234-42
418. Garin EH, Mu W, Arthur JM, Araya C, Shimada M, **Johnson RJ**. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. *Kidney Int* 2010 Aug;78(3):296-302
419. **Johnson RJ**, Murray R. Fructose, exercise and health. *Current Sports Medicine Reports* 2010 Jul-Aug;9(4):253-8
420. **Johnson RJ**, Andrews P, Benner SA, Oliver W. Theodore E Woodward Award. The evolution of obesity: Insights from the mid Miocene. *Trans Am Clin Climatol Assoc*. 2010;121:295-305
421. Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig DI, **Johnson RJ**. Uric acid and hypertension: Cause or Effect? *Current Rheumatol Reports* 2010 Apr;12(2):108-17
422. Imaram W, Gersch C, Kim KM, **Johnson RJ**, Henderson GN, Angerhofer A. Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. *Free Radical Biol and Medicine* 2010 Jul 15;49(2):275-81
423. **Johnson RJ**, Andrews P. Fructose, Uricase and the 'Back to Africa' Hypothesis. *Evolutionary Anthropol* 2010; 19:250-257
424. Li Q, Verma A, Han PY, Nakagawa T, **Johnson RJ**, Grant MB, Campbell-Thompson M, Jarajapu YP, Lei B, Hauswirth WW. Diabetic eNOS knockout mice developed advanced retinopathy. *Invest Ophthalmol Vis Sci*. 2010 Oct;51(10):5240-6010
425. Imaram W, **Johnson RJ**, Angerhofer A. ESR Spin Trapping of the Reaction Between Urate. 3 and Peroxynitrite: the Hydrogen Adduct. *Appl Magnet Reson* 2010,37: 463-472
426. Rodrigues TC, Maahs DM, **Johnson RJ**, Jalal D, Kinney GL, Rivard C, Rewers M, Snell-Bergeon JK. Serum Uric Acid Predicts Progression of Subclinical Coronary

- Atherosclerosis in Individuals without Renal Disease. *Diabetes Care* 2010; 33:2471-3
427. Goldberg R, Nakagawa T, **Johnson RJ**, Thurman J. The role of endothelial cell injury in thrombotic microangiopathy. *Am J Kid Dis* 2010 ;56:1168-74
 428. Rodriguez-Iturbe B, **Johnson RJ**. The role of renal microvascular disease and interstitial inflammation in salt- sensitive hypertension. *Hypertens Res* 2010; 33:975-80
 429. Nakagawa T, Reungjui S, Segal M, **Johnson RJ**. Is There a Dark Side to the Use of Thiazides in Subjects with Chronic Kidney Disease? *Nature Reviews Nephrology* 2010; 6:564-6
 430. Johnson RJ, Sanchez-Lozada LG, Nakagawa T. The effect of fructose on renal biology and disease. *J Am Soc Nephrol* 2010; 21:2036-9
 431. Nakagawa T, Tanabe K, Croker BP, **Johnson RJ**, Grant MA, Kosugi T, Li Q. Endothelial dysfunction as a potential contributor in diabetic nephropathy. *Nature Rev Nephrol* 2011; 7:36-44
 432. Hovind P, Rossing P, **Johnson RJ**, Parving HH. Serum uric acid as a new player in the development of diabetic nephropathy. *J Renal Nutr* (review) 2011; 21: 124–127
 433. Kanbay M, Sanchez-Lozada LG, Franco M, Madero M, Solak Y, Rodriguez-Iturbe, B, Covic A, **Johnson RJ**. Microvascular Disease and Its Role In Brain And Cardiovascular System: A Potential Role For Uric Acid As A Cardiorenal Toxin. *Nephrol Dial Transpl* 2011 Feb;26(2):430-7
 434. Perez-Pozo SE, Schold J, Nakagawa T, Sanchez-Lozada LG, **Johnson RJ**, Lopez-Lillo J. Response to Dr White. *Int J Obes (Lond)*. 2011May; 35:748-7849
 435. Shimada M, Araya C, Ishimoto T, **Johnson RJ**, Garin EH. Minimal change disease: a "two-hit" podocyte immune disorder? *Pediatr Nephrol* 2011 Apr;26(4):645-9
 436. Madero M, Perez-Pozo SE, Jalal D, **Johnson RJ**, Sanchez-Lozada LG. Dietary fructose and hypertension. *Curr Hypertens Reports*. 2011 Feb;13(1):29-35
 437. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. *Diabetes*. 2011 Apr;60(4):1258-69
 438. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicesu M, Covic A, Jalal D, Johnson RJ. Serum Uric Acid Level and Endothelial Dysfunction in Patients with Nondiabetic Chronic Kidney Disease. *Am J Nephrol*. 2011 Mar 8;33(4):298-304.
 439. PanzerU, Jan-Eric Turner J-E, Steinmetz OM, Kurts C, Johnson RJ, Stahl RAK. ISN Forefront Symposium 2010 in Sylt, Germany: 'Induction and Resolution of Renal Inflammation' *Kidney Int* 2011 Apr;79(8):807-13
 440. Kanbay M, Ikizek M, Solak Y, Selcoki Y, Uysal S, Armutcu F, Eryonucu B, Covic A, Johnson RJ. Uric Acid and Pentraxin-3 Levels Are Independently Associated with Coronary Artery Disease Risk in Patients with Stage 2 and 3 Kidney Disease. *Am J Nephrol*. 2011 Mar 10;33(4):325-331
 441. Chen W, Wang H, Liu Q, Chen W, **Johnson RJ**, Dong X, Li H, Sangba, Tan J, Luo N, He H, Yu X. Prevalence and risk factors of chronic kidney disease: a population study in the Tibetan population. *Nephrol Dial Transpl* 2011 May;26(5):1592-9
 442. **Johnson RJ**, Lanaspá MA, Gaucher EA. Uric acid: A Danger Signal from the RNA World that may have a role in the Epidemic of Obesity, Metabolic Syndrome and CardioRenal Disease: Evolutionary Considerations *Semin Nephrol* 2011 Sep; 31:394-399

443. Lanaspá MA, Sautin YY, Ejaz AA, Madero M, Le M, Manitius J, Sanchez-Lozada LG, Nakagawa T, **Johnson RJ**. Uric acid and metabolic syndrome: What is the relationship? *Current Rheumatol Reviews* 2011; 7:162-169
444. **Johnson RJ**, Kanbay M, Sanchez-Lozada LG. Introduction: The Rediscovery of Uric acid in CardioRenal Disease: Introduction *Sem Nephrol* 2011; Sep 31:391-3
445. Basar N, Sen N, Ozcan F, Erden G, Kanat S, Sokmen E, Isleyen A, Yuzgecer H, Ozlu MF, Yildirimkaya M, Maden O, Covic A, Johnson RJ, Kanbay M. Elevated Serum Uric Acid Predicts Angiographic Impaired Reperfusion and 1-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. *J Investig Med*. 2011 Aug;59(6):931-937
446. Rodríguez-Iturbe B, Franco M, Tapia E, Quiroz Y, and **Johnson RJ**. Renal inflammation, autoimmunity and salt-sensitive hypertension. *Clin Exp Pharm Physiol* 2012; 39:96-103
447. Garcia GE, Truong LD, Chen JF, **Johnson RJ**, Feng L. Adenosine A_{2A} Receptor Activation Prevents Progressive Kidney Fibrosis in a Model of Immune-Associated Chronic Inflammation. *Kidney Int* 2011 Aug;80(4):378-88
448. Roncal Jimenez CA, Lanaspá MA, Rivard CJ, Nakagawa T, Sanchez-Lozada LG, Andres-Hernando A, Tanabe K, Madero M, Sautin YY, **Johnson RJ**. Sucrose induces Fatty Liver and Type II Diabetes in Rats Independent of Energy Intake. *Metabolism* 2011 Sep;60(9):1259-70
449. Ishimoto T, Shimada M, Araya CE, Huskey J, Garin EH, **Johnson RJ**. Minimal Change Disease: A CD80 Podocytopathy? *Sem Nephrol* 2011 Jul;31(4):320-5.
450. Arestegui AH, Fuquay R, Sirota J, Swenson ER, Schoene RB, Jefferson JA, Chen W, Yu X, Kelly JP, **Johnson RJ**, Escudero E. High Altitude Renal Syndrome. *J Am Soc Nephrol* 2011 Nov;22(11):1963-8
451. Madero M, Arriaga JC, Jalal D, Rivard C, McFann K, Pérez-Méndez O, Vázquez A, Ruiz A, Lanaspá MA, Jimenez CR, **Johnson RJ**, Lozada LG. The effect of two energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and metabolic syndrome parameters: a randomized controlled trial. *Metabolism*. 2011 Nov;60(11):1551-9.
452. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, **Johnson RJ**. Allopurinol improves endothelial dysfunction, and eGFR in asymptomatic hyperuricemic subjects with normal renal function: A prospective randomized study. *CJASN* 2011 Aug;6(8):1887-94
453. Afsar B, Elsurer R, Covic A, **Johnson RJ**, Kanbay M Relationship between Uric Acid and Subtle Cognitive Dysfunction in Chronic Kidney Disease. *Am J Nephrol*. 2011 Jun 10;34(1):49-54
454. **Johnson RJ**, Avena N, Ishimoto T, Johnson DR, Zahniser N, Gold M. Attention Deficit Hyperactivity Disorder: Time to Reappraise the Role of Sugar? *Postgraduate Medicine* 2011 Sep;123(5):39-49.
455. **Johnson RJ**, Kanbay M, Kang DH, Sanchez-Lozada LG, Feig D. Uric acid: A Clinically Useful Marker to Distinguish Preeclampsia from Gestational Hypertension. *Hypertension* 2011 Oct;58(4):548-9.
456. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, Yang Q, **Johnson RJ**, Yu X. Clinical

- outcome of hyperuricemia in IgA nephropathy clinical outcome: A retrospective cohort study and randomized controlled trial *Kidney Blood Pressure Res* 2011; Nov; 35:153-160
457. Sulikowska B, **Johnson RJ**, Odrowąż-Sypniewska G, Manitius J. Uric acid, Renal Vasoconstriction and Erythropoietin Relationship in IgA Nephropathy Revealed by Dopamine-induced Glomerular Filtration Response. *Kidney Blood Pressure Res* 2011; 35:161-166
458. Mazali FC, **Johnson RJ**, Mazzali M. Use of Uric acid lowering agents limits experimental cyclosporine nephropathy. *Nephron Exp Nephrol* 2011; 120:e12-e19
459. Lapsia V, **Johnson RJ**, Dass B, Shimada M, Kambhampati G, Ejaz NI, Arif AA, Ejaz AA. Elevated Uric Acid Increases the Risk for Acute Kidney Injury. *Am J Med* 2012 Mar; 125(3):302.e9-17.
460. Brymora A, Flisinski M, **Johnson RJ**, Goszka G, Stefanska A, Manitius J. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. *Nephrol Dial Transpl* 2012 Feb;27(2):608-12
461. Shimada M, Ishimoto T, Lee PY, Lanaspá MA, Rivard C, Roncal-Jimenez CA, Wymer D, Mathieson PW, Saleem MA, Garin EH, **Johnson RJ**. Toll-like receptor 3 ligands induce CD80 expression in Human Podocytes via an NFκB Dependent Pathway. *Nephrol Dial Transpl* 2012 Jan;27(1):81-9
462. Le MT, Frye RF, Rivard CJ, Cheng J, McFann KK, Segal MS, **Johnson RJ**, Johnson JA. Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. *Metabolism Clinial and Experimental* 2012; 61:641-651.
463. Ishimoto T, Lanaspá MA, Le MT, Garcia G, Diggle CP, MacLean PS, Jackman MR, Asipu A, Roncal C, Kosugi T, Rivard C, Maruyama S, Rodriguez-Iturbe B, Sanchez-Lozada LG, Bonthron DT, Sautin YY, Johnson RJ. Opposing effects of fructokinase C and A isoforms on Fructose-induced Metabolic Syndrome. *Proc Natl Acad Sci USA* 2012; 109(11):4320-5
464. Tanabe K, Kitagawa W, Garcia ML, Rivard C, Miyazaki M, Schreiner G, Johnson RJ, Nakagawa T. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS deficient mice. *Am J Physiol Renal Physiol*. 2012 May;302(9):F1151-60
465. Shafiu M, **Johnson RJ**, Turner ST, Langaee T, Gong Y, Chapman AB, Gums JG, Johnson JA. Uric acid transporter gene *SLC22A12* polymorphisms associated with obesity and metabolic syndrome in Caucasians with Hypertension. *Kidney Blood Press Res*. 2012 Jun 8;35(6):477-482
466. Ejaz AA, Dass B, Kambhampati G, Ejaz NI, Maroz N, Dhatt GS, Arif AA, Faldu C, Lanaspán MA, Shah G, Johnson RJ. Lowering serum uric acid to prevent acute kidney injury. *Medical Hypothesis* 2012 Jun;78(6):796-9
467. Ejaz AA, Kambhampati G, Ejaz NI, Dass B, Lapsia V, Arif AA, Asmar A, Shimada M, Alsabbagh MM, Aiyer R, **Johnson RJ**. Post-operative serum uric acid and acute kidney injury *J Nephrol*. 2012; 25:497-505
468. Abdelmalak MF, Lazo M, Horska H, Bonnekamp S, Lipkin EW, Balasubramanyam A, Bantle JP, Johnson RJ, Diehl AM, Clark JM. Higher Dietary Fructose Is Associated with Impaired Hepatic ATP Homeostasis in Obese individuals with type 2 diabetes *Hepatology* 2012; 56:952-60

469. Tamura Y, Tanabe K, Kitagawa W, Uchida S, Schreiner GF, Johnson RJ, Nakagawa T. Nicorandil, a K_{ATP} channel opener, alleviates chronic renal injury by targeting podocyte and macrophage. *Am J Physiol Renal Physiol* 2012 Aug;303(3):F339-49
470. Wei X, Xu R, Yang Z, Liao Y, Johnson RJ, Yu X, Chen W. Novel uromodulin mutation in familial juvenile hyperuricaemic nephropathy *Am J Nephrol* 2012; 36:114-20
471. Johnson RJ, Thomas J, Lanaspá MA. Impact of beverage intake on health and the kidneys. *Nutrition Today* 2012; 47:S22-S24
472. Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E, Unal HU, Arslan E, Verim S, Magdaleró M, McFann K, Johnson RJ. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. *Am J Nephrol* 2012 Sep 22;36(4):324-331
473. Li Z, Liu Q, Mao H, Li Z, Dong X, Liu Y, Lin J, Chen W, Wang H, **Johnson RJ**, Yu X, Chen W. Gender Difference in the Association of Hyperuricemia with Chronic Kidney Disease in Southern China. *Kidney Blood Press Res.* 2012 Aug 29;36(1):98-106
474. Kretowicz M, **Johnson RJ**, Ishimoto T, Nakagawa T, Manitius J. The impact of fructose on renal function and blood pressure. *Int J Nephrol* 2011; Article ID 315879, pp1-5
475. Lanaspá MA, Sanchez-Lozada LG, Cicerchi C, Li N, Roncal-Jimenez CA, Ishimoto T, Garcia GE, Thomas JB, Rivard CJ, Andres-Hernando A, Hunter B, Schreiner G, Rodriguez-Iturbe B, Sautin YY and **Johnson RJ**. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. *PLOS One* 2012;7(10):e47948
476. Lanaspá MA, Garcia G, Cicerchi C, Li N, Roncal-Jimenez CA, Rivard CJ, Hunter B, Andres-Hernando A, Ishimoto T, Sanchez-Lozada LG, Thomas J, Hodges RS, Mant CT, **Johnson RJ**. Counteracting Roles of AMP Deaminase and AMP kinase in the development of fatty liver. *PLOS One* 2012; 7(11):e48801
477. Lanaspá MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Sautin YY, **Johnson RJ**. Uric acid-induced hepatic steatosis is mediated by generation of mitochondrial oxidative stress and activation of NADPH oxidase. *J Biol Chem* 2012; 287(48):40732-44
478. Tanabe K, Tamura Y, Lanaspá MA, Miyazaki M, Suzuki N, Sato W, Maeshima Y, Schreiner GF, Villareal F, **Johnson RJ**, Nakagawa T. Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. *Am J Physiol Renal Physiol* 2012; 40(9):1978-84
479. Liu Q, Li Z, Wang H, Chen X, Dong X, Mao H, Tan J, Luo N, **Johnson RJ**, Chen W, Yu X, Chen W. High prevalence and associated risk factors for impaired renal function and urinary abnormalities in a rural adult population from southern China. *PLoS One*. 2012;7(10):e47100
480. Sánchez-Lozada LG, Lanaspá-García MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH, **Johnson RJ**. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations *Nephron Exp Nephrol* 2012 Dec 7;121(3-4):e71-e78
481. Fini MA, Elias A, **Johnson RJ**, Wright RM. Contribution of uric acid to cancer risk recurrence and mortality *Clinical Translational Medicine* 2012; 1:16 (15 August 2012)
482. Quiroz Y, **Johnson RJ**, Rodriguez-Iturbe B. The role of T cells in the pathogenesis of primary hypertension. *Nephrol Dial Transpl* 2012; 27 (Suppl4):iv2-5

483. Hurtado A., Escudero E. Pando J, Sharma S, **Johnson RJ**. Cardiovascular and Renal effects of Chronic Exposure to High Altitude. *Nephrol Dial Transpl* 2012 Dec; 27 Suppl4:iv11-16
484. **Johnson RJ**, Rivard C, Lanaspá MA, Otabachian-Smith S, Ishimoto T, Cicerchi C, Cheeke PR, MacIntosh B, Hess T. Fructokinase, Fructans, Intestinal Permeability, and Metabolic Syndrome: An Equine Connection? *J Equ Vet Science* 2013; 33:120-126
485. Rivard C, Thomas J, Lanaspá MA and **Johnson RJ**. ‘Sack and Sugar’, and the Aetiology of Gout in England between 1650 and 1900. *Rheumatology (Oxford)* 2013; 52:421-26
486. Rodríguez-Iturbe B, Franco M, **Johnson RJ**. Impaired pressure natriuresis is associated with interstitial inflammation in salt-sensitive hypertension. *Curr Opin Nephrol Hypertens* 2013, 22:37–44
487. Sirota JC, McFann K, Targher G, **Johnson RJ**, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. *Metabolism* 2013 Mar; 62:392-9
488. Stenvinkel P, Jani A, **Johnson RJ**. Hibernating bears (Ursidae) – Metabolic Magicians of definite interest for the Nephrologist. *Kidney Int* 2013 Feb; 83:207-212.
489. Turak O, Ozcan F, Tok D, Isleyen A, Sokmen E, Tasoglu I, Aydogdu, S, Seri N, McFann K, **Johnson RJ**, Kanbay M. Serum Uric Acid, Inflammation and Nondipping Circadian Pattern in Essential Hypertension. *J Clin Hypertens* 2013 Jan; 15:7-13.
490. Pons H, Ferrebu A, Quiroz Y, Romero F, Parra G, **Johnson RJ**, Rodríguez-Iturbe B. Immune reactivity to heat shock protein 70 Expressed in the Kidney is Cause of Salt-sensitive Hypertension. *Am J Physiol Renal Physiol* 2013 (Feb); 304:F289-99
491. Ejaz AA, Das B, Lingegowda V, Shimada M, Beaver TM, Ejaz N, Abouhamze M, **Johnson RJ**. Effect of Uric Acid lowering Therapy on the Prevention of Acute Kidney Injury in Cardiovascular Surgery. *Int Urol Nephrol* 2013; 45:449-458.
492. Le MT, Lobmeyer MT, Campbell M, Cheng J, Wang Z, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Gong Y, Johnson RJ, Johnson JA. Impact of genetic polymorphisms of SLC2Aa2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals. *PLOS One* 2013; 8(1):e52062
493. Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Johnson RJ, Kang DH. Uric Acid-induced Phenotypic Transition of Renal Tubular Cells as a Novel Mechanism of Chronic Kidney Disease. *Am J Physiol Renal Physiol* 2013; 304:F471-80
494. Vasiliou V, Sandova M, Backos DS, Jackson BC, Chen Y, Reiga P, Lanaspá M, Johnson RJ, Koppaka V and Thompson DC. ALDH16A1 is a novel non-catalytic protein that may be involved in the etiology of gout via protein-protein interactions with HPRT1. *Chemico-Biol Interactions* 2013; 202:22-31
495. Tapia E, Cristobal M, Garcia-Aroyo FE, Soto V, Monroy-Sanchez F, Pacheco U, Lanaspá MA, Roncal-Jimenez C, Cruz-Robles D, Ishimoto T, Madero M, Johnson RJ, Sanchez Lozada LG. Synergistic effect of uricase blockade plus physiologic amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats. *Am J Physiol Renal Physiol* 2013; 304:F727-36.
496. Franco M, Edilia T, Pacheco U, Bautista R, Santamaria J, Quiroz Y, Johnson RJ, Rodríguez-Iturbe B. Impaired pressure natriuresis resulting in salt-sensitive hypertension is caused by tubulointerstitial immune cell infiltration in the kidney. *Am J Physiol Renal*

Physiol 2013; 304:F982-90

497. Schroff RC, Price KL, Kolatsi-Joannour, Todd AF, Wells D, Deanfield J, Johnson RJ, Rees L, Long DA. Circulating angiopoietin-2 is a biomarker for early cardiovascular disease in children on long-term dialysis. *PLOS One* 2013; 8(2):e56273
498. Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origin of hypertension. *J Peds* 2013; 162:896-902
499. Hohenstein B, Daniel C, **Johnson RJ**, Amann KU, Hugo CPM. Platelets are not critical effector cells for the time course of murine passive crescentic glomerulonephritis. *Platelets* 2013; 24:267-274.
500. Johnson RJ, Sanchez-Lozada LG, Mazzali M, Feig DI, Kanbay M, Sautin YY. What are the key arguments against uric acid as a true risk factor for hypertension? *Hypertension* 2013; 61:948-51
501. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, **Johnson RJ**. The role of uric acid in the pathogenesis of human cardiovascular disease. *Heart* 2013 99:759-766
502. **Johnson RJ**, Stenvinkel P, Martin SL, Sanchez-Lozada LG, Hill JO, Lanaspá MA. Redefining Metabolic Syndrome as a Fat Storage Condition Based on Studies of Comparative Physiology. *Obesity* 2013; 21: 659-64.
503. Inaba S, Sautin YY, Garcia GE, Johnson RJ. What can asymptomatic hyperuricemia and systemic inflammation in the absence of gout tell us? *Rheumatology (Oxford)* 2013;52:963-5
504. Lotan Y, Daudon M, Bruyère F, Talaska G, Strippoli G, Johnson R, Tack I. Impact of fluid intake in the prevention of urinary system diseases. A brief review. *Curr Opin Nephrol Hypertens* 2013 May;22 Suppl 1:S1-10
505. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levin A, Levy A. Evolving importance of kidney disease – from subspecialty to global health burden. *The Lancet* 2013 Jul 13;382(9887):158-69
506. Ishimoto T, Shimada M, Garcia G, Kosugi T, Sato W, Lee P, Lanaspá M, Rivard C, Garin, E, **Johnson RJ**. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. *Nephrol Dial Transpl* 2013 Jun;28(6):1439-46
507. Stenvinkel P, Frobert O, Anderstam B, Palm F, Eriksson M, Bragfors-Helin AC, Qureshi AR, Larsson T, Friebe A, Zedrosser A, Josefsson J, Svensson M, Sahdo B, Bankir L, Johnson RJ. Metabolic Changes in Summer Active and Anuric Hibernating Free-Ranging Brown Bears (*Ursus arctos*) *PLOS One* 2013; 9; 8(9):e72934.
508. Lanaspá MA, Ishimoto T, Li N, Cicerchi C, Orlicky D, Ruzicky P, Rivard C, Inaba S, Roncal-Jimenez CA, Diggle CP, Asipu A, Petrash M, Kosugi T, Maruyama S, Sanchez-Lozada LG, Bonthron DT, Sautin YY, Johnson RJ. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. *Nat Commun*. Sep 11 2013;4:2434
509. Ishimoto T, Cara G, Shimada M, Wasserfall CH, Winter W, Rivard CJ, Araya CE, Saleem MA, Mathieson PW, Johnson RJ, and Garin EH. Serum from Minimal Change Patients in Relapse Increases CD80 Expression in Cultured Podocytes. *Pediatr Nephrol* 2013; 28(9): 1803-1812
510. Maahs DM, Jalal D, Chonchol M, Johnson RJ, Rewers M, Snell-Bergeon JI. Impaired renal function further increases odds of 6 year coronary artery calcification progression in

- adults with type 1 diabetes: the Cacti Study. *Diabetes Care* 2013; 36(9): 2607-14.
- 511.** Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: Which is chasing which? *Nephrol Dial Transpl* 2013; 28(9): 2221-8.
- 512.** Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shariu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspas MA. Sugar, uric acid and the etiology of diabetes and obesity. *Diabetes* 2013; 62(10):3307-15
- 513.** Johnson RJ, Sanchez-Lozada LG. Mesoamerican nephropathy: New Clues to the Cause. *Nature Reviews Nephrol* 2013; 9(10):560-561.
- 514.** Hernández-Ríos R, Hernández-Estrada S, Cruz-Robles D, Hernández-Lobato S, Villalobos-Martín M, Johnson RJ, Rodríguez Castellanos FE, García-Arroyo F, Sanchez-Lozada LG. Low fructose and low salt diets increase mitochondrial DNA in white blood cells of overweight subjects *Exp Clin Endocrinol Diabetes* 2013 Oct; 121: 535-8.
- 515.** Cara-Fuentes G, Araya C, Wei C, Rivard C, Ishimoto T, Reiser J, Johnson RJ, Garin EH. CD80, suPAR and Nephrotic syndrome in a case of NPHS2 Mutation. *Nephrologia* 2013 2013 Sept; 33:727-731.
- 516.** Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Lanaspas MA, Tamura Y, Tanabe K, Ishimoto T, Thomas J, Inaba S, Kitagawa W, Rivard CJ. Umami: the tast the drives purine intake. *J Rheumatol* 2013 Nov; 40:1794-1796
- 517.** Bjornstad P, Snell-Bergeon JK, Rewers M, Jalal D, Chonchol MB, Johnson RJ, Maahs DM. Early Diabetic Nephropathy – a Complication of Insulin Resistance in Type 1 Diabetes. *Diabetes Care* 2013 Nov; 36:367-3683
- 518.** Huskey J, Rivard C, Myint H, Lucia S, Smith M, Shimada M, Ishimoto T, Araya C, Garin EH, **Johnson RJ**. Minimal Change Disease in Graft versus Host Disease: A Podocyte Response to the Graft? *Clin Nephrol* 2013; 80:469-73.
- 519.** Stenvinkel P, Johnson RJ. Kidney biomicry: a rediscovered scientific field that could provide hope to patients with kidney disease. *Archives Medical Research* 2013 Nov;44(8):584-90
- 520.** Nakagawa T, Sato W, Kosugi T, Johnson RJ. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. *J Diabetes Res* 2013:184539
- 521.** Ishimoto T, Lanaspas MA, Rivard CJ, Roncal-Jimenez C, Orlicky D, Cicerchi C, McMahan RH, Abdelmalak MF, Rosen HR, Jackman MR, MacLean PS, Diggle CP, Asipu A, Inaba S, Kosugi T, Sato W, Maruyama S, Sanchez-Lozada LG, Sautin YY, Hil JO, Bonthron DT, Johnson RJ. High Fat and High Sucrose (Western) Diet Induce Steatohepatitis that is Dependent on Fructokinase . *Hepatology* 2013 Nov; 58:1632-1643.
- 522.** Chen W, Roncal-Jimenez C, Lanaspas M, Smits G, Chonchol M, Johnson RJ, Jalal D. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. *Metabolism* 2014 Jan;63(1):150-60
- 523.** Rodriguez-Iturbe B, Pons H, Quiroz Y, Lanaspas MA, Johnson RJ. Autoimmunity in the pathogenesis of hypertension. *Nat Rev Nephrol* 2014 Jan;63(1):150-60
- 524.** Solak Y, Akilli H, Kayrak M, Aribas A, Galpov A, Turk S, Perez-Pozo SE, Covic A, McFann K, Johnson RJ, Kanbay M. Uric acid level and erectile dysfunction in patients with coronary artery disease: A new link? *Journal of Sexual Medicine* 2014;11:165–172
- 525.** Tharabenjasin P, Douard V, Patel C, Krishnamara N, Johnson RJ, Zuo J, Ferraris RP.

- Acute interactions between intestinal sugar and calcium transport in vitro. *Am J Physiol Gastroenterol Liver Physiol* 2014 Jan;306(1):G1-G12
- 526.** Correa-Rotter R, Wesseling C, Johnson RJ. Chronic Kidney Disease of unknown origin in Central America: the case for a Mesoamerican Nephropathy. *Am J Kid Dis* 2014; 63(3):506-520.
- 527.** Maeda-Hori M, Kosugi T, Kojima H, Sato W, Inaba S, Maeda K, Nagaya H, Sato Y, Ishimoto T, Ozaki T, Tsuboi N, Muro Y, Yuzawa Y, Imai E, Johnson RJ, Matsuo S, Kadomatsu K, and Maruyama S. Plasma CD147 reflects histological features in patients with lupus nephritis. *Lupus* 2014; 23:342-352
- 528.** Bjornstad P, Wadwa RP, Sirota JC, Snell-Bergren JK, McFann K, Rewers M, Rivard CJ, Jalal D, Chonchol MB, Johnson RJ, Maahs DM. Serum uric acid and hypertension in adults: a paradoxical relationship in type 1 diabetes *J Clin Hypertens (Greenwich)*. 2014 Apr;16(4):283-8)
- 529.** Kratzer J, Lanaspá MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, Ortlund EA, Johnson RJ, Gaucher E. Evolutionary history and metabolic insights of ancient mammalian uricases. *Proc Natl Acad Sci USA* 2014 Mar 11;111(10):3763-8
- 530.** Thomas J, Lanaspá MA, Schreiner G, Johnson RJ. Epicatechin Protects against Corticosteroid Induced Hepatic Steatosis, *Journal of Steroids & Hormonal Science* 2014; 5:1
- 531.** Kanbay M, Siritopol D, Nistor I, Elcioglu OC, Telci O, Takir M, Johnson RJ, Covic A. Effect of allopurinol on endothelial dysfunction: A Meta-analysis. *Am J Nephrol* 2014; 39:348-356
- 532.** Bjornstad P, Snell Bergeon J,K, McFann K, Wadwa RP, Rivard CJ, Jalal D, Chonchol MB, Johnson RJ, Maahs DM. Serum uric acid and insulin sensitivity in adolescents with and without type 1 diabetes. *J Diabetes Complications* 2014; 16:283-288
- 533.** Vandell AG, McDonough CW, Gong Y, Langaee TY, Lucas AM, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Hydrochlorothiazide-Induced Hyperuricemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *J Intern Med*. 2014 Feb 12. [Epub ahead of print]. PMID: 24612202.
- 534.** Kanbay A, Inonu H, Solak Y, Erden A, Uslu E, Yuksel SA, Ozturk MA, McFann K, Johnson RJ, Kanbay M. Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. *Eur J Int Med* 2014 Jun;25(5):471-6
- 535.** Johnson RJ, Rodriguez-Iturbe B, Roncal-Jimenez C, Lanaspá MA, Ishimoto T, Nakagawa T, Correa-Rotter R, Wesseling C, Bankir L, Sánchez-Lozada LG. Hyperosmolarity drives hypertension and CKD—Water and Salt revisited. *Nat Rev Nephrol* 2014 Jul;10(7):415-20
- 536.** Roncal-Jimenez, C, Ishimoto T, Lanaspá MA, Rivard CJ, Nakagawa T, Ejaz AA, Cicerchi C, Inaba S, Le M, Miyazaki M, Glaser J, Correa-Rotter R, Gonzalez MA, Aragon A, Wesseling C, Sanchez-Lozada LG, Johnson RJ. Fructokinase activity mediates dehydration induced renal injury. *Kidney International* 2014; 86:294-302
- 537.** Cara-Fuentes G, Wei C, Alfons S, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH. CD80 and suPAR in patients with Minimal Change Disease and Focal Segmental Glomerulosclerosis: Diagnostic and Pathogenic Significance. *Pediatr Nephrol* 2014; 29:1363-71

- 538.** Johnson RJ, Glaser J, Sánchez-Lozada LG. Chronic Kidney Disease of Unknown Etiology: A Disease of Global Warming? *MEDICC Review* 2014; 16:79-81
- 539.** Cicerchi C, Li N, Kratzer J, Garcia G, Roncal-Jimenez CA, Tanabe K, Hunter B, Ishimoto T, Rivard CJ, Sautin YY, Gaucher E, Johnson RJ, Lanaspá MA. Uric Acid-dependent inhibition of AMP Kinase induces hepatic glucose production in diabetes and starvation: Evolutionary Implications of the Uricase loss in hominids. *FASEB J* 2014; 28:3339-50
- 540.** Turak O, Afsar B, Ozcan F, Canpolat U, Grbovic E, Mendi MA, Oksuz, F, Siriopol D, Covic A, Caliskan M, McFann K, Johnson RJ, Kanbay M. Relationship between Elevated Morning Blood Pressure Surge, Uric Acid and Cardiovascular Outcomes in Hypertensive Patients. *J Clin Hypertens* 2014; 16:530-535
- 541.** Mohandas R, Sautina L, Beem E, Schuler A, Chan WY, Domsic J, McKenna R, Johnson RJ, Segal MS. Uric Acid Inhibition of Dipeptidyl Peptidase IV *In Vitro* is Dependent on the Intracellular Formation of Triuret. *Exp Cell Res* 2014; 326:136-142
- 542.** Bjornstad P, Maahs DM, Rivard CJ, Pyle L, Rewers M, Johnson RJ, Snell-Bergeon JK. Serum Uric Acid Predicts Vascular Complications in Adults with Type 1 Diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study. *Acta Diabetologica*. 2014 Oct;51(5):783-91
- 543.** Cara-Fuentes G, Kairalla J, Ishimoto T, et al. Rituximab in Idiopathic Nephrotic Syndrome: Does it Make Sense? *Pediatr Nephrol* 2014; 2014 Aug;29(8):1313-9
- 544.** Johnson RJ, Lanaspá MA, Sanchez-Lozada LG, Rivard CJ, Bjornstad P, Merriman TR, Sundborn G. Fat Storage syndrome in Pacific Peoples: A Combination of Environment and Genetics? *Public Health Dialogue* 2014; 20:11-16
- 545.** Merriman TR, Dalbeth N, Johnson RJ. Sugar-sweetened beverages, genes, urate and gout. *Public Health Dialogue* 2014; 20:31-38
- 546.** Choi YJ, Shin HS, Choi HS, Park JW, Jo I, Oh ES, Lee KY, Johnson RJ, Kang DH. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. *Lab Invest* 2014; 94:1114-25
- 547.** Rodriguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ. The immunological basis of hypertension. *Am J Hypertens* 2014; 27:1327-37
- 548.** Couser WG, Johnson RJ. The etiology of glomerulonephritis: Roles of infection and autoimmunity. *Kidney Int* 2014; 86:905-914
- 549.** Lanaspá MA, Ishimoto T, Cicerchi C, Tamura, Roncal-Jimenez CA, Chen W, Tanabe K, Andres-Hernando A, Finol E, Inaba S, Li N, Rivard CJ, Kosugi T, Sanchez-Lozada LG, Petrash JM, Sautin YY, Ejaz A, Kitagawa W, Garcia G, Bonthron DT, Asipu A, Diggie CP, Rodriguez-Iturbe B, Nakagawa T, Johnson RJ. Endogenous Fructose Production and Fructokinase Activation Mediate Renal Injury in Diabetic Nephropathy. *JASN* 2014;25:2526-38
- 550.** Cara-Fuentes G, Wasserfal CH, Wang H, Johnson RJ, Garin EH. Minimal Change Disease: A dysregulation of the podocyte CD80-CTLA-4 Axis? *Pediatric Nephrol* 2014; 29: 2333-40
- 551.** Pando-Kelly J, Johnson RJ, Hurtado A. Microalbuminuria in Adolescents: A comparative study at high altitude and at sea level. *ISN Education* <http://www.theisn.org/global-nephrology/education-by-topic/global-nephrology/microalbuminuria-in-healthy-adolescents->

- [a-comparative-study-at-high-altitude-and-at-sea-level/itemid-1384](#), also in Open Urology and Nephrology Journal, in press
- 552.** Bjornstad P, Maahs D, Rewers M, Johnson RJ, Snell-Bergeon J. ABC goal achievement predicts microvascular but not macrovascular complications over 6-years in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study. *J Diabetes Complications* 2014; 28:762-6
- 553.** Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, **Johnson RJ**. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. *Pediatr Nephrol.* 2014 Sep 20. [Epub ahead of print]
- 554.** Shirashi T, Tamura Y, Taniguchi K, Hiagaki M, Ueda S, Shima T, Nagura M, Nakagawa T, Johnson RJ, Uchida S. Combination of ACE inhibitor with nicroandil provides further protection in chronic kidney disease. *Am J Physiol Renal Physiol* 2014; 307:F1313-1322
- 555.** Sullivan JS, Le MT, Pan Z, Rivard C, Love-Osborne K, Robbins K, Johnson RJ, Sokol RJ, Robbins K, Sundaram SS. Oral fructose absorption in obese children with non-alcoholic fatty liver disease. *Pediatr Obesity* 2014 ([in press](#))
- 556.** Saab K, Kendrick J, Yracheta JM, Lanaspá MA, Pollard M, Johnson RJ. New Insights on the Risk for Cardiovascular Disease in African Americans: The Role of Added Sugars. *JASN* ([in press](#))
- 557.** Johnson RJ, Andrews PA. Thrifty Genes and the Greatest Pandemic in History: A Possible Miocene Connection with the Epidemics of Obesity and Diabetes. *Scientific American* 2015 ([in press](#))
- 558.** Bjornstad P, Maahs DM, Johnson RJ, Rewers M, Snell-Bergeon JK. Estimated Insulin Sensitivity Predicts Regression of Albuminuria in Type 1 Diabetes. *Diabetes Metabolism* ([in press](#))
- 559.** Johnson RJ, Lanaspá MA, Sanchez-Lozada LG, Rodriguez-Iturbe B. Invited Review: The Discovery of Hypertension, Evolving Views on the Role of the Kidneys, and Current Hot Topics. *Am J Physiol Renal Physiol* ([in press](#))
- 560.** Cristóbal-García M, García-Arroyo FE, Tapia E, Osorio H, Arellano-Buendía AS, Pedraza-Chaverri J, Zazueta C, Rodriguez-Iturbe B, Johnson RJ, Sánchez Lozada LG. Decreased renal blood flow induced by long term hyperuricemia is associated with increased oxidative stress and mitochondrial dysfunction in renal cortex. *Am J Nephrol* (submitted)
- 561.** Sulikowska B, Johnson RJ, Wiechecka-Korenkiewicz J, Korenkiewicz J, Marszałek A, Odrowąż-Sypniewska G, Manitius J. Metabolic Syndrome: A marker for Tubulointerstitial Dysfunction in IgA nephropathy?
- 562.** Lanaspá MA, Epperson E, Cicerchi C, Li N, Garcia G, Jain S, Rivard C, Ishimoto T, Thomas J, Shimada M, Sanchez-Lozada LG, Nakagawa T, Hill JO, Jani A, Martin S and Johnson RJ. Alterations in AMP handling during hibernation correlate with patterns of fat synthesis and fatty acid oxidation. *PLOS One* ([in revision](#))
- 563.** A. Ahsan Ejaz, Negiin Pourafshar, Rajesh Mohandas, Bryan A. Smallwood, Richard J. Johnson, and Jack W. Hsu. Uric Acid and the Prediction Models of Tumor Lysis Syndrome in AML *PLOS One* (minor revisions)
- 564.**

CHAPTERS AND LETTERS

1. Couser WG, Adler S, PJ Baker, **Johnson RJ** and Turner DM. Tubulointerstitial immune complex lesions. In Proceedings of the Sixth International Symposium on Paediatric Nephrology. Hannover, West Germany, 1983. Springer-Verlag Heidelberg, 1984, pp. 209-214.
2. Couser WG, Adler S, Baker PJ, **Johnson RJ** and Perkinson DA. Mechanisms of immune complex formation and deposition in glomeruli--an overview. Proceedings of the 1984 International Congress of Nephrology. Springer-Verlag, New York, 1984. pp. 508-526.
3. **Johnson RJ** and Couser WG. Membranous nephropathy. In Current Therapy in Internal Medicine, eds Bayless T.M., Brain M.C., Cherniak R.M., B.C. Decker, Philadelphia, 1984, pp. 1140-1143.
4. **Johnson RJ** and Couser WG: Membranous Nephropathy in Current Therapy in Nephrology and Hypertension. (Ed) Glassock RJ, Decker BC, Phil., 1984, pp. 207-211.
5. **Johnson RJ**, Douglas J, Corey L., Krasney H: Adverse effects with acyclovir and meperidine. (letter) *Ann Int Med* 1985;103:962-963.
6. **Johnson RJ**, Blair A, Ahmad S: Ketoconazole in the treatment of fungal peritonitis. (Letter) *Perit Dial Bull* 1985;5(2):136.
7. Couser WG, Adler S, Baker PJ, **Johnson RJ** and Perkinson DT. In situ formation of immune complexes in renal glomeruli. Proceedings of the Ninth International Convocation of Immunology. Buffalo NY, 1984. Springer-Verlag, 1985, pp. 331-339.
8. **Johnson RJ**: Fish and shellfish poisoning. In The Travel and Tropical Medicine Manual, ed. EC Jong, WB Saunders, Philadelphia, 1987, p. 162-165.
9. Couser WG, **Johnson RJ** and Klebanoff SJ. New mechanisms of oxidant-induced glomerular injury. In Nephrology. Proceedings of the Xth International Congress of Nephrology, Bailliere Tindall, Philadelphia, Vol. 1, p. 495-508, 1988.
10. **Johnson RJ**, Klebanoff SJ and Couser WG. Oxidants in glomerular injury. In Contemporary Issues in Nephrology. eds. Wilson CW, Brenner BM, Stein J, Churchill-Livingston, New York, p. 87-110, 1988.
11. **Johnson RJ**: Non-post streptococcal post-infectious glomerulonephritis. In The Principles and Practice of Nephrology, eds. Klahr S, Jacobsen H, Striker G, BC Decker, Inc., Philadelphia, pps 265-271. 1990.
12. **Johnson RJ**: Platelets in immune mediated glomerular disease. In Proceedings of the Tenth International Congress of Nephrology. Springer-Verlag, New York, pp. 191-200, 1991.
13. Fingerle J, **Johnson RJ**, Majesky MW, Clowes AW and Reidy MA. Proliferation of vascular smooth muscle cells in the absence of platelets. In vivo study in de-endothelialized carotid arteries of thrombocytopenic rats. Platelets and Atherosclerosis, C Kessler, editor. Springer-Verlag, New York, pp 12-17, 1991.
14. **Johnson RJ**: The role of platelets in immune complex nephritis. In Nephrology. Proceedings of the Fourth Asian-Pacific Congress of Nephrology, International Academic Publisher, Beijing, pp. 121-130, 1991.
15. **Johnson RJ** and Couser WG: A reevaluation of the pathogenic mechanisms and treatment

- of hepatitis B associated membranous nephropathy. In Nephrology. Proceedings of the Fourth Asian-Pacific Congress of Nephrology, International Academic Publisher, Beijing, pp. 331-337, 1991.
16. Jong EC and **Johnson RJ**: Fish and shellfish poisoning: Toxic Syndromes, In The Travel and Tropical Medicine Manual (second edition), eds. E. Jong and R. McMullen, W.B. Saunders, Philadelphia, 1994, pp 318-324.
 17. **Johnson RJ** and Kimmel P: Glomerular diseases associated with viral and parasitic infections. The Principles and Practice of Nephrology. (eds. H. Jacobson, G. Striker , S. Klahr) pp. 128-133, 1995.
 18. Gretch DR, **Johnson RJ**, Yamabe H, Wener MH, Corey L, Alpers C and Willson R: Clinical, immunological, and virological features of HCV-associated membranoproliferative glomerulonephritis. Viral Hepatitis and Liver Disease, Springer-Verlag, Tokyo. Pp. 218-221, 1994.
 19. Yoshimura A, Iida H, Floege J and **Johnson RJ**: PDGF and Renal Disease (Chapter) in Molecular Biology of the Kidney in Health and Disease, Marcel Dekker, New York. eds. D. Schlondorff and J. Bonventre, pp. 875-886, 1995.
 20. Hugo C, Pichler R, Brandt J and **Johnson RJ**: Mesangial cell pathophysiology in glomerular injury. In Proceedings of the American Society of Pediatric Nephrology 1994 Educational Symposium, Seattle, WA., 1,2 May, 1994, Pediatr Nephrol (1995) 9:526-536.
 21. **Johnson RJ**, Willson R, Yamabe H, Couser WG, Alpers CE, Wener M, Davis C and Gretch D: Renal manifestations of hepatitis C virus infection. In Kidney and Liver Disease, Romosan I, Helicon Publishers, Romania, 1995.
 22. **Johnson RJ**, Klebanoff SJ, Couser WG: Neutrophils in Immunologic Renal Disease, eds W.G. Couser and E. Neilson, Raven Press, New York, 1997, pp. 547-561.
 23. Stehman-Breen C, Alpers CE, Willson R, **Johnson RJ**: Is there a hepatitis C virus-associated membranoproliferative glomerulonephritis? Am J Kid Dis (Letter), 1997;30:589-590.
 24. Couser WG, **Johnson RJ**: Postinfectious glomerulonephritis, in Immunologic Renal Disease, eds. WG Couser and E Neilson, Raven Press, New York, 1997, pp. 915-944.
 25. **Johnson RJ**, Alpers CE, Gretch D, Yamabe H, Willson R: Renal Disease and the Liver in The Liver and Systemic Disease, ed N Gitlin, Churchill Livingstone, New York, P. 45-58, 1997.
 26. **Johnson RJ**, Burdmann E, Ophascharoensuk V, Barsoum R: Glomerulonephritis associated with infections. In: Comprehensive Clinical Nephrology. RJ Johnson and JF Feehally, (eds.), Mosby, London, 1999.
 27. **Johnson RJ**, Schena FP: Membranoproliferative Glomerulonephritis and Cryoglobulinemia. In: Comprehensive Clinical Nephrology. RJ Johnson and JF Feehally (eds.), Mosby, London, 1999.
 28. **Johnson RJ**, Bakris G, Kurokawa K: Pathogenesis and Natural Cause of Essential Hypertension. In: Comprehensive Clinical Nephrology. RJ Johnson and JF Feehally (eds.), Mosby, London, 1999.
 29. Feehally JF, **Johnson RJ**: Introduction to Glomerular Disease: Pathogenesis and Classification. In: Comprehensive Clinical Nephrology. RJ Johnson and JF Feehally (eds.), Mosby, London, 1999.

30. Feehally JF, **Johnson RJ**: Introduction to Glomerular Disease: Clinical Presentations. In: Comprehensive Clinical Nephrology. RJ Johnson and JF Feehally (eds.), Mosby, London, 1999.
31. Jefferson JA, Haseley L, **Johnson RJ**: Platelet Derived and Fibroblast Growth Factors. In Textbook of Nephrology, Massry SG and Glasscock RJ (eds.), Fourth edition, Baltimore MA, Williams and Wilkins, 1998, pp. 607-611.
32. Weinberger M, **Johnson RJ**: The nonpharmacologic management of hypertension. In: Comprehensive Clinical Nephrology, RJ Johnson and JF Feehally eds, Mosby, London, 1999.
33. Jong EC, **Johnson RJ**: Fish and shellfish poisoning: Toxic Syndromes. In The Travel and Tropical Medicine Journal, 3rd edition, WB Saunders, Orlando, 2000.
34. **Johnson RJ**, Klebanoff SJ, Couser WG. Neutrophils. In Immunologic Renal Diseases, eds. Neilson EG, Couser WG. Lippincott Rowan, 2001.
35. Couser WG, **Johnson RJ**. Post-Infectious Glomerulonephritis In Immunologic Renal Diseases (Second Edition), eds W.G. Couser and E. Neilson, Raven Press, New York, 2001.
36. **Johnson RJ**, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Salt-sensitive hypertension. N Engl J Med 2002 August 8; 347(6):448-449 (letter).
37. **Johnson RJ**, Rennke H, and Feehally J. Introduction to Glomerular Disease: Pathogenesis and classification. In Comprehensive Clinical Nephrology, eds. **Richard J Johnson** and John Feehally. Harcourt, London, 2003.
38. Feehally J, Johnson RJ. Introduction to Glomerular Disease: Clinical Presentations. In Comprehensive Clinical Nephrology, eds. Richard J. Johnson and John Feehally, Harcourt, London, 2003.
39. Weinberger MH, Johnson RJ. Non-pharmacologic treatment of hypertension. In Comprehensive Clinical Nephrology, eds. Richard J. Johnson and John Feehally, Harcourt, London, 2003.
40. Schena FP, Johnson RJ, Alpers CE. Membranoproliferative glomerulonephritis. In Comprehensive Clinical Nephrology, Eds Richard J Johnson and John Feehally, Harcourt, London, 2003.
41. Kanellis J, Bakris G, Kurokawa K, Johnson RJ. Pathogenesis and Natural Course of Essential Hypertension. In: Comprehensive Clinical Nephrology. RJ Johnson and JF Feehally (eds.), Harcourt, London, 2003.
42. Lan HY, Johnson RJ. Mechanisms of tissue scarring: role of SMAD signaling. In: Principles of Molecular Medicine. Marschall Runge, Cam Patterson and William Mitch (eds.), Humana Press, NJ, 2003.
43. Sanchez-Lozada LG, Rodriguez-Iturbe B, **Johnson RJ**, Herrera-Acosta J: Tubulointerstitial injury: early or late event in the pathogenesis of hypertensive nephropathy? Kidney Int 2004; 65:1972 (letter).
44. Johnson RJ, Tisher CC. Chapter 8. Glomerular Diseases, In Nephrology and Hypertension, House Officer Series. 5th edition, eds CC Tisher and CS Wilcox, Lippincott Williams and Wilkins, Philadelphia, 2005. pp 50 - 62
45. Johnson RJ, Tisher CC. Chapter 9. Renal involvement in Systemic lupus erythematosus, In Nephrology and Hypertension, House Officer Series. 5th edition, eds CC Tisher and CS

- Wilcox, Lippincott Williams and Wilkins, Philadelphia, 2005. pp 63 - 67
46. Johnson RJ, Tisher CC. Chapter 14. HIV infection and kidney disease, In *Nephrology and Hypertension*, House Officer Series. 5th edition, eds CC Tisher and CS Wilcox, Lippincott Williams and Wilkins, Philadelphia, 2005. pp 87 - 91
 47. Kanellis J, Kang DH, Feig DI, Johnson RJ. Chapter 5. Asymptomatic hyperuricemia. In "Crystal-Induced Arthropathies: Gout, Pseudogout, and Apatite Associated Syndromes". Eds RL Wortmann, HR Schumacher, MA Becker, and LM Ryan. 2006, pp 81-97 in press.
 48. Kang DH, Johnson RJ. Hyperuricemia, Gout and the Kidney. In *Diseases of the Kidney*, Eighth Edition. Eds RW Schrier and CW Gottschalk. Little Brown Co., Boston, 2005.
 49. Johnson RJ, Floege JF, Rennke H, Feehally JF. Chapter 15. Glomerular Diseases: Classification and pathogenesis. IN Comprehensive Clinical Nephrology, 3rd edition, eds J Feehally, J Floege and RJ Johnson. Elsevier, London, 2007.
 50. Johnson RJ, Bakris G, Rodriguez-Iturbe. Chapter 32. Essential hypertension. IN Comprehensive Clinical Nephrology, 3rd edition, eds J Feehally, J Floege and RJ Johnson. Elsevier, London, 2007.
 51. Lerma EV, Ferder L, Johnson RJ. Chapter 62. Geriatric Nephrology. IN Comprehensive Clinical Nephrology, 3rd edition, eds. J Feehally, J Floege and RJ Johnson. Elsevier, London, 2007.
 52. Rodriguez Iturbe B, **Johnson RJ**. Reply to Dr Jenkins. *Am J Kid Dis* (letter) 2008; 51:1075.
 53. Segal MS, Sanchez-Lozada LG, **Johnson RJ**. Reply to RJ Hine and JS White. *Am J Clin Nutr* (letter) 2008; 87:1063-1065
 54. Johnson RJ, Tisher CC. Chapter 6. Glomerular diseases. In Handbook of Nephrology and Hypertension, eds CS Wilcox and CC Tisher, 6th edition, Lippincott Williams and Wilkins, Philadelphia, 2008.
 55. Segal MS, Johnson RJ. Chapter 11. Renal Involvement in Systemic Lupus Erythematosus. In Handbook of Nephrology and Hypertension, eds. CS Wilcox and CC Tisher, 6th edition, Lippincott Williams and Wilkins, Philadelphia, 2008.
 56. Reungjui S, Johnson RJ. Response to "Thiazide diuretics: rat versus man". *Kidney Int* 2008; 74:831
 57. Feig DI, Kang DH, Johnson RJ. Reply to N Trivedi. *N Engl J Med* 2009; 360:539-41.
 58. Feig DI, Johnson RJ. Allopurinol and the Role of Uric acid in hypertension. Reply to Dr Brinker. *JAMA* 2009; 301:270-271.
 59. Shafiu M, Johnson RJ. Uric acid, fructose, and the kidney. *Handbook of Chronic Kidney Disease Management*, 1e JT Daugirdas, MD, editor, Lippincott Williams & Wilkins, Philadelphia, 2011, pp141-152
 60. Johnson RJ, Rodriguez-Iturbe B, Bakris GL. Primary hypertension , In *Comprehensive Clinical Nephrology*, edition 4, Feehally J, Johnson RJ, Floege J. Elsevier 2010
 61. Johnson RJ, Floege J, Feehally J. Introduction to Glomerular Disease: Histologic Classification and Pathogenesis. In *Comprehensive Clinical Nephrology*, edition 4, Feehally J, Johnson RJ, Floege J. Elsevier 2010
 62. Pichler R Hugo CH, Johnson RJ. Aging and the Kidney. In *Comprehensive Clinical Nephrology*, edition 4, Feehally J, Johnson RJ, Floege J. 4th edition, Elsevier 2010
 63. Sautin YY, Imaram W, Kim KY, Angerhofer A, Henderson GN, Johnson RJ. Uric acid and

- oxidative stress. In *Oxidative Stress in Applied Basic Research and Clinical Practice: Renal Disorders*, and the publisher is The Humana Press / Springer Science, 2010 Part 2, Pages 143-159
64. Kanbay M, Sanchez-Lozada LG, Madero M, **Johnson RJ**. Reply to Dr White. *Nephrol Dial Transpl* 2011 Oct; 26:3420-3421
 65. Nakagawa T, **Johnson RJ**. Endothelial nitric oxide synthase. *Contrib Nephrol*. 2011;170:93-101. Kar N Lai (and Sydney Tang (editors)
 66. Kang DH, Kanbay M, Johnson RJ. Hyperuricemia, Gout and the Kidney. In *Diseases of the Kidney*, Tenth Edition. Eds RW , Ron Falk, Bruce Molitoris, Eric Neilson. Little Brown Co., Boston, 2011.
 67. **Johnson RJ**, Lanaspá MA, Roncal-Jimenez C, Sanchez-Lozada LG Effects of excessive fructose intake on health. *Annals of Internal Medicine* 2012 Jun 19;156(12):905 (Letter)
 68. Madero M, Sanchez-Lozada LG, Johnson RJ. Fructose likely does have a role in hypertension. *Hypertension* 2012 Jun;59(6):e54 (letter to editor)
 69. Johnson RJ, Bakris GL, Rodriguez-Iturbe B. Primary Hypertension, in *Comprehensive Clinical Nephrology*, edition 5, Johnson RJ, Floege J and Feehally J, editors. Elsevier 2013
 70. Johnson RJ, Floege J, Feehally J. Introduction to Glomerular Disease: Histologic Classification and Pathogenesis, in *Comprehensive Clinical Nephrology*, edition 5, Johnson RJ, Floege J and Feehally J, editors. Elsevier 2013
 71. Kanbay M, Turak O, Johnson RJ. Reply to Serum Uric Acid Still Carries Controversies about its Role in Endothelial Dysfunction *J Clin Hypertens* 2013; 15:297 (letter)
 72. Fini M, Johnson RJ, Stenmark K, Wright R. Hypertension, Nitrate-Nitrite, and Xanthine Oxidoreductase catalyzed nitric oxide generation: Pros and Cons. *Hypertension* 2013 Sept; 62(3):e9.
 73. Andrews P, Johnson RJ. Gibbons and hominoid ancestry. In *Taxonomic Tapestries: the threads of behavioural, evolutionary and conservation research*. Eds AM Behie and MF Oxenham. 2014. London, UK.
 74. Wadhwa A, Inaba S, Johnson RJ. Uric acid and hypertension—is there really a link? In *Chronic Kidney Disease and Hypertension*, Edited by Edgar Lerma and Matt Weir, Springer, 2014
 75. Sanchez-Lozada LG, Madero M, Reungjui S, Johnson R.J. Sugars, Fructose, Hypertension and Kidney Disease, in *Dietary Sugars and Health*, eds Goran MI, Tappy L, Le K-A, and Ulijaszek S, Taylor and Francis, London, 2014.
 76. Jefferson JA, Escudero E, Johnson RJ, Swenson ER, Hurtado A. Increased Oxidative Stress at High altitude. *Chest* 2014; 145:423
 77. Fini MA, Wright RM, Stenmark KR, Daniels SR, Johnson RJ. Metabolically Healthy but Overweight and/or Obese: Is Uric Acid an Underdiagnosed Mediator of Adverse Outcome? *Am J Med* (letter) 2014;127; e21
 78. Kang DH, Johnson RJ. Chapter 35. Uric acid metabolism and the Kidney. In *Chronic Kidney Disease*, eds M Rosenberg and P Kimmel, Elsevier, Philadelphia, 2014
 79. Cara-Fuentes G, **Johnson RJ**, Reiser J, Garin EH. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance: Response. *Pediatr Nephrol*. 2014 Aug;29(8):1467-8

80. Correa-Rotter R, Wesseling C, **Johnson RJ**. In Reply to 'Pesticides and the Epidemic of CKD in Central America'. *Am J Kidney Dis*. 2014 Sep;64(3):477-8
81. Johnson RJ. Introduction, to *The Cobe Story*, by RM Collins, 2014, ISBN 978-1-939685-12-4